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RNA viruses are responsible for many of the most recent threats to human health by 
emerging infectious diseases, including epidemics caused by Influenza, Zika, Dengue 
and novel Coronaviruses. The body’s first line of defence against viruses is the innate 
immune system. Pattern recognition receptors (PRR) detect pattern associated molecular 
patterns (PAMPs), such as incoming viral genomes. The RIG-I like receptor family sense 
viral RNA in the host cell cytoplasm, with RIG-I sensing double stranded regions of RNA 
with an exposed 5’ triphosphate group, present in viruses such as Influenza and Zika. 
The resulting signalling platform activates both IRF3 and NF-κB, resulting in induction of 
an antiviral response. Early sensing of infection is essential for effective clearance of 
virus infection with minimal damage to the host. 
In this study we set out to understand the contribution of the linear ubiquitin chain 
assembly complex (LUBAC) to the sensing of RNA and RNA viruses by RIG-I. By using 
synthetic RNAs, 3p-hpRNA and Poly(I:C), and RNA viruses to specifically stimulate RIG-I, 
we confirmed the requirement of signalling proteins MAVS and NEMO for activation of 
IRF3 and NF-κB in this context. TBK1 and IKKε were shown to function redundantly to 
activate IRF3 but not NF-kB. Linear ubiquitin chains are produced exclusively by the 
tripartite E3 ligase LUBAC, made up of HOIP, HOIL and SHARPIN, and are required for 
NF-κB activation by PRR such as TLR3 and MDA5 signalling. Here we show that the 
catalytic component HOIP, and HOIL-1, are required for activation of both IRF3 and NF-
κB-dependent antiviral signalling during RIG-I activation. Conversely, SHARPIN is not 
required for either IRF3 or NF-κB-driven responses, an observation that helps rectify 
previous inconsistencies in the literature. Expression of a catalytic dead mutant of HOIP, 
and the resultant loss of M1 chains, only partially abrogated activation of IRF3 and NF-
κB, suggesting LUBAC has an additional mechanism for regulating RIG-I signalling. HOIP 
and SHARPIN were shown interact with both NEMO and TBK1 after stimulation of RIG-I, 
suggesting LUBAC acts as a scaffold to recruit proteins to the signalling complex. We 
have therefore defined the different roles of individual LUBAC components in RIG-I 
signalling and established that this complex is essential for innate immune sensing of 
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RNA viruses are responsible for many of the most recent threats to human health by emerging 
infectious diseases, including epidemics caused by Influenza, Zika, Dengue and novel Coronaviruses. 
The body’s first line of defence against viruses is the innate immune system. Pattern recognition 
receptors (PRR) detect pattern associated molecular patterns (PAMPs), such as incoming viral 
genomes. The RIG-I like receptor family sense viral RNA in the host cell cytoplasm, with RIG-I sensing 
double stranded regions of RNA with an exposed 5’ triphosphate group, present in viruses such as 
Influenza and Zika. The resulting signalling platform activates both IRF3 and NF-κB, resulting in 
induction of an antiviral response. Early sensing of infection is essential for effective clearance of 
virus infection with minimal damage to the host. 
In this study we set out to understand the contribution of the linear (M1-linked) ubiquitin chain 
assembly complex (LUBAC) to the sensing of RNA and RNA viruses by RIG-I. By using synthetic RNAs, 
3p-hpRNA and Poly(I:C), and RNA viruses to specifically stimulate RIG-I, we confirmed the 
requirement of signalling proteins MAVS and NEMO for activation of IRF3 and NF-κB in this context. 
TBK1 and IKKε were shown to function redundantly to activate IRF3 but not NF-κB. M1-linked 
ubiquitin (M1-Ub) chains are produced exclusively by the tripartite E3 ligase LUBAC, made up of 
HOIP, HOIL and SHARPIN, and are required for NF-κB activation by PRR such as TLR3 and MDA5 
signalling. Here we show that the catalytic component HOIP, and HOIL-1, are required for activation 
of both IRF3 and NF-κB-dependent antiviral signalling during RIG-I activation. Conversely, SHARPIN is 
not required for either IRF3 or NF-κB-driven responses, an observation that helps rectify previous 
inconsistencies in the literature. Expression of a catalytic dead mutant of HOIP, and the resultant 
loss of M1 chains, only partially abrogated activation of IRF3 and NF-κB, suggesting LUBAC has an 
additional mechanism for regulating RIG-I signalling. HOIP and SHARPIN were shown interact with 
both NEMO and TBK1 after stimulation of RIG-I, suggesting LUBAC acts as a scaffold to recruit 
proteins to the signalling complex. We have therefore defined the different roles of individual LUBAC 
components in RIG-I signalling and established that this complex is essential for innate immune 
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Chapter One: Introduction 
1.1 Sensing of viruses by the innate immune system 
1.1.1 Overview of the innate immune system 
The environment in which we live contains vast numbers of pathogens and toxic substances that 
threaten our health. Because of this, our immune system has evolved to protect us, based at least in 
part on its ability to recognise ‘non-self’ molecules and to differentiate them from ‘self’ molecules, a 
conceptual framework first described by Janeway1, as well as its ability to recognise ‘self’ damage 
signals to protect against danger2. Our immune system can be divided into two parts: the innate 
immune system, which forms the first line of defence against pathogen infection, tissue injury and 
genotoxic stress; and the adaptive immune system, which consists of co-ordinated receptor-antigen 
interaction-specific responses against known pathogens and is generally activated by the innate 
immune system, with some exceptions3. Activation of the adaptive immune system occurs through 
the clonal expansion of cells expressing the correct antigen-specific receptor corresponding to the 
invading pathogen4. Thus, the immediate activation of innate immune system, possible due to 
expression of its components in almost all cells of the body, is crucial for prevention of infection and 
maintenance of homeostasis5. 
Almost all cells and tissues in the body contribute to the innate immune system, which is made up of 
three main components: physical barriers, which shield our cells from external substances and 
pathogens, predominantly comprised of the skin in humans6; secreted defence mechanisms7; and 
general immune responses in specialist and non-specialist cells8.  
Non-specialist epithelial cells form the majority of our physical barrier to infection meaning that they 
are generally the cells first infected by pathogens and the first line of defence of innate immune 
system. Because of this, cellular systems like the mucosal surface of the lung epithelium are a critical 
innate immune interface9. The crux of the role of epithelial cells is their ability to detect pathogens, 
generally occurring through recognition of pattern associated molecular patterns (PAMPs) by 
pattern recognition receptors (PRR). Recognition activates a variety of intracellular signalling 
cascades, resulting in expression of many genes and synthesis and secretion of many molecules, 
including chemokines, cytokines, pro-inflammatory lipids and complement10,11. Together, these 
genes and secreted molecules orchestrate the early immune response by enabling the recruitment 
of multiple specialist immune cell populations.  
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There are a broad range of specialist innate immune cells, which although specialist, differ from 
adaptive immune cells as they do not express antigen-receptors and do not have the capacity for 
immunological memory12. The best known of these are neutrophils, macrophages, myeloid-derived 
suppressor cells (MDSC), innate lymphoid cells (ILCs), dendritic cells (DCs) and natural killer (NK) 
cells, all of which have unique responses to infection or damage13. Macrophages are the primary 
phagocytic component of the immune system, capable of engulfing pathogens and dead cells and 
producing both pro- or anti-inflammatory mediators, dependent on subset and environmental 
cues14,15. Neutrophils are also capable of phagocytosing bacteria and fungi13, as well as releasing 
granules to degrade proteins from larger pathogens16. Additionally, neutrophils undergo NETosis, 
where they release extrusions of their own nuclear and mitochondrial DNA as a neutrophil 
extracellular trap (NET) to kill or immobilise microbes17. The subset of MDSCs is comprised of 
neutrophils and monocytes, and is activated during pathological immune activation, acting to 
prevent dangerous persistent stimulation of myeloid cells through suppression of NK and T cell 
activation18. ILCs are made up of three subtypes of cells with wide-ranging effector functions, 
contributing to immunity by secreting effector cytokines and regulating the function of other innate 
and adaptive specialist immune cells, complementing the function of T cells in adaptive immunity19. 
DCs have many functions that both directly influence innate immunity and are critical for the 
induction of adaptive immunity. Innate functions include the production of IL-12 and Type I IFN and 
induction of innate lymphocyte expansion, whereas adaptive functions consist of antigen capture 
and processing and migration to T cell areas in lymphoid organs20. Finally, NK cells, often considered 
ILCs, are one of the main effector lymphocytes of the innate immune system. They are capable of 
cytokine production and cytolytic functions, as well as regulatory functions through their interaction 
with other immune cell subsets21. 
1.1.2 Importance of the innate immune system 
The importance of the innate immune system is highlighted by its conservation through evolution. 
First appearing 750 million years ago, its key features that allow the generation of a response to 
invading pathogens are found in every species in the tree of life, conserved between kingdoms as 
disparate as plants, invertebrates and mammals22,23. In prokaryotic organisms, this is based around 
the ability to degrade invading pathogens, but this has become more complex in eukaryotic 
organisms, which generated additional mechanisms to maintain cellular integrity and survival, 
generally based around the binding of foreign elements and differentiation from ‘non-self’22. 
Conserved through evolution, the more complex the organism, the more complex and sophisticated 
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the immune system it possesses became, illustrating the competitive ‘struggle for existence’ 
between species. 
This importance is further highlighted by the phenotypes seen in individuals who have dysregulated 
innate immune systems. Immunodeficiency disorders resulting from impairment of the immune 
system are split into two groups: primary immunodeficiency, caused by genetic defects, and 
secondary immunodeficiency, resulting from environmental factors. Together, these are a 
heterogenous group of around 150 diseases, each with differing phenotypes. Primary 
immunodeficiencies affecting the innate immune system include disorders in phagocytes, preventing 
pathogen phagocytosis and resulting in recurrent and severe bacterial and fungal infection; or in 
complement, causing development of autoimmune conditions like rheumatoid arthritis and systemic 
lupus erythematosus24. They also include deficiencies caused by mutations in PRRs or PRR signalling 
components. Secondary immunodeficiencies are most regularly caused by malnutrition-induced 
protein deficiency or drug treatments, both of which lead to suppression of immunity, or chronic 
infection, as in the case of HIV-induced acquired immune deficiency syndrome (AIDS)25.  
Conversely, persistent stimulation of the innate immune system can be equally as damaging. Chronic 
inflammation is a result of a breakdown of self-tolerance, resulting in higher and persistent 
production of cytokines. This is often induced by pathogen infection, but also by things like 
bystander activation and superantigen-crosslinking26. Persistent activation can result in oxidative 
stress and tissue damage, causing wide-ranging injury including neurodegeneration, cancer and 
multi-organ failure27,28. Specific examples include Type I diabetes, where the immune system targets 
insulin producing cells29; arthritis, where the immune system attacks the joints30; and multiple 
sclerosis, where immune-mediated damage to the myelin sheaths surrounding neurones slows nerve 
transmission31. A group of autoimmune diseases, type I interferonopathies, are associated with the 
constitutive overproduction of type I interferon (IFN-I), a central component of the innate immune 
response. This results in systemic auto-inflammation, combined with varying levels of auto-immunity 
or immunodeficiency32. This includes AGS which is caused by mutations in one or more of seven 
genes, encoding primarily DNA and RNA binding proteins that normally protect cellular RNAs from 
detection by PRRs, resulting in constitutive activation32. Aicardi Goutières Syndrome (AGS) presents 
as a severe mental and physical handicap in infants. Mutations in PRRs RIG-I and MDA5 cause 
hypersensitivity or spontaneous activation of receptor signalling and are linked with AGS and 
Singleton-Merten syndrome and systemic lupus erythematosus (SLE)33,34, whilst TLR3 mutations have 
been associated with IAV-driven pathologies including encephalopathy and pneumonia35,36. RIG-I and 
MDA5 are also be implicated in auto-immunity when mutations cause dysregulated RNA 
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metabolism, with excess or mis-localised immunostimulatory RNAs resulting in their constitutive 
activation. 
1.1.3 Sensing of pathogens by pattern recognition receptors 
The majority of pathogens are first detected by germline encoded receptors called pattern 
recognition receptors (PRR), occurring in the first infected cells, which are often not specialist 
immune cells. Different families of these receptors sense a wide range of PAMPs not encoded in host 
cells, such as DNA and RNA species with ‘non-self’ characteristics and bacterial- and fungal-specific 
components, which then signal to activate immune responses, as shown in Figure 1.1.  
One family of PRRs is the Toll like receptors (TLRs). They are membrane bound and predominantly 
detect bacteria, through the recognition of lipoproteins in Gram-positive bacteria (TLR2 and either 1 
or 6), peptidoglycans (TLR2), lipopolysaccharide (LPS) (TLR4) and flagellin (TLR5). Most TLRs can also 
reside in endosomes, enabling them to function in this compartment. Here TLRs 3, 7, 8, and 9 sense 
endosomal DNA and RNA of bacterial and viral origin37–39. Like TLRs, a second family of PRRs, the C-
type Lectin Receptors (CLRs), also function at the cell surface. Predominantly, they sense fungal 
carbohydrates like β-glucan and Mannans to activate signalling, however they can also function to 
modulate TLR signalling40,41. Like some TLRs, NOD-like receptors (NLRs) also respond to intracellular 
pathogens, recognising various ligands like peptidoglycan, flagellin, viral RNA and fungal hyphae, as 
well as detecting damage associated molecular patterns (DAMPs) from host cells42. Both CLRs and 
NLRs can also sense viruses through the detection of viral-specific lipids and proteins present in the 
viral envelope40. However, viral detection predominantly occurs through receptors that detect their 
nucleic acid genomes43. Both TLRs and RLRs sense viral RNA, with TLRs sensing RNA in the 
endosome44,45 and RLRs in the cytoplasm of cells46. Viral DNA is sensed by TLR947, as well as other 
cytosolic DNA sensors like DNA-PK, IFI16, RNA Pol III, ZBP1, AIM2 and cGAS48–53. The rapid and highly 
efficient response generated by activation of PRRs is possible because all pathogens can be sensed 
by multiple PRRs, and most if not all PRRs sense multiple pathogens. 
The outcomes of PRR signalling are determined by the adaptor proteins through which each 
receptor signals. Many receptors contain specific protein/protein interaction domains such as 
caspase-recruitment domains (CARDs) or Toll/interleukin-1 receptor (TIR) domains, through which 
they initiate downstream signalling following ligation. TLRs signal through the TIR domain-containing 
adaptor proteins MyD88 and TRIF, activating both IRF3 and NF-κB resulting in transcription of IFN-I 
and pro-inflammatory cytokines38. CLRs generally function to activate or modulate NF-κB, via the 
Ras/Raf pathway, but can also internalise pathogens for degradation and antigen presentation 
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through Syk, dependent on cell-type and their ability to cross-talk with other PRRs41. NLRs also 
activate NF-κB, but additionally can induce the formation of distinct inflammasomes with ASC and 
pro-caspase 1, resulting in secretion of potent pro-inflammatory cytokines and activation of a cell 
death mechanism called pyroptosis54,55. NOD1 and 2 also activate autophagy to digest intracellular 
bacteria or viruses through the formation of autolysosomes56. Nucleic acid sensors predominantly 
signal to activate both IRF3 and NF-κB, albeit through different adaptor proteins, with DNA sensors 
signalling through the adaptor protein STING, TLRs through MyD88/TRIF and RLRs through MAVS. 
DNA sensors AIM2 and IFI16 can also activates non-canonical inflammasome formation57. 
 
Figure 1.1 PRR sensing in non-specialist immune cells 
PRRs sense distinct PAMPs and activate signal transduction pathways, including activation of IRF3, NF-κB and 
inflammasomes. Transcription factors IRF3 and NF-κB enter the nucleus and activate the transcription of Type I 




1.2 Sensing of RNA viruses 
As previously described, intracellular sensing of RNA viruses occurs by two PRR families: TLRs and 
RLRs. Despite sensing similar or overlapping RNA species often from the same viruses, their 
functions are not redundant, as they are expressed in distinct cell populations or cellular 
compartments (see Table 1.2.1). 
PRR Expression Location Agonist Human-infecting viruses 
detected 
RIG-I Ubiquitous Cytoplasm 5' ppp dsRNA 
short dsRNA 
5' ppp ssRNA 
AU-rich 3' UTR 
RNase L cleavage 
products 
Circular viral RNA 
pU/UC HCV genomic 
RNA 
Flaviviruses (including DENV, 
ZIKV, WNV, HCV), 
Coronaviruses (including 
SARS, MERS, SARS-CoV-2), 
Paramyxoviruses (SeV, MV), 
Adenoviruses, Rotaviruses, 
Picornaviruses,  Rheoviruses, 
NDV, RSV, VSV, IAV/IBV, 
EBOV, JEV, Vaccinia virus, 
RVFV, Lassa virus, Nipah virus, 
Rabies virus, HIV, HepB  
MDA5 Ubiquitous Cytoplasm Long dsRNA (>1kb) 




EMCV, CBV, Rhinovirus), 
Flaviviruses (including DENV, 
WNV, HCV), Coronaviruses 
(SARS, SARS-CoV-2), 
Rotaviruses, Enteroviruses, 
MV, HBV,  Saffold virus, 
Vaccinia virus, EBOV and HIV 
LGP2 Ubiquitous Cytoplasm dsRNA Picornaviruses (including 












Flaviruruses (DENV, WNV, 
HCV), Coronaviruses, 
Herpesviruses (HSV-2, EBV), 
Rotaviruses, Coxsackievirus, 




Endosome ssRNA, R848, CL097 Flaviviruses (HCV, DENV, 
WNV), Coronaviruses (SARS), 
Herpesviruses (HSV-1, KSHV) 




Endosome ssRNA, R848, CL095, 
CL097 
Flaviviruses (HCV, DENV, 
WNV), Coronaviruses (SARS), 
Herpesviruses (HSV-1, KSHV) 
IAV, HIV-1, HBV 
Table 1.2.1: Expression, cellular localisation, agonists and viruses detected by RNA sensing PRR 
Adapted from 66,71,72. 
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This table contains a non-exhaustive list of families of viruses detected by the various receptors, as well as 
individual viruses of interest for their importance in either human disease or previous scientific studies. 
Abbreviations: Sendai virus (SeV), Newcastle Disease Virus (NDV), Respiratory Syncytial Virus (RSV), Measles 
virus (MV), Vesicular Stomatitis Virus (VSV), Influenza A virus (IAV), Ebola virus (EBOV), Japanese Encephalitis 
virus (JEV), Hepatitis C Virus (HCV), West Nile virus (WNV), Rift Valley fever virus (RVFV), Murine Norovirus 
(MNoV), Encephalomyocarditis virus (EMCV), Kaposi's sarcoma-associated herpesvirus (KSHV),  
1.2.1 Toll like receptors 
TLRs are type I transmembrane proteins and those that sense RNA reside in the endosomal 
membrane with the ligand binding domain projecting into the endosomal interior. Because of this, in 
order for naked viral RNA to be detected by TLRs, viruses must first be internalised by either 
autophagy or receptor-mediated endocytosis61–63. TLR3 senses both long dsRNA and branched RNA 
structures, which occur due to complementary regions in ssRNA stems44,64–66. TLR7 and 8 are very 
closely related and both sense ssRNA, but their expression profiles differ. TLR7 is predominantly 
expressed in plasmacytoid DCs and B cells, with inducible expression also detected in non-immune 
cells, and TLR8 is more strongly expressed in myeloid cells67. 
Once activated, TLR7 and TLR8 recruit MyD8868, and signal to activate NF-κB and Mitogen-Activated 
Protein Kinases (MAPK) through recruitment of IL-1 receptor-associated kinases (IRAKs), TRAF6 and 
IRF7, as well as IFN-I through IRF5 and 767. TLR3 signals through the alternative adaptor protein 
TRIF/TICAM-158, resulting in the recruitment of TRAF proteins and RIP1. IFN-I is then activated by 
IRF3, requiring TRAF3 and TBK167 and NF-κB is activated through TRAF6 and RIP170. TRIF-dependent 
signalling can also induce apoptosis, via caspase 871,72.  
1.2.2 RIG-I-like receptors 
The RIG-I-like family of receptors (RLRs) sense RNA in the cytoplasm of infected cells and consist of 
three proteins: retinoic acid-inducible gene I (RIG-I), melanoma differentiation-associated protein 5 
(MDA5) and laboratory of genetics and physiology 2 (LGP2). The proteins share a similar domain 
structure with two domains that allow for detection of RNA (Figure 1.2.2), the C terminal domain 
(CTD) that binds RNA, and a central helicase domain, which works with the CTD to detect immuno-
stimulatory RNAs. As RIG-I and MDA5 also have two N-terminal caspase activation and recruitment 
domains (CARDs), they are capable of inducing downstream signalling through MAVS73. Because 
LGP2 lacks this CARD domain, it is incapable of activating downstream signalling. Instead, it is 
thought to regulate the activation of RIG-I and MDA574.  
LGP2 negatively regulates RIG-I signalling by various methods, such as competitively binding to and 
sequestering the 5’ ends of immunostimulatory RNA75, preventing K63-linked ubiquitination of RIG-I 
by TRIM2575 and preventing binding of RIG-I to MAVS to initiate downstream signalling76, all of which 
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occur independently of LGP2’s catalytic activity77. Conversely, LGP2 promotes MDA5-mediated 
signalling outcomes, previously seen in response to EMCV and Poliovirus infection78,79, likely due to 
its ability to bind RNA ends and promote the internal binding of MDA5 to the RNA duplex and 
nucleation80. This process may occur through synergistic activation with RIG-I, requiring the helicase 
activity of both proteins81. 
 
Figure 1.2.2 Domain structure and function of RLR family and MAVS adaptor protein. Adapted from: 46.  
RIG-I and MDA5 are comprised of three major domain types: tandem caspase activation and recruitment 
domains (CARD), responsible for downstream signal transduction; a central DEAD box RNA helicase domains 
made of three subdomains (Hel1, Hel2i and Hel2), responsible for RNA-mediated ATP-hydrolysis; and a C-
terminal domain (CTD) that binds RNA. In resting cells, an interaction between the CARD2 and Hel2i domains 
hold both RIG-I and MDA5 in an auto-inhibited state, released by RNA binding. LGP2 also contains a helicase 
and CTD, but no CARD domains. MAVS consists of a single CARD domain, a proline-rich region (PRR) and a 






1.3.1 Activation of RIG-I and MDA5 by distinct RNAs 
Despite being localised in the same cellular compartment and signalling through the common 
adaptor protein MAVS, RIG-I and MDA5 are activated by distinct RNA species, determined by the 
Helicase-CTD motifs of the two proteins, which adopt different orientations relative to dsRNA82. The 
requirements for RIG-I activating RNAs are better characterised, with no concrete molecular 
structure of a MDA5 ligand yet determined.  
The first identified requirement for a RIG-I-activating RNA was a 5’ triphosphate group83,84, which 
induces activation due to the shape and orientation of the RIG-I CTD RNA binding pocket that 
interacts with the modified 5’ end of the RNA85,86. Since then, it has been discovered that RNAs with 
a 5’ diphosphate can also be accommodated by the CTD binding pocket87,88, such as those found in 
Reoviruses. In addition to phosphorylation of the 5’ end of RNA, the structure of the nucleic acid 
itself also determines its RIG-I activating nature, as the 5’ terminal nucleotide must be unmethylated 
at its 2′-O position in order to be accommodated by the RIG-I CTD87. Additionally, the nucleotide 
bound by the 5’ triphosphate also needs to be base paired to a complementary strand of RNA89,90, 
required so the double-stranded region of RNA can be bound by the helicase domain, as it is this 
stable interaction with the RNA that displaces the CARD domains to activate signalling. Initially, it 
was thought that the preferred RNA conformation for potent RIG-I activation was blunt ended 
dsRNA structures89,90, but subsequent studies have suggested that a stem loop formed from a single-
stranded region of RNA with complementarity to itself is in fact a better RIG-I ligand, again due to 
the shape of the RNA binding pocket of RIG-I91. 
From these observations, it is currently believed that RIG-I binds to RNAs with regions of 
complementarity that drive secondary structure and a 5’ multi-phosphate modification. However, 
due to discrepancies between the properties of various RIG-I-activating RNAs, such as those with  
sub-optimal 5’ or 3’ ends or ssRNA with internal poly-U/A-rich motifs, it has been proposed that 
some preferential features of RIG-I ligands may compensate for lack of another92,93.  
The ability of RIG-I to recognise these specific features found only on viral RNAs is what allows it to 
differentiate ‘self’ from ‘non-self’94–96. The presence of 5’ phosphate groups and lack of 2’-O-
methylation in viral RNAs is caused by the ribonucleoside triphosphate used by viral 
polymerases97,98, and the common formation of the pan-handle structure by viral RNAs occurs due 
to the complementarity of 5’ and 3’ regions of negative-sense RNA viral genomes89,99. Cellular RNAs 
are capped at the 5’ end, with the cap shielding the phosphate groups and containing ribose 2’-O-
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methylation. This feature is exploited by some viruses such as Flaviviruses, which mimic cellular 
RNAs by encoding a viral 2′-O-methyltransferase to add to 2’-O-methyl group to the 5’ end of its 
RNAs to evade recognition100. Mammalian rRNAs and tRNAs are not capped but evade recognition as 
their 5’ end is only monophosphorylated, which has been shown to be discriminated against by RIG-
I101.  
The activating properties of MDA5 ligands are less well characterised, although it is thought to sense 
predominantly long double-stranded RNA, originating from early studies showed that MDA5 was 
essential for the IFN-I response to Poly(I:C)102,103. Stimulation is sequence-independent but length-
specific, with MDA5 able to discriminate between RNAs based on their length and regions of 
secondary structure104–106. This property is enabled by the ability of MDA5 to form filaments along 
RNA, which are more stable on longer RNAs, resulting in a stronger immune response94,95. MDA5 
may also be preferentially activated by more complex, branched RNA structures, as it is more 
strongly activated by Poly(I:C) than other dsRNA analogues that cannot form branched structures107. 
MDA5 is essential for activation of the immune response to the Picornavirus family, including 
Encephalomyocarditis virus (EMCV), Rhinovirus and Coxsackie B virus, due to their positive-strand 
ssRNA genome. However, unlike RIG-I, which is the sole sensor of many viruses, MDA5 only plays a 
partial role in detection of the majority of viruses it senses104.  
1.3.2 Activation of RIG-I 
Upon binding to RNA, RIG-I surrounds the RNA, with three separate protein domains interacting with 
it108. The HEL1 domain interacts with the RNA backbone of both strands of RNA, HEL2i binds to the 
minor groove of the RNA backbone, important for the specific recognition of RNA, and the CTD 
forms a cavity with a positively charged centre to accommodate dsRNA109. As the CARDs of RIG-I 
domain compete with RNA for the same binding site in the helicase domain, binding of RNA by RIG-I 
results in the release of the CARD domains of RIG-I from the auto-inhibited conformation110.  
However, the binding of activating RNA by RIG-I alone is not sufficient to activate downstream 
signalling, which also requires its ATPase activity111–113. The active ATPase domain in RIG-I is formed 
by the two helicase domains following the conformational change induced when RIG-I binds RNA114. 
This structural change enables catalysis of ATP by the ATPase domain, allowing RIG-I to release the 
bound RNA105,106,110. It also allows RIG-I to discriminate against host RNAs, as ATP catalysis quickly 
displaces RIG-I from self-RNAs but not from 5' triphosphate dsRNA115,116. Secondly, and more 
importantly, ATP hydrolysis by the ATPase domain drives oligomerisation of RIG-I by allowing RIG-I 
translocation from the 5’ end of RNA towards the stem region, giving space for the binding of 
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another RIG-I monomer116. The 5’ppp end of the RNA throttles the translocation of RIG-I, delaying its 
unbinding from RNA and enabling a second RIG-I monomer to bind and form a stable dimer116. This 
oligomeric confirmation of RIG-I on immunostimulatory RNA allows the tetramerization of the CARD 
domains that is required for interaction with a single MAVS CARD domain and subsequent 
downstream signalling activation113,117–119.  
RIG-I must also transition from the cytoplasm to the mitochondrial associated membranes (MAMs) 
to interact with MAVS. This requires formation of a complex between RIG-I, TRIM25 and the 
mitochondrial-targeting chaperone 14-3-3ε120. RIG-I can then bind the MAVS CARD domain to 
stimulate self-perpetuating MAVS oligomerisation on the outside of the mitochondria, propagating 
the signal from RIG-I and enabling its downstream signalling activity113,117. The exact mechanism by 
which MAVS oligomerisation is triggered remains controversial, although all proposed mechanisms 
suggest the requirement for post-translational modifications of RIG-I. 
The best characterised RIG-I-activating post-translational modifications are anchored and un-
anchored K63-linked ubiquitin chains117,119,121. Anchored K63-ubiquitin chains are first conjugated to 
lysine 164 or 172 of RIG-I, allowing ubiquitination of 8 additional sites122. These ubiquitin chains, as 
well the non-covalent interaction of RIG-I with unanchored K63-ubiquitin chains, act to stabilise the 
oligomerised RIG-I CARD domains by binding along the outer rim of the tetramer, holding it in a 
signalling-competent “lock-washer” conformation117,123. Initially, ubiquitination of RIG-I CARD was 
thought to be the sole responsibility of TRIM25124,125, enabled by removal of phosphorylation 
modifications on the RIG-I CARD and CTD by protein phosphatase 1 (PP1)126. However, more recently 
it was shown to function redundantly with, or probably even secondarily to Riplet127, an E3 ligase 
that modifies both the CARD and the CTD of RIG-I128–130. Additional E3 ligases Mex-3 RNA binding 
family member C (MEX3C) and TRIM4 have been shown to conjugate K63-ubiquitin chains to the 
RIG-I-CARD131,132, although the role of this in downstream signalling is unknown133.  
1.3.3 The RIG-I signalling pathway 
RIG-I activation induces signalling outcomes through a downstream signalling cascade, shown in 
Figure 1.3.3. Oligomerisation of MAVS, which may form highly ordered filaments, occurs through a 
helical extension model, where the helical assembly of RIG-I-CARDs is extended by the binding of a 
MAVS CARD to form a larger filament117,118. This filamentous ‘active’ state MAVS activates 
downstream signalling 134, resulting in activation of both IRF3 and NF-κB, however the exact 
mechanism by which this occurs is contested. 
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Upon oligomerisation, the increased proximity of multiple tumour necrosis factor receptor–
associated factor (TRAF) binding sites in enables recruitment of TRAF proteins to the PRR domain of 
MAVS73, with TRAF2, 3 and 5 binding to the PVQET motif135–138 and TRAF6 binds to the PGENSE and 
PEENEY motifs139. Recruitment activates the E3 ligase activity of TRAF proteins, leading to synthesis 
of K63-linked ubiquitin chains that serve as a scaffold for the recruitment and activation of many 
downstream signalling proteins135,137,138,140,141.  Although there is some level of redundancy 
between the TRAF proteins and M1-ubiquitin chain-specific E3 ligase Linear Ubiquitin Chain 
Assembly Complex (LUBAC) for this function135,142,143, the generation of K63-linked ubiquitin 
chains is required144–147. 
One of the proteins recruited to the K63-ubiquitin chains synthesised by TRAF proteins is NF-κB 
essential modulator (NEMO), also known as IKK gamma148. NEMO is thought to be one of the key 
players in the activation of both branches of the RIG-I signalling pathway and is required for 
activation of IRF3, 7 and NF-κB143,149. NEMO-mediated NF-κB activation occurs through recruitment 
of the canonical IKK complex proteins IKKα and β, which phosphorylate IκBα to induce its K48-linked 
ubiquitination and subsequent degradation. This releases active NF-κB subunits to allow 
dimerization and translocation into the nucleus150. NEMO-mediated IRF3 activation occurs through 
recruitment of the non-canonical IKK complex Serine/Threonine kinases TBK1 and IKKε, which 
directly activate IRF3143,149. Their recruitment has been suggested to be mediated both through the 
IKK complex in a NEMO-dependent manner, and in a NEMO-independent manner through pre-
association with the TRAF proteins143, although multiple additional adaptor proteins have also been 
suggested to facilitate this. 
The first discovered of these was the TANK/NAP1/SINTBAD complex, which was suggested to recruit 
TBK1 to the RIG-I signalling complex using the TBK1-binding domains found in all three proteins151–
153, a finding supported by the fact that proper function of NEMO has been suggested to rely on its 
TANK binding capacity154. However, their involvement has since been disputed as cells lacking all 
three proteins show no defect in RIG-I signalling outcomes143. Optineurin, a NEMO-related protein 
localised to the Golgi apparatus, also shares the TBK1-interaction domain present in TANK, NAP1 and 
SINTBAD, leading to its implication in TBK1 binding and activation155,156. However, it has also been 
shown to act as a negative regulator of RIG-I-mediated IRF3 and NF-κB activation157,158, disputing its 
previously suggested role in TBK1 recruitment. It is not known whether TBK1 and IKKε are recruited 
to the RIG-I signalling complex by the same mechanism, although the direct recruitment of IKKε, but 
not TBK1, to ubiquitinated MAVS has demonstrated159. Because of this, and the differing cytoplasmic 
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localisation of TBK1 and IKKε, it is highly likely that they are recruited differently, despite their 
redundant functions.  
In addition to their recruitment, TBK1 and IKKε also need to be activated to drive activation of IRF3. 
This is mediated by auto-phosphorylation on Serine 172160, resulting in the reorganisation of its 
activation segment to enable phosphorylation of substrate proteins161. This generally occurs by the 
auto-catalytic mechanism of trans-autophosphorylation, induced at a high local concentration of 
TBK1134,161, such as when TBK1 is brought into signalling complexes via pre-association with adaptor 
proteins. However, proximity-induced trans-autophosphorylation is also reported to be induced by 
optineurin, which binds ubiquitinated TBK1 to form complexes at the Golgi162–164. In addition to 
phosphorylation, K63-linked polyubiquitination of both TBK1 and IKKε is also required for activation 
of TBK1165,166. 
TBK1 and IKKε activate IRF3 via phosphorylation of Serine 386167–169. Despite being functionally 
redundant, their differential expression determines their respective roles in immunity, with TBK1 
ubiquitously expressed but IKKε only basally expressed in pancreas, thymus, spleen and specialist 
immune cells170, but upregulated during immune signalling171,172. In addition to activating IRF3, IKKε 
has also been suggested to directly activate the ISGF3 complex through phosphorylation of STAT 




Figure 1.3.3: A schematic of the RIG-I signalling pathway 
RIG-I binds to activating RNA species and is post-translationally modified, including the addition of K63-linked 
ubiquitin chains by both TRIM25 and Riplet. In a complex with TRIM25 and 14-3-3, RIG-I translocates to MAVS-
containing mitochondrial membranes where the CARD domains interact and induce oligomerisation of MAVS. 
TRAF proteins are recruited to oligomerised CARD domains and conjugate K63-linked ubiquitin chains, which 
recruit NEMO, TBK1 and/or IKKε. TBK1 and IKKε are also recruited to NEMO and IKKε to ubiquitinated MAVS. 
NEMO then activates NF-κB through recruitment of the IKK complex and TBK1/IKKε activate IRF3. 
1.3.4 Outcomes of RIG-I signalling 
As previously described, RIG-I signalling results in the activation of IRF3 and NF-κB. Once activated, 
these transcription factors translocate to the nucleus, where they bind to specific sites in the 
promoter regions of many genes, inducing their transcription. 
The interferon regulatory factor (IRF) family of transcription factors are an important feature of anti-
viral immunity, regulating both innate and adaptive responses174. Once activated by 
phosphorylation, they form either homo- or hetero-dimers to become transcriptionally active175. 
IRF3 and 7 are the principal activators of IFN-I transcription after stimulation of cytosolic nucleic acid 
receptors. IRF3’s ubiquitous expression allows it to initiate early IFN-I induction and IRF7 is 
upregulated in response to IFN, sustaining IFN-I activation in a feed-forward regulation loop176,177. In 
addition to IFN-I, IRF3 can also activate transcription of genes including CXCL10, CCL5, ISG56 and 
interleukins like IL-12, -15 and -23178–183.  
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The IFN-I family consists of a single IFNβ and 13 sub-types of IFNα, as well as some other less well 
characterised proteins IFNε, IFNκ and IFNω184. IFNβ is produced by most cell types in response to IRF 
activation and IFNα is predominantly activated by IRF7 in specialised immune cells176,177. IFNα and β 
are secreted from cells and both bind to the IFNα receptor (IFNAR), activating the canonical IFN-I-
induced signalling pathway shown in Figure 1.3.4. This includes the JAK/STAT pathway, where 
kinases Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2) are activated by IFNAR, and in turn 
phosphorylate the transcription factors signal transducer and activator of transcription (STAT) 1 and 
2185. Once activated, STAT1 and 2 form homo-and hetero-dimers, of which hetero-dimers bind to 
IRF9, and in some cases IKKε, to form the IFN-stimulated gene factor 3 (ISGF3) complex. This 
complex binds to ISRE promoter elements, activating transcription of hundreds of interferon-
stimulated genes (ISGs), which constitutes an antiviral immune response186,187. Homodimers of 
STAT1 or 2 bind the GAS promoter, which activates an inflammatory response through transcription 
of genes like IRF1 and CXCL9.  
The Type III IFN (IFN-III) family, consisting of IFNλ1-4, is also frequently activated by virus infection 
188. IFN-IIIs signal through an independent receptor, interferon lambda receptor 1 (IFNLR1). IFNLR1 
is predominantly expressed in epithelial cells and some immune cell subsets, suggesting a function 
for IFN-III predominantly at mucosal surfaces189. Like IFNAR, IFNLR1 also activates ISGs through the 
canonical JAK-STAT pathway. 
ISG transcription is activated predominantly by IFN-I-mediated IFNAR activation, however expression 
of some ISGs like ISG56 occurs directly through IRF3190, which binds to their promoter independently 
of IFN-I activation. Generally, ISGs function is to control virus levels in infected cells and to protect 
neighbouring cells from infection. This is managed by proteins like MX1, which inhibits viral 
replication191 and IFITM proteins, which inhibit viral entry into cells192. Other ISGs, such as protein 
kinase R (PKR), zinc-finger antiviral proteins (ZAPs), tripartite motif (TRIM) family proteins and 
viperin also act synergistically as a positive feedback mechanism to enhance the antiviral response 
by further activating PRR signalling pathways193. One of the most highly induced ISGs is ISG15, which 
is a ubiquitin-like modifier protein that is covalently attached to other proteins, giving rise to many 
effects, such as sustained transcription of IRF3 through increased stability194, and inhibition of cell 
cycle progress through destabilisation of cyclin D1195. IFN further mediates the production of certain 
ISGs through activation of Phosphatidyl-Inositol 3-Kinase (PI3K) signalling196, as IFN-I binds to insulin 
receptor substrate-1 (IRS-1), which in turn binds PI3K to activate its regulatory subunit197. IFN can 
also modulate the function of ISGs through inducing alternative splicing, which in the case of ADAR1 
alters its cellular localisation198.  
16 
 
Activation of other signalling kinases like Janus-activated kinase (JNK), Extracellular signal-regulated 
kinase (ERK) and p38 mitogen-activated protein kinase (MAPK) by IFN-I and IFN-III is also essential 
for full immune activation and IFN-mediated control of certain viruses199,200. Activation of p38 MAPK 
is required for optimal ISG expression, as well as IFN-mediated control of certain viruses201–203. Erk 
mediates both IFNα-driven apoptosis and IFN-I induced inhibition of T-reg cell suppression of T and 
NK cells201,204, but also is essential for the transcription of Isg15 and Isg54 in mice205. In comparison, 
JNK signalling appears only to be weakly activated, but can promote pro-apoptotic and anti-viral 
signalling204,206. Finally, IFN activation also controls virus infection and immune gene transcription 
through affecting the expression of cellular miRNAs and lncRNAs207,208. 
 
Figure 1.3.4: A simplified pathway of activation of the IFN response by RIG-I 
Adapted from: 189,209 
IRF3 produced during RIG-I signalling binds to the IRES element in the promoter of both IFN-I and IFN-III genes, 
initiating their expression. Once expressed, they are secreted and bind to either IFNAR or IFNL1R on the 
surface of nearby cells, activating the Jak-STAT signalling cascade. Formation of the ISGF3 complex activates 
ISG transcription through binding to the ISRE element in their promoter, whilst STAT1 and STAT2 homodimers 
bind to the GAS element and activate pro-inflammatory genes.  
The other major transcription factor activated by RIG-I signalling is NF-κB. The NF-κB family of 
transcription factors consists of 5 structurally-related proteins: p50, p52, p65 (RelA), RelB and c-Rel. 
Once activated by degradation of IκBα, both homo- and hetero-dimers of these proteins mediate 
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transcription by binding to the κB enhancer elements in the promoters of target genes150. The 
primary function of NF-κB is to activate the transcription of pro-inflammatory genes, but the exact 
inflammatory response varies between cell types. In innate immune cells like macrophages, NF-κB 
induces transcription of cytokines (tumour necrosis factor alpha) TNF-α, interleukins IL-1β, IL-6 and 
IL-12p40 and cyclooxygenase-2210, whereas in T cells, NF-κB activation regulates T cell receptor (TCR) 
signalling211,212. NF-κB also regulates inflammasome activation, as the transcription inflammasome 
proteins NLRP3, pro-IL-1β and pro-IL-18 are dependent on NF-κB-activation, occurring 
predominantly through the post-translational modification of signalling pathway proteins or by 
binding proteins. 
1.3.5 Regulation of RIG-I signalling 
As described earlier, RIG-I is subjected to both activating and inhibitory post-translational 
modifications to control its RNA binding ability and ATPase activity, as well as to regulate activation 
of downstream signalling, shown in Figure 1.3.5. The ubiquitination of RIG-I by TRIM25 and Riplet is 
opposed by several de-ubiquitylating enzymes (DUBs), including ubiquitin specific peptidases (USP) 3 
and 21 and Cylindromatosis (CYLD), both of which specifically cleave K63-linked ubiquitin chains. 
M1-linked ubiquitination of TRIM25 by LUBAC also prevents RIG-I ubiquitination as it destabilises the 
TRIM25-RIG-I interaction213. Conjugation of differently linked ubiquitin chains, K48-linked ubiquitin, 
to the CARD and CTD of RIG-I by the E3 ligases Casitas B-lineage lymphoma proto-oncogene (Cbl) 
and ring finger proteins (RNF) 122 and 125, targets it for degradation214,215. This K48-ubiquitination is 
prevented by SUMOylation of RIG-I by TRIM38.  Premature activation of RIG-I is prevented by 
phosphorylation of its CARDs by protein kinase C (PKC) isoenzymes PKCα and PKCβ and the CTD by 
casein kinase II (CKII)216,217, modifications that prevent TRIM25 binding and K63-linked 
ubiquitination218,219. The ATPase activity of RIG-I can also be positively regulated by PACT, which 
binds to the CTD of RIG-I to stimulate its ATPase activity220,221, and RNA binding protein DEAH-box 




Figure 1.3.5: Regulation of RIG-I by post-translational modifications and binding proteins 
Adapted from 46.  
RIG-I signalling is regulated by deamidation (-NH3), phosphorylation (P), SUMOylation (SUMO), ubiquitination 
(U), deacetylation (-Ac) and binding proteins. Activating modifications are found in the green section above the 
RIG-I schematic and inhibitory modifications in the red section below. Modifications are indicated by a dashed 
black arrow, with inhibition of these modifications indicated by a red dashed arrow with a flat head. Binding is 
indicated by a solid black arrow. Proteins responsible for modifying/binding are named for each modification. 
 
Signalling is also regulated by post-translational modification of MAVS. Oligomerisation of MAVS 
requires K63-linked ubiquitination, catalysed by TRIM31223. This is promoted by O-GlcNAcylation at 
Ser366 of MAVS224, and phosphorylation by IKKε, which prevents the interaction of Fas-associated 
factor 1 (FAF1) with MAVS225. Recruitment of both TBK1 and IKKε to MAVS is promoted by TRIM-21 
mediated K27-linked ubiquitination and K63-linked ubiquitination of MAVS138,226, although K27-
linked ubiquitination by MARCH8 can also promote lysosomal autophagy of MAVS by NDP52227. 
MAVS is also modified by K48-linked ubiquitin chains at multiple sites by multiple E3 ligases: 
TRIM25228, AIP4229, PCBP1230, TAX1BP231, Smurf1, 2 and Ndfp1232,233, OTUD1234, MARCH5235 and 
RNF5236, all of which mediate degradation of MAVS by various mechanisms. These ubiquitin chains 
are removed by OTUD4 to stabilise MAVS230, and their formation is inhibited by various proteins like 
cyclophilin A, which competes with TRIM25 for MAVS binding237. Phosphorylation of MAVS by TBK1 
and IKKβ also positively regulates MAVS signalling by mediating recruitment of IRF3238, a mechanism 
blocked by PPM1A239.  
In addition to regulation by host proteins, RIG-I signalling is also negatively regulated by many RNA 
viruses to subvert their detection. Firstly, many viruses disguise their RNA, for example by encoding 
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a 2′-O-methyltransferase or covalently bonding either viral or host proteins to the 5’ end of their 
RNAs240–242. Additionally, viral proteins bind and sequester their own RNA to prevent detection243. 
After detection of viral RNA, subversion of signalling generally occurs through the prevention of 
ubiquitination of RIG-I by TRIM25, whose activity is directly inhibited by the NS1 protein of Influenza 
A virus (IAV) and Respiratory Syncytial virus (RSV)244,245, as well as proteins encoded by human 
papilloma virus (HPV), Epstein Barr virus (EBV), multiple Paramyxoviruses246,247 and Dengue virus 
(DENV) sub-genomic RNA248. The E3 ligase Riplet is also targeted by multiple viral proteins to inhibit 
ubiquitination of RIG-I249,250, and multiple viral-encoded DUBs function to remove ubiquitin 
modifications251. Downstream signalling is blocked by many viral proteins that inhibit RIG-I’s binding 
to MAVS252–254, or sequester it to a cellular location from which it cannot signal255.  
MAVS is itself also inhibited by many by viral proteins that either cleave or degrade it. Cleavage 
occurs through viral proteases encoded by Hepatitis C virus (HCV)256, Seneca Valley virus257, human 
rhinovirus C258, and coxsackievirus B3 (CVB3)259 and Hepatitis A260. Degradation of MAVS is mediated 
by viruses that promote the conjugation of K48-linked ubiquitin chains, such as Hepatitis B virus 
(HBV), HCV, Severe Acute Respiratory Syndrome (SARS) coronaviruses and rotaviruses261–264. 
Downstream signalling is inhibited by viral proteins that block the interaction of TRAF proteins with 
MAVS, such as human metapneumovirus (hMPV) M2-2, IAV NS1, HCV NS5A and the Nipah virus V 
protein265–268. Downstream signalling proteins are also targeted by viruses, mediated by direct 
interaction, prevention of signalling complex formation as is the case with SARS-CoV-2 Membrane 
protein269, or through mediating degradation, like the FMDV protein Lpro that targets TBK1270. As 
these signalling proteins are often common to many signalling pathways, their inhibition can block 
viral detection and downstream signalling from multiple receptors. 
1.4 Viruses 
1.4.1 Viruses as infectious agents 
Viruses are one of the five major categories of infectious agents and are obligate intracellular 
parasites. Previously described as “entities hovering on the threshold of life”271, they are simply 
made up of a nucleic acid genome encapsulated in a shell of proteins and sometimes lipids, meaning 
that they are dormant until they have entered a host organism. Viruses are a simple but incredibly 
diverse class of pathogen, ranging in size from only 20 nm for Parovirus particles to approximately 1 
μm for Ebola, and encoding anywhere between four and multiple-hundred proteins.  
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Viruses infect all known cellular organisms, including bacteria, fungi, metazoans and archaea, as well 
as all classes of animal and plant. For humans, virus entry into the body occurs predominantly 
through the mucous membranes in the nose, mouth, eyes, or breaches in the skin barrier. Infection 
arises through direct contact with contaminated objects, airborne droplet transmission, or via 
vectors such as mosquitos. Generally, the life cycle of a virus in a host cell has three main stages: 
entry, genome replication and exit272. Viruses enter cells by attachment to the cell membrane, 
penetration into the host cell cytoplasm, and uncoating of the protein shell to release its nucleic acid 
material. The viral genome is then used for replication and expression of viral proteins, which are 
assembled into new virus particles that are released from the cell. Viral infection often results in 
disease, caused by the disruption of normal cellular processes by the virus, often due to the hijacking 
of the cellular machinery to enable viral replication, production of viral proteins and release of new 
virus particles272.  
Since their discovery, viruses have been classified by many methods including shared morphology 
and genome type, with standard taxonomy determined by evolutionary relationships. The most 
commonly used classification today is the Baltimore classification, which is based on how messenger 
RNA is synthesised by the virus during its replication cycle273. Within this framework, there are four 
classes of RNA viruses: those with a double-stranded genome (Group III), those with either a positive 
(Group IV) or negative sense (Group V) single-stranded genome, and single stranded RNA viruses 
with a DNA intermediate in their life cycle (Group VI).  
1.4.2 The impact of viruses on humanity 
Humanity has felt the impact of viruses for long before their existence was discovered, most 
markedly by their ability to cause epidemic disease, a feature that began with the agricultural 
revolution, which put humans into contact with many new viruses, and has been further progressed 
by human migration, domestication of livestock and, most importantly to modern day society, the 
fact that most people now live in large, densely-populated communities271. Despite the invention of 
vaccines within this period, viruses have been the cause of the deadliest infectious events of the last 
100 years, including the 1918 Spanish Influenza outbreak, which is estimated to have killed 21 
million people274, the HIV/AIDS pandemic that has resulted in over 30 million people living with AIDS 
worldwide275, and the recent COVID-19 pandemic, which is likely to exceed the mortality of any 
novel virus since then. Virus infection is also the cause of a huge socio-economic burden276, as 




1.4.3 RNA viruses known to activate RIG-I 
In this study we are focused on the composition and outcomes of the RIG-I signalling complex, as 
well as how it is regulated. To enable our study of this, we employed multiple RNA viruses known to 
stimulate RIG-I, including respiratory viruses Sendai virus and IAV and arborvirus ZIKV. 
1.4.3.1 Sendai virus 
Sendai virus (SeV) is a Paramyxovirus with a single-stranded negative sense RNA genome and a lipid 
envelope containing glycoproteins as well as haemagglutinin (HA) and neuramidase (NA) proteins278. 
Despite its ability to infect humans, natural infection with SeV only appears to occur in the upper 
respiratory tract of rodents279,280. SeV is a potent and specific activator of RIG-I, producing one of the 
best characterised natural RIG-I agonists, a 546 nucleotide copyback genome RNA species281,282. This 
is especially true for the Cantell strain of the virus, which potently activates RIG-I due to the 
production of large amounts of defective interfering (DI) RNA genomes, produced when the 
polymerase leaves the cRNA template and back-copies the 5’ end of the viral RNA product during 
replication283. This results in short RNAs with perfect 5’ and 3’ complementarity that are 
preferentially bound by RIG-I over full-length viral. RIG-I’s specificity for SeV is also conferred by the 
SeV V protein, which inhibits the helicase activity of MDA5 to prevent MDA5-mediated signalling284. 
Additionally, the expression of the SeV C protein is absent from many DI-producing strains of SeV, 
preventing its well described inhibition of RIG-I285,286.  
Due to its ability to potently activate RIG-I, inducing a strong IFN-I response, SeV is used in basic and 
applied biology as a tool for delivering molecules into cells and for commercial generation of 
IFN287,288. More recently, SeV has been optimised for use in gene therapy techniques and as a virus 
vaccine adjuvant289,290. 
1.4.3.2 Influenza A virus 
Influenza A virus (IAV) is one of three strains of Influenza, all of which belong to the 
Orthomyxoviridae family of RNA viruses. IAV has a segmented single-stranded negative-sense RNA 
genome and is an enveloped virus. Like with SeV, the viral envelope contains the surface proteins 
hemagglutinin (HA), which allows it to bind to receptors on the surface of cells to facilitate viral 
entry, and neuraminidase (NA), which enables viral replication and release291. Influenza A viruses are 
further classified by their antigenic variation, determined by the combination of HA and NA variants 
expressed on the viral envelope, with 16 variants of HA and 9 variants of NA identified292.  
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IAV is one of the major causes of respiratory infections in humans and animals293, infecting between 
9 and 45 million Americans every year and generally causing constitutional and upper respiratory 
tract symptoms like fever, headache, cough and sore throat. However, cardiac, musculoskeletal and 
neurologic complications can result in severe disease highly pathogenic to humans294, with annual 
outbreaks resulting in approximately half a million deaths, mostly in the very young and old295–297. 
Much of the impact of IAV is enabled by its ability to undergo changes in the antigens present in its 
surface glycoproteins. This occurs both by antigenic drift, which makes small changes to the virus 
year on year; and antigenic shift, where reassortment of the viral genome with pre-existing strains, 
often from other species like pigs and chickens, results in a major change in the viral genome, often 
the cause of emergent pandemic strains of the virus298.  
IAV is predominantly sensed by detection of its RNA genome or host RNA present in dying IAV 
infected cells by PRR at the mucosal surface and in respiratory epithelial cells. This is generally 
mediated through RIG-I and NLRP3 in the cytoplasm, and TLR3, 7 and 8 in the endosome299. 
Detection by TLRs results in the production of pro-inflammatory cytokines and chemokines, 
restriction of virus replication and recruitment of innate and adaptive immune cells. Detection of IAV 
by RIG-I, which occurs both in the cytoplasm and nucleus of infected cells300, depends heavily on the 
production of both defective interfering panhandle genomes and short aberrant mini-viral RNAs 
during natural IAV infection301,302, resulting in activation of pro-inflammatory cytokines through NF-
κB and IFN-I by IRF3299.  
To help avoid detection by the majority of PRRs, IAV replicates in the nucleus of cells, like 
Bornaviruses and Orthomyxoviruses. Whilst in the nucleus, these viruses ‘steal’ mRNA cap structures 
from host RNAs to avoid detection by nuclear RIG-I303. Antagonism of innate immune signalling by 
IAV infection is predominantly mediated by NS1, which has functions as wide-ranging as binding and 
sequestering RNA, shielding RNA from detection by RIG-I, inhibiting the ubiquitination of RIG-I by 
TRIM25, blocking host gene expression and interfering with the function of ISGs like PKR and OAS304. 
1.4.3.3 Zika virus 
Zika virus (ZIKV) is a Flavivirus, closely related to Dengue (DENV) and Chikungunya (CHIVKV). It has a 
positive-sense single-stranded RNA genome encoding a polyprotein that is cleaved into three 
structural and seven non-structural proteins including a protease, helicase and RNA-dependent RNA 
polymerase (RdRp)305. Unlike both SeV and IAV, ZIKV is spread by a vector: the Aedes mosquito, 
although it can also be vertically transmitted during pregnancy306. First discovered in rhesus 
macaques in Uganda in 1947, ZIKV-mediated human disease was identified in 1952. After over 50 
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years of almost no identified cases of natural infection, ZIKV outbreaks began in 2007. Generally, 
symptoms were mild: fever, headaches, rashes, joint pain and conjunctivitis. However, more recent 
outbreaks have linked ZIKV infection with congenital microcephaly in new-borns and Guillian-Barre 
syndrome in adults307,308. 
ZIKV is detected by TLRs 3 and 7, initiating signalling cascades that activate an IFN-I and ISG 
response, as well as triggering apoptosis309. RIG-I also recognises the 5’ non-coding region of viral 
genomes and signals through MAVS to activate a pro-inflammatory and IFN-I response through NF-
κB and IRFs 3 and 7310. ZIKV infection also activates the cGAS-STING signalling axis311. The induction 
of both IFN-I and ISGs like IFIT1-3, Viperin and OAS1 by TLRs and RLRs restricts ZIKV replication312,313.  
ZIKV, like other flaviviruses, encodes many proteins to antagonise PRR signalling pathways. The ZIKV 
NS3 proteins binds the molecular chaperone 14-3-3 to inhibit translocation of RIG-I314; the NS4A 
protein binds to the CARD domain of MAVS, preventing its interaction with RIG-I252,315; and NS1, 
NS2a, 2b and 4b proteins reduce RIG-I-mediated TBK1 phosphorylation316. ZIKV NS5 binds both TBK1 
and TRAF6, preventing their interaction317, and also binds endogenous IRF3 to prevent IFN-I 
promoter activation 316. ZIKV can also inhibit the cGAS-STING pathway through cleavage of STING 
by NS2b3318, as well as Jak-STAT signalling319. 
1.5 LUBAC and M1-ubiquitin chains 
1.5.1 Ubiquitin 
Ubiquitin is a small, highly conserved and highly stable globular protein, expressed almost invariantly 
in every organism from yeast to humans320. In a process called ubiquitination, ubiquitin is conjugated 
to many proteins as a post-translational modification to regulate many cellular processes, from 
protein degradation and DNA damage responses to intracellular signalling and protein trafficking320. 
Ubiquitination of a target protein requires catalysis by an enzymatic cascade shown in Figure 1.5.1, 
consisting of three proteins: the E1 ubiquitin activating enzyme, the E2 conjugating enzyme and the 
E3 ubiquitin ligase. In order to conjugate ubiquitin to its substrate protein, the E1 enzyme activates 
ubiquitin by binding to its C terminus, a reaction which requires ATP. Activated ubiquitin is then 
transferred to the E2 conjugating enzyme, which forms a complex with the E3 ligase that binds the 
target substrate protein. This results in transfer of the ubiquitin moiety from the E3 to a lysine 
residue on the substrate protein321. To form ubiquitin chains, the E3 then unbinds the used E2 and 
binds to a new E2-ubiquitin complex and repeats the transfer of ubiquitin onto a residue on the 
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already-conjugated ubiquitin monomer. There are only two known E1 enzymes, about 40 E2 
enzymes, but over 600 known E3 ubiquitin ligases322. Such diversity in E3 ligase enzymes is required, 
as they confer substrate specificity, determined by protein and non-protein interaction domains, 
recruitment motifs, and sometimes ubiquitin chain-type specificity323. E3 ligases are classified into 
three types: RING (Really Interesting New Gene), HECT (Homologous to E6AP C-Terminus) and RBR 
(RING-between-RING), based on the structure and mechanism of action of their ligase domain. RING 
E3 ligases catalyse direct transfer of ubiquitin from the E2 to the substrate protein, whereas HECT 
and RBR ligases use a two-step process to catalyse this, via a cysteine residue in the E3323. 
 
 
Figure 1.5.1: The ubiquitination system  
Adapted from 321,324 
The E1 activating enzyme binds and activates ubiquitin, requiring ATP. It then transfers ubiquitin to the E2 
conjugating enzyme, which binds the E3 ligase, forming a complex that can bind the substrate protein. 
Ubiquitin is then transferred from the E2 to a lysine on the surface of the substrate protein, either directly, for 
RING ligases, or via a catalytic cysteine on the E3, for HECT and RBR ligases. 
 
The ability of ubiquitin to modulate such a broad range of processes is determined by its ability to 
form very diverse modifications, referred to as the ubiquitin code320. Substrate proteins can be 
modified by a single ubiquitin molecule at a single lysine residue, termed mono-ubiquitination; or at 
multiple lysine residues, multi-mono-ubiquitination. Once a substrate is modified by a single 
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ubiquitin, polyubiquitination occurs through the binding of additional ubiquitin moieties to the initial 
ubiquitin325.  
Polyubiquitination results in the formation of 8 different types of homotypic chains, due to the 
binding of additional ubiquitin moieties onto one of seven lysine residues on the previous ubiquitin, 
or its N-terminal methionine. M1-linked, otherwise known as linear, ubiquitin chains are joined in a 
head-to-tail fashion via the C-terminal carboxyl group and the N-terminal methionine. These 
different linkage types (M1, K6, K11, K27, K29, K33, K48 and K63-linked) have different functional 
significances. K48-linked ubiquitin chains are the most common modification, marking proteins for 
proteolytic degradation to regulate many cellular processes like cell division and development, the 
stress response and immune signalling pathways326. Both K11- and K29-linked chains have been 
established as secondary proteasomal degradation signals, with K11-linked chains used generally in 
cell cycle regulation326,327. Other ubiquitin chain-linkage types are non-degradative, with K6-linked 
chains possibly involved in mitochondrial homeostasis328 and K33-linked chains predominantly 
involved in protein trafficking and signalling regulation329. The remaining chain types, K63-, K27- and 
M1-linked ubiquitin chains are involved in the regulation of diverse signalling pathways. The most 
common of these are K63-linked chains321, which have a similar structure and function to M1-linked 
chains331. K27-linked chains are the least well understood but are thought to serve as scaffolds in the 
DNA damage response, recruiting downstream signalling proteins327. 
Heterotypic ubiquitin chains, characterised by the modification of multiple residues of a single 
ubiquitin moiety in the ubiquitin chain, are more recently discovered332. Their function can differ 
from or improve the function of either of chain linkage-types it is comprised of, thought to occur due 
to an increased concentration of ubiquitin close to the substrate protein. For example, K11/K48-
linked heterotypic chains result in more efficient proteasomal degradation than seen with K11 or 
K48-linked chains alone, by improving recognition of the substrate protein by the proteasome333. 
Similarly, K29/K48- and K48/K63-linked ubiquitin chains reveal novel pathways to proteasomal 
degradation334,335. M1/K63-linked chains, generated by the modification of K63-linked chains with 
M1-linked chains to form branched or mixed hetero-typic structures mediated the recruitment of 
kinases and activation of NF-κB and inflammatory signalling downstream of many immune 
receptors336–338, with the mixed chains improving signalling outcomes by more efficiently bringing 
together downstream signalling proteins like NEMO and the TAK1 complex339,340, increasing the 
speed and accuracy of signalling332. 
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1.5.2 LUBAC  
Unlike other ubiquitin linkages, which are generated by multiple E3 ligases, only the Linear Ubiquitin 
Chain Assembly Complex (LUBAC) is capable of generating M1-linked ubiquitin chains in humans341. 
LUBAC is a 600 kDa complex of unknown stoichiometry composed of three subunits: HOIL-1-
interacting protein (HOIP), Heme-oxidised IRP2 Ubiquitin ligase-1 (HOIL-1), and Shank-associated RH 
domain-interacting protein (SHARPIN)341–344, shown with interactions indicated in Figure 1.5.2. The 
complex is formed by interactions between the ubiquitin-like (UBL) domains of HOIL-1 and SHARPIN 
and the ubiquitin associated (UBA) and nuclear protein localisation 4 (Npl4) zinc finger (NZF) 
domains of HOIP342–345, stabilised by long-term interactions between the LUBAC tethering motif 
(LTM) domains of HOIL-1 and SHARPIN346,347. 
 
Figure 1.5.2: Schematic representation of the domain structure and interactions between the LUBAC 
components. Adapted from 331. 
Domains of each LUBAC component consist of LUBAC tethering motif (LTM), ubiquitin-like (UBL), nuclear 
protein localisation 4 (Npl4) zinc finger (NZF), really interesting new gene (RING), in-between-RING (IBR), 
peptide:N-glycanase/UBA- or UBX-containing proteins (PUB), zinc finger (ZF), ubiquitin-associated (UBA), linear 
ubiquitin chain determining domain (LDD) and pleckstrin homology (PH). Interactions between proteins 
indicated by thick double-headed arrows and long-distance stabilising interactions by dashed double-headed 
arrows. 
 
Both HOIP and HOIL-1 are RBR E3 ligases, but only HOIP is capable of generating M1-linked ubiquitin 
chains, a unique function enabled by the position of its linear ubiquitin chain determining domain 
(LDD) 345,346,348–350. HOIL-1 and SHARPIN function as part of the LUBAC complex to stabilise HOIP in an 
active conformation, with HOIP otherwise auto-inhibited by interactions between its RBR domain 
and N-terminus349. In addition to removing the auto-inhibition, binding of either SHARPIN or HOIL-1 
to HOIP facilitates the E2 enzyme-mediated loading of HOIP, enabling ubiquitination to occur346. 
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HOIL-1 and SHARPIN are also required for the stability of HOIP expression in some contexts342–
344,347,349,351. 
Despite earlier reports that HOIL-1 only has very week ligase activity, dispensable for LUBAC 
activity349, it has more recently shown to play a vital role in LUBAC’s function. First, initial 
ubiquitination of NEMO was shown to require catalysis by the RBR domain of HOIL-1 as well as 
HOIP352. HOIL-1 is also able regulate to the E3 ligase activity of LUBAC by mono-ubiquitination of all 
three subunits, which in turn directs HOIP to auto-ubiquitinate itself, preventing generation of M1-
linked ubiquitin chains353. Finally, HOIL-1 can generate an atypical oxyester ubiquitin linkage, 
enabling conjugation of ubiquitin to serine and threonine residues on substrate proteins, instead of 
the typical lysine, resulting in the HOIL-1-catalysed conjugation of ubiquitin chains to IRAK1, 2 and 
MyD88, as well as itself and SHARPIN354. Generation of oxyester linkages by HOIL-1 has been 
suggested to catalyse M1-linked ubiquitination through a co-ordinated relay between HOIL-1 and 
HOIP, as well as promote the generation of heterotypic K63/M1-ubiquitin chains in both TNF and 
TLR signalling338,355, with varying signalling outcomes355,356.  
SHARPIN does not have a ligase domain so is incapable of generating ubiquitin chains itself, however 
it helps determine the target of M1-ubiqutination, directing it to NEMO during TLR signalling330,331. It 
also appears to have a specific function in protecting cells from immune receptor-driven cell 
death343,357–360, although the exact mechanism by which this occurs is unknown. SHARPIN functions 
as a regulator of anti-apoptotic and anti-pyroptotic pathways343,359,361, meaning that it is regarded as 
a proto-oncogene362, upregulated in many types of human cancer with a specific role as a metastasis 
gene and prognostic marker for breast cancer363. Cancer regulation is thought to primarily occur 
through SHARPIN’s role in LUBAC, controlling activation of the NF-κB pathway resulting in 
upregulation pro-survival genes364, and through LUBAC-mediated ubiquitination and degradation of 
PKCζ, enhancing tumour size and adaptation365. 
1.5.3 Regulation of LUBAC 
The constitutive activation of LUBAC even in the absence of upstream signalling, due to the binding 
of HOIL-1 and SHARPIN to HOIP removing auto-inhibition of HOIP342–344, means that its function must 
be tightly regulated. This negative regulation is carried out by the deubiquitinases (DUBs) OTU 
Deubiquitinase With Linear Linkage Specificity (OTULIN) and Cylindromatosis (CYLD), proteases 
which bind to and cleave M1-linked ubiquitin chains366–369. OTULIN hydrolyses only M1-linked 
ubiquitin chains, due to its highly selective binding of M1-chains and a specific mechanism of 
substrate-assisted catalysis caused by the binding position of the proximal ubiquitin in M1-linked 
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chains that activates the protease366,367. Conversely, CYLD hydrolyses both K63-linked and M1-linked 
ubiquitin chains368,369. In addition to hydrolysing M1-linked ubiquitin chains, OTULIN, but not CYLD, 
also prevents LUBAC from auto-ubiquitination367,370–372. The DUB A20 can also bind to M1-linked 
ubiquitin chains but does not hydrolyse them373,374.  
To enable regulation, both OTULIN and CYLD form complexes with LUBAC. For OTULIN, this occurs 
through the binding of the PIM domain of OTULIN to the PUB domain of HOIP371,375, whereas for 
CYLD, complex formation is mediated by the adaptor protein Spermatogenesis-associated 2 
(SPATA2), which interacts with the USP domain of CYLD and the PUB domain of HOIP, resulting in a 
CYLD-SPATA2-LUBAC complex376–379. Only either OTULIN or SPATA2 can bind to the PUB domain of 
HOIP, so each LUBAC complex is regulated by only one of either OTULIN or CYLD374,380. 
Disassembly of M1-linked ubiquitin chains by OTULIN and CYLD negatively regulates activation of NF-
κB in many signalling pathways. It is thought that the DUBs regulate LUBAC differently in different 
signalling contexts, as only CYLD translocates with LUBAC to the TNF-RSC374,375,378, and depletion of 
OTULIN results in differing outcomes in different cell-types381. As A20 can’t hydrolyse M1-linked 
ubiquitin chains upon binding, it instead negatively regulates TNFRSC signalling by blocking the 
binding of NEMO to M1-linked ubiquitin chains382,383. Conversely, the formation of K63-/M1-linked 
heterotypic chains prevents cleavage of K63-linked chains by A20, regulating signalling 
pathways373,374. 
LUBAC is also targeted by pathogen effector proteins, preventing its function. Viral effectors include 
HCV protein NS3332, which binds the NZF2 domain in HOIP to compete for NEMO binding and 
porcine reproductive and respiratory syndrome virus (PRRSV) proteins Nsp1α, which prevents the 
HOIP-SHARPIN interaction. Bacterial effectors inhibit NF-κB activation by degrading M1-ubiquitin 
chains, like the M1-linked ubiquitin-specific DUB RavD encoded by Legionella; or by targeting LUBAC 
for degradation like Shigella K48-linked ubiquitin specific ligases IpaH1.4 and IpaH2.5331. Conversely 
Salmonella typhimurium and Mycobacterium tuberculosis are thought to enhance LUBAC 
activity384,385, although the reasons for this are unknown. 
1.5.4 The importance of LUBAC in humans 
The importance and biological significance of LUBAC in human physiology are best illustrated by the 
study of disease-causing mutations in both HOIP and HOIL-1. Mutation of HOIP results in 
dysregulation of the immune system, resulting in immunodeficiency and increased susceptibility to 
repeated bacterial and viral infection infections, caused by impaired NF-κB in fibroblasts and B 
cells386,387. Contrastingly, mutation of HOIP also causes PBMC-driven auto-inflammation, induced by 
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aberrant cell death and hypersensitivity of monocytes causing excessive pro-inflammatory cytokine 
production. However, additional clinical characteristics like amylopectinosis and systemic 
lymphangiectasia only occurred when mutation resulted in reduced HOIP expression, destabilising 
LUBAC386. HOIP has also been implicated in activated B-cell-diffuse large B-cell lymphoma (ABC-
DLBCL), caused by increased association of HOIP and HOIL-1, resulting in chronic activation of the B-
cell receptor388,389. 
Mutations in HOIL-1 have been identified and characterised in in 16 individuals, with similarly wide-
ranging phenotypes to HOIP: immunodeficiency and increased susceptibility to infection, auto-
inflammation and amylopectinosis390–392. Again, immunodeficiency and auto-inflammation were 
caused by impaired signalling in fibroblasts and B cells, but hypersensitive monocytes, suggesting 
HOIL-1 mutant phenotypes are predominantly caused by impaired function of LUBAC392. However, 
the presence of additional clinical symptoms not seen in HOIP mutant patients, such as muscle 
weakness and cardiomyopathy, both resulting from dysregulated glycogen storage, demonstrates 
the significance of LUBAC-independent roles of HOIL-1390–392.  
Mutations in the E2 ligase that associates with HOIP and HOIL-1, UBE2L3, have been linked with 
systemic lupus erythematosus and other autoimmune diseases393,394. Similarly, mutations in the 
LUBAC-specific DUB OTULIN, abolishing its catalytic activity, are found in patients with an auto-
immune disease characterised by severe inflammation381,395. 
Attempts to delete LUBAC components in mice compound the importance shown by human 
mutation. Full deletion of both HOIP and HOIL-1 results in embryonic lethality due to endothelial 
damage caused by aberrant TNF-driven cell death351,396,397, as does endothelial-specific deletion of 
HOIP and expression of a catalytically inactive HOIP mutant337,396,398. Conversely, mice with B cell and 
alveolar epithelial cell-specific deletions of HOIP are viable397,399, highlighting the importance of 
LUBAC in maintenance of the vascular architecture of the endothelium during embryogenesis. Mice 
expressing a truncated version of HOIL-1 show similar clinical manifestations to HOIL-1 mutation in 
humans, with amylopectin-like deposits and an extreme susceptibility to certain infections400,401. 
No disease-causing SHARPIN mutations have yet been identified in humans, and SHARPIN-deficient 
mice are viable, caused by a mutation in exon one of SHARPIN that introduces a premature STOP 
codon402, displaying an inflammatory skin phenotype termed chronic proliferative dermatitis (cpdm), 
but without developmental issues402,403.  
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1.5.5 LUBAC-mediated regulation of immune signalling pathways 
LUBAC was first shown to be capable of generating M1-linked ubiquitin chains in 2006341, and was 
later described to modulate immune signalling, specifically NF-κB activation and TNF-RSC 
signalling401,404–406. Since then, LUBAC has been shown to regulate cell death signalling322,407; 
activation of NF-κB by many ligands including IL-1β, CD-40, peptidoglycan (PGN), and 
LPS336,337,342,343,408,409; NOD2 signalling410; TLR signalling 337,357,411–413; and RLR signalling 214,399,414,415.  
The best characterised mechanism of LUBAC-mediated regulation is during TNFR signalling, shown in 
Figure 1.5.5. Upon activation by TNFα, the TNF receptor recruits TNFR type 1-associated DEATH 
domain protein (TRADD), TRAF2, RIP1 and cellular inhibitor of apoptosis proteins (cIAPs) 1 and 2. 
LUBAC is recruited by binding to the K63-linked ubiquitin chains produced by cIAP1/2. At this point, 
LUBAC adds M1-linked ubiquitin chains to both RIP1 and NEMO401,404, as well as to pre-established 
K63-linked chains, generating K63-/M1-linked heterotypic chains336,337. This results in the formation 
of the TNF receptor signalling complex I (TNF-RSC-I) and increased recruitment of NEMO339,416, 
promoting its oligomerisation and allowing activation of IKKα and β, which in turn enable activation 
of NF-κB through phosphorylation of its inhibitor IκBα. In the absence of LUBAC, or indeed cIAPs, 
TBK1 and IKKε are not recruited to the TNF-RSC, meaning that RIPK1 is not phosphorylated417. Un-
phosphorylated RIP1 is active, driving formation of TNF-RSC-II and activation of apoptosis through 
caspase 8, or necroptosis through formation of the RIP1 necrosome with RIP3 and MLKL418.  
 
Figure 1.5.5: LUBAC-mediated regulation of the signalling outcomes of the TNF-RSC.  
Adapted from 419,420. 
LUBAC mediates formation of the receptor signalling complex I by enabling recruitment of NEMO to activate 
NF-κB, and recruitment of TBK1, to phosphorylate RIP1 and keep it in its inactive state. LUBAC is recruited to 
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K63-linked chains on RIP1 generated by cIAPs. In turn, modification of RIP1, NEMO and pre-existing K63-linked 
chains with M1-linked ubiquitin chains results in efficient recruitment of NEMO and downstream signalling. 
Dashed grey arrows represent protein recruitment to the signalling complex, with solid black arrows 
representing modifications performed by the protein from which they originate.  
 
LUBAC functions similarly in other immune signalling pathways, conjugating M1-Ub chains to other 
targets including RIPK2, TRADD, TNFR1 itself, IRAK1/2/4 and MyD88420. M1-/K63-linked heterotypic 
chains are also conjugated to NEMO in IL-1β and MAVS signalling, RIPK1 in TLR3 signalling, and RIPK2 
in NOD2 signalling336,337.  
LUBAC is also implicated in the immune response to intracellular bacteria, with HOIP binding to the 
ubiquitin coat already assembled on the surface of bacteria and in turn assembling M1-linked chains 
on the surface, acting as a signalling platform and recruiting NEMO and Optineurin to stimulate 
xenophagy and NF-κB activation421–423. Additionally, LUBAC is recruited to cytoplasmic protein 
aggregates, modifying them with M1-ubiquitin. In the case of Huntingtin, this shields the surface of 
the misfolded protein from unwanted interactions known to contribute to Huntingdon’s disease424. 
LUBAC also functions in adaptive immunity, regulating regulatory T cell development and 
homeostasis425, and T and B cell differentiation397,426. It also functions in non-immune signalling 
pathways, regulating genotoxic stress-induced NF-κB activation406. Furthermore, the recently 
identified broad landscape of interacting proteins of LUBAC and its respective DUB OTULIN, suggests 
that LUBAC has additional functions we don’t yet understand427. 
1.5.6 LUBAC and RNA sensing 
To date, LUBAC has been shown to regulate signalling downstream of three RNA sensors: TLR3, 
MDA5 and RIG-I. Whilst LUBAC’s role in TLR3 and MDA5 signalling is clear357,415, research surrounding 
its role in RIG-I signalling is conflicting135,214,358,399. 
In TLR3 signalling, LUBAC forms part of the TLR3-RSC and HOIP and SHARPIN are both required for 
TLR3-driven NF-κB and MAPK signalling357. Additionally, LUBAC was found to inhibit TLR3-mediated 
cell death induction, through restricting formation of the TLR3-induced death-inducing signalling 
complex (DISC) composed of cIAP1/2, FADD, RIP1 and caspase 8428,429, with cells lacking either HOIP 
or SHARPIN sensitised to Poly(I:C) and IAV-induced cell death357. This is reinforced by a previous 
study that implicated SHARPIN in TLR3-driven NF-κB activation in BMDCs404. LUBAC is also required 
for the MDA5-driven antiviral response to murine norovirus (MNoV) and Theiler's murine 
encephalomyelitis virus (TMEV), with reduced IFN-I and IFN-III responses in MEF cells expressing a 
truncated version of HOIL-1 and in HOIL-deficient BMDC, as well as limiting virus replication415.  
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1.5.7 LUBAC and RIG-I signalling 
In studies using a variety of cell lines and techniques, individual LUBAC components shown to 
contribute differently to RIG-I-driven signalling outcomes.  
Firstly, through overexpression studies, HOIP and either HOIL-1 or SHARPIN were shown to 
negatively regulate RIG-I signalling214,358,430, but this was disputed by experiments using knockout or 
knockdown cell lines. Studies using knock-down techniques showed that HOIP contributed modestly 
to RIG-I signalling, with cells expressing a reduced level of HOIP having similar or reduced IRF3 and 
NF-κB-driven signalling outcomes in response to infection with VSV and IAV WSN in both MEF and 
A549 cells135,214,399. However, studies in cells expressing a truncated version of HOIL-1, or cells where 
HOIL-1 expression is reduced, have yielded conflicting results about its influence on RIG-I signalling. 
HOIL-1 was shown to negatively regulate RIG-I-driven IFN-I and NF-κB activation in some 
studies135,214,358,431, but to have no effect on or be required for RIG-I-driven responses in others399,415. 
Finally, SHARPIN had mixed effects on RIG-I driven immune signalling, with cells lacking SHARPIN 
shown to have both increased and reduced IFN-I activation in response to VSV and SeV infection, but 
consistently reduced NF-κB-driven signalling135,358. Varying mechanisms have been suggested for 
LUBAC’s influence on RIG-I signalling outcomes, with LUBAC suggested to bind and mediate the 
degradation of TRIM25214, to conjugate M1-linked ubiquitin chains to NEMO to prevent its 
interaction with TRAF3 and the formation of the MAVS-TRAF3 signalling complex358, and to function 
redundantly with TRAF proteins to generate ubiquitin chains for the recruitment of downstream 
signalling proteins135. 
As seen with many other immune receptors, including TLR3357, LUBAC is suggested to regulate RIG-I-
driven cell death, although again with varying outcomes. Cells lacking SHARPIN were sensitised to 
VSV-driven cell death358, but mice expressing a truncated version of HOIL-1 showed improved 
survival and reduced cell death in the lungs during IAV infection399. Furthermore, LUBAC has been 
implicated in driving the RLR-induced IRF3-mediated pathway of apoptosis (RIPA)432. This occurs 
through LUBAC-mediated conjugation of M1-Ub chains to IRF3, mediating the binding of Bax by IRF3, 
allowing it to initiate the release of the cytochrome C from the mitochondria, which both induces 
apoptosis433 and restricts viral replication434,435. 
1.5.8 M1-ubiquitin chain-independent functions of LUBAC 
The majority of the functions of LUBAC rely on its ability to generate M1-linked ubiquitin chains, with 
the catalytic activity of the HOIP RBR domain shown to be required for driving NF-κB and MAPK 
activation downstream of multiple immune receptors348,396,397,412,436, as well as for prevention of TNF-
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driven cell death, by enabling recruitment of TBK1 and IKKε to the TNF receptor signalling 
complex396,417. 
However, LUBACs role in some signalling pathways does not rely on its ability to generate M1-linked 
ubiquitin chains. The ubiquitin ligase activity of HOIP is dispensable for B cell-receptor mediated 
activation of NF-κB and ERK, despite being responsible for TNF and CD-40-induced NF-κB and ERK in 
B cells397. Similarly, the catalytic activity of HOIP is dispensable for T cell receptor (TCR)-mediated NF-
κB activation, but not TNF-mediated NF-κB activation in T cells436. This is further reinforced by the 
fact that silencing of OTULIN in T cells affects TNF-driven but not TCR-mediated NF-κB activation436. 
Despite the non-requirement for LUBACs enzymatic activity in these pathways, no alternative 
mechanism of regulation, such as acting as a scaffold protein, has been proposed. 
1.5.9 LUBAC-independent functions of HOIL-1 and SHARPIN  
Both HOIL-1 and SHARPIN have additional roles outside of LUBAC. For HOIL-1, these roles focus 
predominantly on its role as an K48-linked ubiquitin ligase, regulating multiple cellular pathways by 
targeting signalling proteins for degradation437. Targets includes oxidised iron regulatory protein 2 
(IRP2), whose iron-dependent ubiquitination and degradation results in expression of iron-
containing protein ferritin438,439, since disputed440. Similarly, HOIL-1 induces the degradation of 
Bach1, preventing its repression of haem oxygenase 1 (HO-1) transcription, activating haem 
metabolism and resolution of oxidative stress441–443. 
HOIL-1 also independently regulates specific immune signalling through: the binding and mediation 
of degradation of PKCβ and PKCζ, regulating protein kinase C signalling and tumour cell survival 
during hypoxia365,444–446; the binding and degradation of TAB2 and 3, regulating TNF and IL-1 induced 
NF-κB activation440; ubiquitination and degradation of pregane X receptor (PXR), a transcriptional 
regulator that affects multiple immune and inflammatory responses447,448; and interaction with eyes 
absent (Eya) 1 and 2, co-activators of essential transcription factors for organ development449,450. 
Outside of LUBAC, SHARPIN plays a role in prevention of cancer progression. This occurs through the 
binding of SHARPIN to Protein arginine methyltransferase 5 (PRMT5), resulting in epigenetic 
regulation of chromatins with cancer metastasis-related genes451; and through association with Yes-
associated protein (YAP), promoting its degradation and cancer progression452. SHARPIN is also 
implicated in regulating the development and function of Treg cells425,453–455, promoting lymphocyte 
migration456 and preventing unnecessary platelet aggregation457. Additionally, SHARPIN interacts 
with and inhibits integrin to regulate cellular adhesion458, as well αIIbβ3 to enable platelet 
aggregation, MHC-I antigen presentation and inflammation457. Finally, SHARPIN has also been 
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identified as a genetic risk factor for Alzheimer’s disease 459,460, due to its role in mediating Aβ 
protein clearance, preventing pathogenic Aβ accumulation seen in Alzheimer’s.  
1.6 Thesis aims and objectives 
The role of LUBAC and M1-linked ubiquitin chains downstream of many immune signalling receptors 
is well characterised, with clear and consistent signalling outcomes and even in some cases, a 
specifically defined mechanism of action. This is not the case for RIG-I signalling, with conflicting 
signalling outcomes and multiple contradictory mechanisms attributed to LUBAC. These previous 
studies utilised overexpression systems and incomplete knockdown or knockout systems to study 
the role of LUBAC, and often the contribution of individual LUBAC components has been attributed 
to the complex as a whole. Therefore, the aim of this project was to understand how HOIP, HOIL-1 
and SHARPIN, the LUBAC complex as a whole, and M1-linked ubiquitin chains regulate the RIG-I 
signalling complex and its outcomes. To understand the mechanism by which LUBAC regulates the 
composition of the RIG-I signalling complex and its outcomes, a better understanding of what 
proteins were involved and what their individual contribution to signalling outcomes was needed. 
As such, this work aimed to: 
• Define and generate a system by which the RIG-I signalling mechanism and its outcomes can 
be measured, 
• Characterise the contribution of individual components thought to be in the RIG-I signalling 
complex to signalling outcomes in our system, 
• Assess the individual contribution of HOIP, HOIL-1, SHARPIN and M1-linked ubiquitin chains 
to RIG-I signalling outcomes, 





Chapter Two: Materials and Methods 
2.1 Maintenance of cell lines 
2.1.1 Wild-type cell lines 
Cell lines used for experiments in this study are shown in Table 2.1.1. A549 and MEF cells were a 
kind gift from the lab of Henning Walczak (University of Cologne) and U251 cells were from Dr. 
Nerea Irigoyen (University of Cambridge). 
Cell line Species Origin Tissue Cell Type 
A549 Human Lung Adenocarcinomic human alveolar 
basal epithelium 
HaCaT Human Skin Transformed aneuploid immortal 
keratinocytes 
HEK293T Human Kidney Immortalised embryonic kidney  
(Madin-Darby Canine 
Kidney) MDCK 
Dog Kidney Kidney epithelium 
MEF Mouse Skin Immortalised embryonic 
fibroblasts 
U251 Human Brain Glioblastoma astrocytoma 
Vero African green monkey 
(Chlorocebus sp) 
Kidney Kidney epithelium 
Table 2.1.1: Wild-type cell lines used in this study 
Model cell lines used for these studies, their species, origin tissue and cell type. 
2.1.2 Edited cell lines 
To study the function of various proteins in RIG-I signalling, cell lines deficient for these proteins 
were used, which were either developed as part of this project using CRISPR/Cas9 technology 
described in Chapter 2.2 or were kind gifts from collaborators. Wild-type parental cell lines used for 
generation of knockout cells were used for comparison in the following studies. The origin of edited 
cell lines is detailed in Table 2.1.2.  
Cell line Developed (group) Location Reference 
A549 RIG-I -/- This study University of Cambridge (unpublished) 
A549 TKO 
(TANK/NAP1/SINTBAD -/-) 
Henning Walczak University of Cologne  
A549 OPTN -/- Henning Walczak University of Cologne 333 
A549 NEMO -/- Henning Walczak University of Cologne 333 
A549 NEMO -/- + TAP-NEMO Henning Walczak University of Cologne 333 
A549 RIP1 -/- Henning Walczak University of Cologne  
A549 HOIP -/- Henning Walczak University of Cologne 334 
A549 HOIP -/- + TAP-HOIP-
WT 
Henning Walczak University of Cologne 334 
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A549 HOIP -/- + TAP-HOIP-
C885S 
Henning Walczak University of Cologne 333 
 
A549 SHARPIN -/- This study University of Cambridge (unpublished) 
MEF TNF -/- HOIL +/- Henning Walczak University of Cologne 335 
MEF TNF -/- HOIL -/- Henning Walczak University of Cologne 335 
Table 2.1.2: Genetically edited cell lines used in this study 
 
2.1.3 Maintenance conditions 
All cell lines were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) with 4.5 g/L D-glucose, 
8mM L-glutamine and Sodium Pyruvate (Gibco), supplemented with 10% foetal calf serum (FCS, Pan 
Biotech) and 100 U/mL Penicillin and Streptomycin (Gibco). Cells were incubated at 37°C, 5% CO2 
and 3% O2 in a humidified incubator. 
2.1.4 Passaging cells 
Cells were passaged when they reached approximately 95% confluence. Monolayers were washed 
twice with sterile PBS (Sigma) and incubated with Trypsin/EDTA (Lonza) until they began to detach 
from the bottom of the flask. Detached cells were resuspended in DMEM 10% FCS and either 
counted and seeded for experiments, or approximately 10% were transferred to a new flask to 
continue passaging. 
2.1.5 Seeding cells for experiments 
Cells were trypsinised as described above (2.1.4), mixed 1:1 with Trypan Blue (Sigma), and live cells 
that had not taken up the Trypan blue were counted using a haemocytometer. For qPCR, ELISA and 
Vitality Assay analyses, cells were seeded in 6-well plates, at 70% confluence for transfection of 
synthetic RNAs (5.5x105 cells per well), and 80-90% confluence for virus infection (6x105 cells per 
well). For phosphoblotting, cells were seeded in 10 cm dishes at 80% confluence (3x106 cells per 
dish). For phos-flow analysis, cells were seeded in 6 cm dishes at 80-90% confluence (1x106 cells per 
dish). For co-immunoprecipitation cells were seeded in 15 cm dishes at 70% confluence (5x106 cells 
per dish). For qPCR and ELISA, either duplicate or triplicate wells were seeded for each experimental 
condition (n=2 or 3) and for phosphoblotting, co-IP or phos-flow one dish was seeded per condition 
(n=1).  
2.2 Generation of cell lines by CRISPR/Cas9 
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 technology was used to 
generate RIG-I and SHARPIN deficient A549 cells as part of this study. 
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2.2.1 CRISPR Guide Design 
The human genomic sequences of RIG-I and SHARPIN were identified on ENSEMBL 
(http://www.ensembl.org/index.html: DDX58 (RIG-I) ENSG00000107201 and SHARPIN 
ENSG00000179526). The correct start codons were identified by translation of the exon DNA 
sequence using Expasy (www.web.expasy.org/translate/) and comparing it to the protein sequence 
on Uniprot (www.uniprot.org/). Small guide (sg)RNAs were designed using Benchling 
(www.benchling.com) by selecting the first few of the gene of interest after the start codon. From 
suggested guides, the ones with the best on- and lowest off-target effects, not located over an 
intron-exon junction, were chosen. Guides were synthesised as forward and reverse complimentary 
DNA oligonucleotides (IDT) with BbsI restriction sites, to enable annealing into the pSpCas9(BB)-2A-
GFP (PX458) plasmid (Addgene #48138), created by the Zhang lab336 and donated by Geoffrey Smith 
(University of Cambridge). Guide sequences responsible for successful knock-out of RIG-I and 
SHARPIN are shown in Table 2.2.1. 
Gene  Exon targeted Guide sequence Orientation 
DDX58 1 AAAGTCCAGAATAACCTGCA  antisense  
SHARPIN 2 CCTAGTCCGAGGTGCCACCG sense 
Table 2.2.1: sgRNAs used for CRISPR/Cas9 knockout generation 
Target gene and exon, guide sequence and orientation used for successful generation of knockout A549 cells 
2.2.2 Cloning of constructs 
sgRNA DNA oligos were diluted to 10 μM in nuclease free water (NF-H2O) and 5 μL of each forwards 
and reverse guide was combined in a polymerase chain reaction (PCR) tube (Starlab) and heated to 
75 °C for 15 minutes using a Veriti thermocycler (Applied Biosystems). The thermocycler was then 
switched off and allowed to cool to room temperature to allow annealing. Annealed primers were 
diluted to 20 nM in NF-H2O. 
3 μg of pSpCas9(BB)-2A-GFP (PX458) plasmid was digested with BbsI-HF (NEB), run on a 1% agarose 
gel at 120 V, visualised using a UV light box and excised using a scalpel. DNA was extracted from the 
agarose gel using a QIAquick Gel Extraction Kit (Qiagen) and eluted in 10 μL NF-H2O. The DNA 
concentration and purity was measured using a NanoDrop 2000 spectrophotometer.  
sgRNAs were ligated into the digested plasmid at a 3:1 (insert:plasmid) molar ratio using T4 DNA 
ligase (Promega). The ligated plasmid was transformed into Stbl3 E. Coli by heat-shocking, allowed to 
grow for 1 hour at 37 °C, spread onto LB agar with Carbenicillin (50 μg/mL) and incubated at 37 °C 
for 16 hours. Colonies were picked and grown in 5 mL LB Carbenicillin at 37 °C for 16 hours for a 
Miniprep; or 8 hours for a maxiprep, before being diluted in 250 mL LB Carbenicillin and grown at 37 
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°C for 16 hours. DNA was purified using a QIAprep Spin Miniprep/Maxiprep kit (Qiagen) and DNA 
concentration was measured using a NanoDrop 2000 spectrophotometer.  
Constructs were sequenced to ensure that the guide had been inserted into the plasmid in the 
correct orientation, without introducing any additional mutations. 
2.2.3 Transfection of CRISPR constructs 
A549 cells were seeded at 70% confluency in a 10 cm dish and 5 μg of each plasmid was transfected 
using TransIT-LT1 transfection reagent (Mirus) at a ratio of 3 μL per μg DNA, in 1 mL of OptiMEM 
(Gibco). TransIT-LT1 and OptiMEM were incubated for 5 minutes, DNA was added, and the mix was 
incubated for a further 1 hour before being added dropwise onto cells in DMEM 10% FCS 1% P/S.  
2.2.4 Cell Sorting and Cloning 
After 24 hours, GFP fluorescence was checked using a fluorescence microscope to indicate positively 
transfected cells. A further 24 hours later, GFP-expressing cells were collected using a Mo Flo Sorter 
(Beckman Coulter) and clonal populations were established by single cell sorting into a 96-well plate. 
Clonal cell lines were established by passaging  until they were in a 6-well plate. 
2.2.5 Confirmation of successful knock-out 
Putative knock-out clones were first screened by Western blotting (2.6) to check for absence of 
expression of the target protein. From clones lacking expression, genomic DNA was extracted and 
the region around the site targeted by the guide was amplified by PCR, cloned into a pcDNA4/TO 
plasmid and sequenced. The primers used to amplify the target site in RIG-I were forwards 
TAGCTCGGATCCAGGGAAACGAAACTAGCCCG and reverse 
GAGCTGGAATTCTGCTGCGGAGATCTTACCAC. SHARPIN-knockout clones were not sequenced. Clone 
sequences were aligned with those from WT A549 cells to check for mutations at the target site. 
After identification of the start codon, mutated sequences were translated using Expasy 
(www.web.expasy.org/translate/) to confirm that the mutations introduced changed the amino acid 
sequence and/or introduced premature stop codon, terminating the sequence.  
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2.3 Stimulation of cells  
2.3.1 Transfection of synthetic RNAs 
High molecular weight (HMW) Poly(I:C) and 3p-hpRNA (both Invivogen) were diluted in NF-H2O to 
concentrations of 1 mg/mL and 0.1 mg/mL respectively and stored at -20°C.  
For qPCR and ELISA, cells were seeded in 6-well plates and transfected 16 hours later with 1 μg of 
synthetic RNA per well. For phosphoblotting, cells were seeded in 10 cm dishes and transfected 16 
hours later with 5 μg of RNA. For phos-flow cells were seeded in 6 cm dishes and transfected 16 
hours later with 2 μg of RNA. TransIT-LT1 (Mirus) was used at a ratio of 3 μL per μg of RNA and was 
added to OptiMEM (Gibco) (200 μL per well, 400 μL per 6 cm dish and 1 mL per 10 cm dish), mixed 
and incubated for 5 minutes. RNA was added and the mix was incubated for a further 30 minutes. 
Half of the media was removed to leave 1 mL per well, 2 mL per 6 cm dish, or 5 mL per 10 cm dish of 
complete media remaining. The transfection mix was added dropwise to the cells, which were then 
incubated for the indicated time. 
2.3.2 IFNα stimulation 
Cells were seeded at 70% confluence and after 16 hours, IFNα (Sigma) diluted in (1 mL per well, 3 mL 
per 6 cm dish, 5 mL per 10 cm dish and 10 mL per 15 cm dish) DMEM 10% FCS 1% P/S to a 
concentration of 100 U/mL, was added to cells and incubated for 24 hours. 
2.3.3 TNFα stimulation 
Cells were seeded at 80-90% confluency in 10 or 15 cm dishes. 16 hours later, TNFα (Peprotech) 
diluted to 200 ng/mL in 5 mL per dish DMEM 10% FCS 1% P/S, was added to cells and incubated for 
the indicated time. 
2.4 Virus infection 
2.4.1 Sendai virus 
The Cantell strain of Sendai virus (SeV), a kind gift from Steve Goodbourne (St. Georges University), 
and was stored at -80 °C. After initial dose-response tests, A549 cells were infected at a 1:300 
dilution and MEF and HEK293T cells at a 1:100 dilution, in DMEM 2.5% FCS 1% P/S (1 mL per well, 3 
mL per 6 cm dish and 5 mL per 10 cm dish) and incubated for the indicated time. A single infection 




2.4.2.1 Generation and titration of virus stocks 
Influenza A/Puerto Rico/8/1934 (IAV PR8 WT) virus was a kind gift from Wendy Barclay (Imperial) 
and NS1 mutant viruses IAV PR8 NS1 R38A, K41A and R38A+K41A were a generated in the lab of 
Paul Digard (University of Edinburgh) and provided by Rupert Beale (The Francis Crick Institute). IAV 
stocks were grown in MDCK cells, infected at a multiplicity of infection (MOI) of 0.01 virus particles 
per cell in minimum essential media (MEM) 0.3% BSA 1% P/S 2 μg/mL TPCK-Trypsin. After 48 hours 
or once significant cytopathic effects (CPE) was seen, the supernatant was harvested, and detached 
cells were pelleted by centrifugation for 10 minutes at 724 x g at 4°C. The remaining virus-containing 
supernatant was aliquoted into 2 mL vials and stored at -80 °C. 
To quantify the amount of virus generated, duplicate 10-fold serial dilutions of the IAV stock were 
carried out in MEM 0.3% w/v BSA 2 μg/mL TPCK-Trypsin. 500 μL of each dilution was added to 
confluent MDCK cells in a 6-well plate and incubated on a rocker at 37 °C. After 1 hour, the inoculum 
was removed and replaced with a 50:50 mix of 2% low melting point (LMP) agarose and 2x MEM 
(20% 10X MEM, 8mM L-glutamine, 0.45% Na2CO3, 0.4% non-essential amino acids (NEAA), 4% 
HEPES, pH 7.4) 0.6% BSA. Cells were incubated for 48 hours, or until plaques were seen by the naked 
eye. 1 mL of Neutral red (Sigma) diluted 1:20 with MEM 0.3% w/v BSA was added on top of the 
overlay and incubated for approximately 6 hours at 37 °C before the stain was aspirated, and 
plaques were counted in wells containing between 30 and 150 plaques. The number of plaques was 
multiplied by the dilution factor of the well and doubled to calculate the number of plaque forming 
units (PFU) per mL. 
2.4.2.2 Infection of cells 
A549 and MEF cells were seeded with a spare well or dish, which 16 hours later was trypsinised and 
counted. Total cell number was calculated and if cell numbers were within 10% of each other, cells 
were infected at a MOI of 5. 
2.4.2.3 Virus growth curve analysis 
Cells were infected with IAV PR8 WT and R+K at the indicated MOI, with each condition in triplicate. 
At the stated time, the supernatants were collected and stored at -80 °C. Supernatants were titrated 
onto confluent MDCK cells in 6-well plates and plaques were counted, as described in 2.4.2.1. Data 
shown is the mean value across biological and technical replicates and standard deviation is 
represented as error bars.  
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2.4.3 Zika virus 
2.4.3.1 Generation of and titration of virus stocks 
ZIKV/H.Sapiens/Brazil/PE243/2015 (ZIKV PE243) was a gift from Dr. Nerea Irigoyen. ZIKV stocks were 
grown in Vero cells, infected at MOI 0.01 in DMEM 0% FCS, 1% P/S, 8mM L-Glutamine with 20 mM 
HEPES. Virus was incubated on the cells for 1 hour at 37°C, then removed and DMEM 10% FCS, 1% 
P/S, 8mM L-Glutamine with 20 mM HEPES was added to the cells, which were returned to the 
incubator. Virus was harvested by collection of the supernatant on the cells at day 3 and day 5 post-
infection, followed by centrifugation for 10 minutes at 724 x g at 4°C. Supernatants were stored at -
80 °C. To quantify the amount of virus generated, virus stocks underwent triplicate 10-fold serial 
dilutions in serum-free DMEM. 400 μL of dilutions were added to Vero cells in duplicate and 
incubated for 1 hour at 37°C. At this point, the inoculum was removed and replaced with a 50:50 mix 
of 3% LMP agarose and 2x MEM 4% FCS. Cells were incubated for 5 days before being fixed 
overnight at room temperature using formal saline (4% formaldehyde, 0.9% sodium chloride, 90% 
H2O) and then stained with Toluidine Blue. Plaques were counted and PFU was calculated as 
previously described. This work was all done by Dr. Nerea Irigoyen and Charlotte Lefevre in the 
Department of Virology, University of Cambridge. 
2.4.3.2 Infection of cells 
A549 cells were trypsinised, counted, seeded at 90% confluency in a 6 well plate (6.5x105 cells per 
well) and incubated for 6 hours. Cells were infected with ZIKV PE243 at MOI 3 in 500 μL DMEM 2.5 % 
FCS 1% P/S per well and incubated for 1 hour, rocking every 10 minutes. After 1 hour, the inoculum 
was removed and 2 mL DMEM 2% FCS 20 mM HEPES was added to each well and infected cells were 
incubated for the indicated time. All infections were done in triplicate per condition. This was done 
together with Dr. Nerea Irigoyen and Charlotte Lefevre in the Department of Virology, University of 
Cambridge. 
2.4.3.3 Virus growth curve analysis 
A549 cells were seeded at a confluence of 60-70% and infected with ZIKV at an MOI of 0.01 in 
triplicate. After the indicated time Supernatant was collected and stored at -80 °C and titrated onto 
confluent Vero cells as previously described (2.4.3.1). Data shown is the mean value across biological 
and technical replicates and standard deviation is represented as error bars. This work was all done 




2.5.1 Cell Lysis and RNA Extraction 
Cells were seeded in 6-well plates in either duplicates or triplicates per condition and stimulated or 
infected as previously described. For all experiments except ZIKV infection, at the indicated time 
points, cells were washed twice with 1 mL PBS and then lysed by addition of 250 μL lysis buffer (4 M 
Guanidine Thiocyanate, 25 mM Tris pH7, 143 mM 2-mercaptoethanol (2-ME) followed by 250 μL 
70% ethanol. Lysates were passed through a silica spin column (Epoch) by centrifugation for 3 
minutes at 18000 x g at 4 °C. The column was washed once with 500 μL wash buffer 1 (1M Guanidine 
Thiocyanate, 25 mM Tris pH7, 10% ethanol) and twice with 500 μL wash buffer 2 (25 mM Tris pH 7, 
70% ethanol) by centrifugation for 1 minute at 18000 x g at 4 °C. RNA was eluted by addition of 50 
μL NF-H2O and centrifugation for 1 minute, the eluate was reapplied to the column and eluted for a 
second time. Eluted RNA was stored at -80 °C. 
After infection with ZIKV for the indicated time, cells were washed twice with 1 mL PBS cells and 
scraped in 250 μL lysis buffer (Polysome buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM MgCl2, 
1 mM DTT), 5 % Triton X-100, 12.5 U/mL DNase I, 1% DTT). Mechanical lysis was performed by 
passing the lysate through a 26-gage needle 30 times. Insoluble material was pelleted by 
centrifugation at 18000 x g for 20 minutes at 4 °C. A phenol/chloroform (1:1 600 μL) extraction was 
performed, followed by a chloroform extraction (600 μL). RNA was precipitated by recovery of the 
aqueous phase and addition of 60 μL 3M sodium acetate pH 4.8 and 1.8 mL ice cold 100% ethanol. 
Samples were incubated for 1 hour at -80 °C and RNA pelleted by centrifugation at 18000 x g for 15 
minutes at 4 °C. The pellet was washed in 200 μL ice cold 95% ethanol before air drying and 
resuspension in 11 μL NF-H2O. RNA was stored at -80 °C. This was done by Dr. Nerea Irigoyen and 
Charlotte Lefevre in the Department of Virology, University of Cambridge. 
2.5.2 cDNA synthesis 
RNA concentration and purity were determined using a NanoDrop 2000 Spectrophotometer. 500 μg 
of RNA, 1 μL of 10 mM deoxynucleotides (dNTPs) and 500 ng of oligo(dT) (both Thermo Scientific) 
were incubated at 65°C for 5 minutes using a Veriti thermocycler (Applied Biosystems). 10 U of 
RNaseOUT (Invitrogen), 50 U of Superscript III Reverse Transcriptase (Invitrogen), 4 μL of 10x First 
Strand buffer and 1 μL of 0.1 M dithiothreitol (DTT) were added and the mix was incubated at 50°C 





cDNA samples were analysed by quantitative polymerase chain reaction (qPCR) using primers to 
amplify specific regions of the genes of interest, ordered as DNA oligos (IDT). Target genes and 
primer sequences for human and murine cells can be found in Table 2.5.3.1A and B respectively. 




Forwards ACC CAG AAG ACT GTG GAT GG 
Reverse TTC TAG ACG GCA GGT CAG GT  
IFNB1 interferon beta 1 
Forwards ACA TCC CTG AGG AGA TTA AGC A 
Reverse GCC AGG AGG TTC TCA ACA ATA G 
CXCL10 
C-X-C motif chemokine ligand 
10 
Forwards GTG GCA TTC AAG GAG TAC CTC  
Reverse GCC TTC GAT TCT GGA TTC AGA CA 
DDX58 DExD/H-box helicase 58  
Forwards CTC TGC AGA AAG TGC AAA GC 





Reverse CAT GGG GTA ACT TGG CTC CTT 
IFNA2 interferon alpha 2 
Forwards AGT CAA GCT GCT CTG TGG GC 
Reverse GTG AGC TGG CAT ACG AAT CA 
IFNL1 interferon lambda 1 
Forwards CGC CTT GGA AGA GTC ACT CA 
Reverse GAA GCC TCA GGT CCC AAT TC 
CCL5 C-C motif chemokine ligand 5 
Forwards CCC AGC AGT CGT CTT TGT CA 
Reverse TCC CGA ACC CAT TTC TTC TCT 
ISG15 ISG15 ubiquitin like modifier 
Forwards AGC ATC TTC ACC GTC AGG TC 
Reverse GAG GCA GCG AAC TCA TCT TT 
ISG54/IFIT2 
interferon induced protein 
with tetratricopeptide repeats 
2 
Forwards CTG AAG AGT GCA GCT GCC TG 
Reverse CAC TTT AAC CGT GTC CAC CC 
NFKBIA NFKB inhibitor alpha 
Forwards CTC CGA GAC TTT CGA GGA AAT 
Reverse GCC ATT GTA GTT GGT AGC CTT 
TNFA tumour necrosis factor a  
Forwards AGG CGC TCC CCA AGA AGA CAG G 
Reverse CAG CAG GCA GAA GAG CGT GGT G 
IL6 interleukin 6 
Forwards ACA ACC ACG GCC TTC CCT ACT T 
Reverse CAC GAT TTC CCA GAG AAC ATG TG 









Forwards GTT GGA TAC AGG CCA GAC TTT GTT G 
Reverse GAT TCA ACT TGC GCT CAT CTT AGG C 
Ifnb1 interferon beta 1 
Forwards GCC TAG GTG AGG TTG ATC T 
Reverse AGC TCC AAG AAA GCA CGA ACA T 
Ifna4 interferon alpha 4 
Forwards GGW ACA CAG TGA TCC TGT GG 
Reverse AGG GCT CTC CAG AYT TCT GCT CTG 
Ifnl2/3 interferon lambda 2/3 
Forwards CCG GAT CCT GTC CCC AGG GCC ACC AGG C 
Reverse GAG AAT TCC AGG TCA GAC ACA CTG GTC TCC 
Cxcl10 
C-X-C motif chemokine ligand 
10 
Forwards ACT GCA TCC ATA TCG ATG AC 
Reverse TTC ATC GTG GCA ATG ATC TC 
Isg56/Ifit1 
interferon-induced protein 
with tetratricopeptide repeats 
1 
Forwards CTG AAG AGT GCA GCT GCC TG 
Reverse CAC TTT AAC CGT GTC CAC CC 
Isg15 ISG15 ubiquitin like modifier 
Forwards GCA AGC AGC CAG AAG CAG ACT CC 
Reverse CGG ACA CCA GGA AAT CGT TAC CCC 
Il6 interleukin 6 
Forwards GTA GCT ATG GTA CTC CAG AAG AC 
Reverse ACG ATG ATG CAC TTG CAG AA 
Nfkbia NFKB inhibitor alpha 
Forwards CTG CAG GCC ACC AAC TAC AA 
Reverse CAG CAC CCA AAG TCA CCA AGT 
Table 2.5.3.1B: Primers used to detect mRNA transcription in murine cell lines 
 
2.5.3.2 qPCR protocol 
qPCR reactions were set up in a MicroAmp 384-well plate (Thermo Scientific). In addition to the 
experimental duplicates/triplicates for each condition, technical duplicates were done for each cDNA 
sample and target gene combination. 2 μL of diluted cDNA was added to 5 μL SyGreen HiROX mix 
(PCR Biosystems) and 1 μL of each forward and reverse primer (IDT) at 10 μM (final concentration of 
0.5 μM for each). The plate was loaded into a Viia7 Real-Time PCR machine (Thermo Scientific) and 
the programme was run as per the Thermocycling parameters shown in Table 2.5.3.2.  
 Rate Temperature Time 
  25C  
Increase @ 1.9C/s 95C  
 95C 20 seconds 
40x cycles to 
amplify 
 95C 1 second 
Decrease @ 1.6C/s 60C 20 seconds 
 Increase @ 1.9C/s 95C 15 seconds 
Melt curve Decrease @ 1.6C/s 60C 60 seconds 
Increase @ 0.05C/s 95C  




2.5.3.3 ΔΔCt calculations 
Melt curves generated by qPCR were checked for presence of a single symmetrical peak, indicative 
of a single specific dsDNA amplicon generated during amplification of each gene with the specific 
primers. The raw cycle threshold (Ct) value for each amplicon was collected. Mean Ct values were 
calculated for technical duplicates, excluding those that appeared to be outliers compared to their 
technical and experimental replicates. ΔCt was calculated by subtracting the Ct value for the gene of 
interest from the Ct value of the reference gene: GAPDH in human cells and HPRT in murine cells. 
ΔΔCt was calculated by subtracting the ΔCt from each treated sample (e.g., each infection time point 
or stimulation condition) from the ΔCt of its relevant untreated sample. Once calculated, ΔΔCt 
values were used to generate a fold change value, using the calculation 2𝛥𝛥𝐶𝑡, as an increase of one 
in Ct value results in a doubling of the amount of DNA in the PCR reaction. The mean fold change 
values calculated from experimental replicates were plotted as a bar chart, with standard deviation 
indicated by error bars. 
2.6 Western blotting 
2.6.1 Harvesting cell lysates 
Cell lysates were harvested differently depending on the application of the lysate.  
2.6.1.1 Harvesting whole cell lysate 
For Western blotting analysis of total protein levels, whole cell lysate was harvested from resting 
cells. Cells were trypsinised and resuspended in DMEM 10% FCS, pelleted by centrifugation (724 x g, 
4 minutes, 4 °C) and washed twice by resuspension in PBS followed by centrifugation. Pelleted cells 
were resuspended in lysis buffer, approximately 100 μL per 2.5x106 cells. The lysis buffer used for 
A549 and U251 cells was radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl pH 8, 1% 
Nonidet P-40 (NP-40), 0.5% sodium deoxycholate, 0.1% SDS, 150 mM NaCl) and for MEF cells was 30 
mM Tris-HCl pH 7.4, 1% Triton X-100, 20 mM NaCl, 2 mM KCl, 2 mM EDTA and 10% glycerol.  
2.6.1.2 Harvesting lysates during infection or stimulation 
When harvesting cells for Western blotting during stimulation or infection, all reagents used during 
lysis were ice cold and the whole procedure was done on ice. At the indicated time point, cells were 
washed once in 5 mL PBS, then scraped into 5 mL of PBS and transferred to a falcon tube. Cells were 
pelleted by centrifugation (724 x g, 4 minutes, 4 °C) and resuspended in 115 μL of the lysis buffers, 
with protease inhibitors (Roche) and phosphatase inhibitors (Sigma). 
46 
 
For both applications, cells were lysed for 30 minutes on ice and 10 minutes on a rotating wheel at 4 
°C and insoluble material was pelleted by centrifugation (18000 x g, 10 minutes, 4 °C). A sample was 
taken for determination of protein concentration, and then 6x loading buffer (300 mM Tris-HCl pH 
6.8, 12% SDS, 60% glycerol, 0.6% bromophenol blue, 600 μM 2-ME) was added to the remaining 
cleared lysate. Whole cell lysates were stored at -20 °C until use and lysates for phosphoblotting 
were snap-frozen in a dry ice-ethanol bath and stored at -80 °C until use. 
Protein concentration was determined by bicinchoninic acid (BCA) assay (Thermo Scientific) to 
enable equal loading of protein samples. 
2.6.1.3 Harvesting lysates from ZIKV infection 
Following ZIKA infection, cells were washed twice with 1 mL PBS and scraped into 250 μL lysis buffer 
(Polysome buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM MgCl2, 1 mM DTT), 5 % Triton X-100, 
12.5 U/mL DNase I and 1% DTT. Mechanical lysis was performed by passing the lysate through a 26-
gage needle 30 times. Insoluble material was pelleted by centrifugation at 18000 x g for 20 minutes 
at 4 °C. 6x loading buffer (300 mM Tris-HCl pH 6.8, 12% SDS, 60% glycerol, 0.6% bromophenol blue, 
600 μM 2-ME) was added to the 50 μL of complete lysate, which was stored at -20 °C before use. 
Total protein concentration was not calculated or used to normalise loading with these lysates. This 
work was done together with Dr. Nerea Irigoyen and Charlotte Lefevre in the Department of 
Virology, University of Cambridge, who also analysed these samples by Western blotting. 
2.6.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
Except for those used for analysis of co-immunoprecipitation experiments (BioRad 4-20% Tris-
Glycine gels), SDS-PAGE gels were made using a Bio-Rad Protean III system: made up of a separating 
gel (10% (all stimulation except ZIKV) or 12% (ZIKV) polyacrylamide, 390 mM Tris (pH 8.8), 0.1% SDS, 
0.1% ammonium persulphate (APS), 0.04% tetramethyl ethylenediamine (TEMED)) and a stacking gel 
(5% polyacrylamide, 130 mM Tris (pH 6.8), 0.1% SDS, 0.1% APS, and 0.1% TEMED). 
Protein samples were defrosted on ice then boiled at 98 °C for 5 minutes. Insoluble material was 
pelleted by centrifugation at 18000 x g for 30 seconds. For Western blotting of whole cell lysates and 
phosphoblotting using A549 cell lysates, 50 μg of protein was loaded per well. For phosphoblotting 
using MEF cell lysates, 100 μg of protein was loaded per well. 
47 
 
Gels were run in a Mini-PROTEAN Tetra Vertical Electrophoresis Cell (BioRad) at 90 V for 30 minutes 
and 120 V for the remaining time (approximately 1.5 hours) using a Tris-Glycine running buffer (25 
mM Tris, 192 mM glycine, 0.1 % SDS). 
2.6.3 Transfer 
A stack comprising of (bottom to top) blotting paper (BioRad), 0.2 μm nitrocellulose membrane 
(Amersham), SDS-Page gel and blotting paper was pre-soaked in transfer buffer (25 mM Tris, 192 
mM glycine, 20% methanol) for 5 minutes, assembled and then placed in a Pierce Power Blotter 
semi-dry transfer machine (Thermo Scientific). Proteins were transferred at 25 V for 30 minutes (if 
50 μg of protein was loaded) or 45 minutes (if 100 μg of protein was loaded)  
2.6.4 Immunoblotting 
After transfer, membranes were blocked for 1 hour in Tris buffered saline 0.1% Tween-20 (TBST) 5% 
skim milk powder. After quickly washing twice with TBST, membranes were incubated with a 
primary antibody for 16 hours at 4 °C. Details of primary antibodies, their dilutions and diluents are 
shown in Table 2.6.4A. After 16 hours, membranes were washed 3 times for 5 minutes in TBST, 
incubated with secondary antibody for 1 hour at room temperature in the dark and washed 3 times 
for 10 minutes in TBST. Details of secondary antibodies are shown in Table 2.6.4B. Membranes were 
dried and stored in the dark at room temperature before imaging. 
Antibody Company Code Dilution/diluent 
RIG-I (D-12) Santa Cruz sc-376845 1:1000/TBST 
MAVS (E-3) Santa Cruz sc-166583 1:1000/TBST 
TRAF2 Home-made (Henning Walczak lab, 
University of Cologne) 
1:1000/TBST 
IKKgamma/NEMO (DA10-12) Cell Signaling Technology #2695 1:1000/TBST 
RIP1 (D94C12) Cell Signaling Technology #3493 1:1000/TBST 
IRF3 [EPR2418Y] Abcam ab68481 1:1000/TBST 
NAK/TBK1 [EP611Y] Abcam ab40676 1:1000/TBST 
IκBα (L35a5)- MEF Cell Signaling Technology #4814 1:1000/TBST 
α-Tubulin (DM1A) Millipore 05-829 1:5000/TBST 
ZIKV E protein GeneTex GTX133314 1:1000 PBST 
GAPDH Sigma G8795 1:20000 PBST 
IRF3 (phospho S386) [EPR2346] Abcam ab76493 1:1000/TBST 
Phospho-TBK1 (Ser172) D52C2 Cell Signaling Technology #5483S 1:1000/TBST 
Phospho-IκBα (Ser32/36) (5A5) Cell Signaling Technology #9246 1:1000/TBST 
Phospho-IRF3 (Ser396) (4D4G) Cell Signaling Technology #4947 1:500/TBST  
Ku70 [N3H10]  Abcam ab3114 1:1000/TBST 
phospho-IKKε (Ser172) (D1B7) Cell Signaling Technology #8766S 1:500/TBST 
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IKKε (D61F9) XP Cell Signaling Technology #3416 1:500/TBST 
TANK R&D AF4755 1:1000/TBST 
HOIP (human; full length), pAb Ubiquigent 68-0013-
100 
1:1000/TBST 




KU86 (B-4) Santa Cruz sc-515736 1:1000/TBST 
Phospho-RIP (Ser166) (D1L3S) Cell Signaling Technology #65746 1:500/TBST 
RIP3 (B-2) Santa Cruz sc-374639 1:1000/TBST 
Flag Sigma #F7425 1:1000/TBST 
Table 2.6.4A Primary antibodies used for Western blotting 
Listed in order of appearance 
 
Antibody Company Code Dilution/diluent 
Goat anti-rabbit 680 RD Li-Cor 926-68071 1:10000/TBST 
Goat anti-mouse 800 CW Li-Cor 926-32210 1:10000/TBST 
Donkey anti-Goat 800-CW  Li-Cor 926-32214 1:10000/TBST 
Goat anti-Human IgG 800-CW Li-Cor 926-32232 1:10000/TBST 
Table 2.6.4B Secondary antibodies used for Western blotting 
2.6.5 Detection 
Blots were imaged by a Li-Cor Odyssey CLx, and images were processed using the programme Image 
Studio. 
2.7 Enzyme-linked immunosorbent assay (ELISA) 
A DuoSetELISA assay (R&D) was used to detect the presence of human CXCL10/IP-10 in the 
supernatants of infected or stimulated A549 cells. 
2.7.1 Sample preparation 
Cells were seeded in 6-well plates with biological duplicates per condition and were either 
stimulated or infected as previously described. At the stated time point, 1 mL of the supernatant was 
collected and stored at -20 °C. 
2.7.2 ELISA 
Initial optimisation assays were done to determine the dilution factor of samples to enable CXCL10 
levels to fall within the standard curve, with samples diluted in PBS 1% PBS. Samples were diluted as 
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appropriate and the assay procedure was performed as described in the kit protocol, with technical 
duplicates done for each experimental sample, using TMB (Abcam) used as the substrate solution 
and 0.3 M H2SO4 as the stop solution.  
2.7.3 Analysis 
The optical density of each sample was measured using a LUMIstar Omega. The blank-corrected 
optical density at 450 nm was subtracted from that at 540 nm. A 4-parameter fit standard curve was 
applied to the standards of known concentration and used to calculate the amount of CXCL10 in 
experimental samples. Dilutions were accounted for, and mean values generated from technical and 
experimental replicates were plotted as a bar chart, with standard deviation indicated by error bars. 
2.8 Phos-flow  
2.8.1 Fixing cells 
After stimulation or infection, cells were washed twice in PBS, detached with trypsin and 
resuspended in DMEM 2.5% FCS. Cells were pelleted by centrifugation at 600 x g for 6 minutes and 
fixed in 100 μL per 1x106 cells of PhosFlow Lyse/Fix buffer (BD Bioscience) at 37 °C for 10 minutes. 
Fixation was stopped by addition of 1 mL of PBS 1% FCS and cells were stored at 4 °C overnight in 
PBS. 
2.8.2 Staining cells 
Cells were pelleted by centrifugation and further fixed and permeabilised in 1 mL of 88% methanol 
PBS at 4 °C for 30 minutes. Cells were washed 3 times in PBS 1% FCS, each time pelleted by 
centrifugation at 850 x g for 6 minutes at 4 °C. Cells were incubated with primary antibody diluted in 
PBS 1% FCS (25 μL per 1x106 cells), for 1 hour at room temperature in the dark. Details of antibodies 
used in these experiments are shown in Table 2.8.2. The washing steps were repeated, and cells 
were resuspended in filtered PBS in FACS tubes and stored at 4 °C until analysis was done, either 
immediately or the following day. Control samples, no antibody, single antibody and positive control 
samples, were also stained under the same conditions. 
Antibody Company Code Dilution/diluent 
Phospho-IRF-3 (Ser396) (D6O1M) Rabbit 
mAb (Alexa Fluor® 647 Conjugate) 
Cell Signaling #10327 1:25/PBS 1% FCS 
PE Rabbit Anti- Active Caspase-3 Clone C92-
605 
BD Pharmingen 550821 1:10/PBS 1% FCS 
Table 2.8.2: Antibodies used for phos-flow analysis 
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2.8.3 Analysis of samples 
Samples were analysed by flow cytometry using the Attune NxT Acoustic Focusing Cytometer (Fisher 
Scientific) and analysed in FlowJo Version 10. The gating strategy used for analysis is shown in Figure 
2.8.3. 
 
Figure 2.8.3: Gating strategy for phos-flow analysis in FlowJo 
Dot plots showing forward scatter (FSC) against side scatter (SSC) to differentiate cells from debris, FSC-height 
against FSC-area to differentiate singlets (in the diagonal plane) from aggregated cells and Alexa-647 against 
PE to gate around negative cells in negative control (no antibody and no stimulation) samples. 
2.9 LUBAC overexpression in HEK cells 
2.9.1 Constructs 
For overexpression of HOIP, HOIL-1 and SHARPIN in HEK cells, plasmids encoding N terminally V5- 
and His-tagged proteins were used, generated in the lab of Henning Walczak (University of Cologne), 
337,338. 
2.9.2 Transfection of overexpression constructs 
HEK293T cells were seeded in 6-well plates at 60 % confluency (3x105 cells per well). Cells were 
transfected with the indicated amount of DNA, either empty vector (pcDNA4), or HOIP or HOIL-1 
overexpression plasmids. 200 μL per well of OptiMEM, 3 μL per μg of DNA Polyethyleneimine (PEI, 
Polysciences) and expression plasmids were mixed and incubated at room temperature for 20 
minutes. Half of the media was removed to leave 1 mL of complete media per well and 200 μL of the 
transfection mix was added to each well. Cells were incubated for 24 hours, after which the media 
was replaced with an inoculum containing Sendai virus at a 1:100 dilution in DMEM 2.5% FCS and 
cells were incubated for a further 16 hours.   
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2.10 Cell death analysis 
2.10.1 Methods of inducing cell death 
2.10.1.1 Staurosporine 
A549 cells were treated with staurosporine (STS, Cell Guidance Systems) to induce caspase-3 
dependent apoptosis. 2 μM STS, dissolved in DMSO, was diluted in DMEM 10 % FCS, added to cells 
and incubated for the indicated time. As STS was diluted in DMSO, A549 cells were also treated with 
an equivalent dilution of DMSO in DMEM 10 % FCS, to check that any toxicity seen was due to STS 
and not just DMSO. 
2.10.2 Methods of measuring cell death 
2.10.2.1 Imaging CPE 
Phase contrast images of live cells were taken using a Zeiss Axio microscope with a 10 times 
magnification lens.  
2.10.2 Measuring active caspase 3-expressing cells 
After stimulation, fixing and staining of cells was done as per section 2.8, using PE Rabbit Anti-Active 
Caspase-3 antibody. 
2.10.3 Vitality Assay 
After stimulation, cells were washed twice with PBS, trypsinised and resuspended in DMEM 2.5% 
FCS to a total volume of 1 mL per 5x105 cells (1 well). The cell suspension was mixed with NC-250 
Solution 6, containing VB-48 vitality dye and propidium iodide (PI), at a 20:1 dilution and this was 
added to a NC-slide. The slide was loaded into the Nucleocounter NC-250 and the Vitality assay was 
run.  
Images of the stained cells were acquired, and these were automatically used to generate scatter 
plots and histograms showing PI and VB-48 fluorescence intensity. Once this was acquired for all 
samples, cells from a control sample were used to gate around as healthy (VB-48 ‘high’ and PI ‘low’). 
The same gates were applied to all experimental samples. Gating of ‘healthy’ control cells is shown 
in Figure 2.10.2A and the relevant scatter plot and histogram, as well as the gating strategy used is 
shown in Figure 2.10.2B. Loss of VB-48 fluorescence intensity after 8 hours of treatment with 2 μM 
STS is demonstrated in Figure 2.10.2C. The percentages of cells in each gate were used to generate a 




Figure 2.10.2: NC-250 vitality assay parameters 
A) Image taken of A549 WT cells stained with Solution 6 containing VB-48 dye (blue) and PI, indicating non-
viable cells (orange). Automatically generated scatter plots with gating strategy and histogram of VB-48 
fluorescence intensity of A549 WT cells that are A) unstimulated and B) 8 hour treatment with 2 μM STS. 
2.11 Co-immunoprecipitation 
2.11.1 TNFα stimulation and harvesting for Flag-IP 
A549 cells stably expressing a tandem affinity purification (TAP)-tagged HOIP and NEMO were 
seeded in 15 cm dishes at 70% confluence (5x106 cells per dish) and incubated for 40 hours. Cells 
were stimulated with 500 ng/mL TNFα for the indicated times. Cells were washed twice in 5 mL cold 
PBS and scraped in 1 mL cold lysis buffer (30 mM Tris-HCl pH7.4, 120 mM NaCl, 2 mM EDTA, 2 mM 
KCl, 10% Glycerol, 1% Triton-X100) with protease inhibitors (Roche) and phosphatase inhibitors 
(Sigma). Cells were lysed for 30 minutes on ice and 10 minutes on a rotating wheel at 4 °C. Insoluble 
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debris was pelleted by centrifugation at 16200 x g for 30 minutes at 4 °C. 35 μL of cleared lysate was 
taken for an input sample and 7 μL of 6x loading buffer was added to the remainder. 
2.11.2 SeV infection and harvesting for Flag-IP 
A549 cells stably expressing a tandem affinity purification (TAP)-tagged HOIP and NEMO were 
seeded in 15 cm dishes at 70% confluence (5x106 cells per dish) and incubated for 16 hours. Cells 
were stimulated with 100 U/mL IFNα and incubated for 24 hours before being infected with SeV for 
the indicated time. A single infection mix was made, cells were infected sequentially and harvested 
together. Cells were washed twice in 5 mL cold PBS and scraped in 0.5 mL lysis buffer 1 (100 mM 
NaCl, 40 mM Tris-HCl, pH 7.5, 1 mM CaCl2, 1 mM MgCl2) with protease inhibitors (Roche) and 
phosphatase inhibitors (Sigma). Cells were lysed for 30 minutes on ice and 40 minutes on a rotating 
wheel at 4 °C. Insoluble debris was pelleted by centrifugation at 16200 x g for 10 minutes at 4 °C and 
cleared lysate was transferred to a new Eppendorf tube. Pellets were resuspended in 0.5 mL lysis 
buffer 2 (100 mM NaCl, 40 mM Tris-HCl, pH 7.5, 1 mM CaCl2, 1 mM MgCl2, 1% Triton X-100 and 
0.1% SDS) with protease inhibitors (Roche) and phosphatase inhibitors (Sigma) and twice subjected 
to sonification at 20 Hz for 10 seconds, with a minute on ice between. Sonicated samples were 
subjected to centrifugation at 16200 x g for 20 minutes at 4 °C. Cleared lysates from pre- and post-
sonification were combined. 35 μL of cleared lysate was taken for an input sample and 7 μL of 6x 
loading buffer was added to the remainer. 
2.11.3 Flag-IP and washing 
25 μL per sample of Flag-M2 beads (Sigma), pre-washed once with PBS and 3 times with the 
respective lysis buffer, were added to the cleared lysates and this was incubated on a rotating wheel 
at 4 °C for 16 hours. Beads were pelleted by centrifugation at 2,400 x g for 5 minutes at 4 °C and 
unbound material was removed using a 1 mL needle with a 20-gage syringe. Beads were washed by 
addition of 1 mL of respective lysis buffer (without protease or phosphatase inhibitors) followed by 
centrifugation as before. The washing procedure was repeated four more times. 40 μL of 2x loading 
buffer with 330 mM DTT was added to beads.  




2.12 Statistical analysis 
Significance was determined by a one tailed student’s T test for two independent means. All data 
produced met the requirements of two independent samples with the same variance and normal 
data distribution. The null hypothesis stated that there was no difference between the means of the 
two populations (H0: u1 – u2 = 0, where u1 is the mean of the first population and u2 the mean of 
the second). The equation used for this calculation was  𝑝 𝑣𝑎𝑙𝑢𝑒 =














Data was deemed significant if the p value was <0.05 and significance is represented on graphs by P 




Chapter Three: Developing tools to 
study RIG-I signalling in A549 cells 
3.1 Introduction 
The importance of RIG-I in sensing certain viral infections has been highlighted by the use of knock-
out mice and the characterisation of disease-causing RIG-I mutation in humans339,340. Loss-of-
function mutations confer increased susceptibility to virus infection, whereas gain-of-function 
mutations that render RIG-I constitutively active result in exaggerated or spontaneous production of 
anti-viral and pro-inflammatory cytokines. The sensing of viruses by RIG-I in the first infected cells in 
the body is crucial for effective infection control and clearance with minimal damage to the host. 
Due to the nature of the viruses detected by RIG-I, this usually occurs in epithelial cells, often at 
mucosal surfaces like those found in our airways.  
The aims of this chapter were to generate tools that could be used to study signalling mechanisms 
downstream of RIG-I. To do this, we used synthetic RNA ligands and RNA viruses known to activate 
RIG-I and tested their efficacy in our chosen model system. The response to each stimulus was 
measured and quantified by qPCR to measure the transcription of genes known to be activated by 
IFN-I, IRF-3 and NF-κB; Western blotting and phos-flow analysis to observe the activation of known 
RIG-I signalling pathway components; and ELISA to measure chemokine secretion. The specificity the 
ligands for RIG-I was determined by the generation and testing of A549 cells deficient in RIG-I. Data 
generated in this chapter demonstrates that stimulation of A549 cells with 3p-hpRNA, Poly(I:C), SeV, 
IAV R+K and ZIKV PE243 induces an IFN-I response, with SeV and ZIKV also activating IFN-III and NF-
κB-dependent responses, all of which were completely dependent on RIG-I expression.  
3.2 RNA sensing in A549 cells 
3.2.1 A549 cells as a model for studying RIG-I signalling 
When investigating a signalling pathway, to ensure that any data generated is reliable, accurate and 
close to what would happen physiologically, the choice of an appropriate model system is very 
important. Many viruses known to activate RIG-I in vivo, such as Sendai virus (SeV) and Influenza A 
virus (IAV), are respiratory viruses, therefore ideally primary human alveolar cells would be used. 
However, primary cells are not very tractable for studies involving cell signalling analyses or genetic 
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manipulation. Therefore, A549 cells, a transformed human lung adenocarcinoma cell line that has 
similarities to human basal alveolar epithelial cells was chosen.  
Although cancer cell lines allow flexibility to study cell signalling pathways in detail using genetic 
manipulation techniques, they can also have flaws as model. Cancer is driven by genetic alterations, 
some of which map to signalling networks resulting in dysregulated signalling outcomes. For 
example, many carcinoma cell lines, including A549 cells, downregulate nucleic acid sensing 
machinery to allow them to remain undetected by the immune system341–343. Despite this, the prior 
use of A549 cells in many studies of RNA sensing suggested they could be a suitable model for RIG-I 
signalling analysis97,344,345.  
Although previous literature indicates that A549 cells can function as a good model for RIG-I 
signalling, there are often differences between batches of commonly used mammalian cancer cell 
lines, so we empirically tested the RIG-I signalling capability of our A549 cells. Consistent with 
previous literature, we found that A549 cells expressed high levels of RIG-I signalling pathway 
proteins MAVS, TRAF2, NEMO, RIP1, IRF3, TBK1 and IκBα (Figure 3.2.1A). Although RIG-I expression 
was barely detectable by Western blotting in resting A549 cells, it was strongly upregulated by 
stimulation with IFNα (Figure 3.2.1B).  
 
Figure 3.2.1: A549 cells express many of the components of the RIG-I signalling machinery 
Western blotting analysis of A) signalling pathway proteins in resting A549 WT cells and B) RIG-I in A549 cells 
either resting or after 24h stimulation with IFNα at 100 U/mL.   
3.2.2 A549 cells generate an immune response to stimulation with 
synthetic RNAs 
To confirm that A549 cells can sense non-self RNA in the cytoplasm, they were transfected with 
three synthetic RNA species that activate RIG-I: Poly(I:C), 5’ppp-dsRNA and 3p-hpRNA. 
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Poly(I:C) is a long synthetic double stranded (ds)RNA analogue that predominantly activates TLR3 
and MDA578,346–348. However, smaller or branched fragments of Poly(I:C) have been shown to 
preferentially activate RIG-I95,167,349–353. 5’ppp-dsRNA is a short, blunt ended, double stranded 
(ds)RNA duplex with a 5’triphosphate group. The helicase domain of RIG-I is known to recognise 
short dsRNA duplexes, but the 5’ triphosphate group, which distinguishes the foreign RNA from 
5’capped cellular RNAs, is recognised by RIG-I C-terminal domain (CTD)83,354. These two structures 
are thought to be necessary and sufficient to induce RIG-I activation89,90,355. 3p-hpRNA is a short 
single-stranded RNA with a 5’ triphosphate generated by in vitro transcription of a region of the IAV 
genome (sequence shown in Fig 3.2.2A), which self-anneals into regions of double stranded 
secondary structures such as hairpin or panhandles (predicted structure shown in Fig 3.2.2B), 
therefore should also activate RIG-I. 
After stimulation of RIG-I by transfection with these synthetic RNAs, transcription of immune genes 
was measured by qPCR. IFN-I and chemokine genes IFNB1 and CXCL10 were chosen as a direct 
readout of RIG-I activation due to their biological significance in antiviral immunity. Their 
transcription, activated by the IRF and NF-κB families of transcription factors, is strongly induced by 
signalling from many pattern recognition receptors, including nucleic acid sensors like RIG-I213,356,357. 
IFNB1, a type-I interferon, is one of the most potent antiviral products of PRR signalling, however it is 
often only expressed by a small subset of cells358,359. It’s transcription is regulated by an 
enhanceosome comprised of transcription factors such as NF-κB and IRF3 or IRF7360,361. CXCL10 
transcription provides a near-digital readout of RIG-I activation as levels of background expression in 
the absence of PRR activation are very low, but its transcription is strongly induced as a result of RIG-
I ligation. Its transcription is activated directly by NF-κB or IRF3, alongside other transcription factors 
depending on the context357.  
A549 WT cells were stimulated by transfection of high molecular weight (HMW) Poly(I:C), and qPCR 
analysis showed transcription of both IFNB1 and CXCL10 (Figure 3.2.2C). This confirmed both the 
successful transfection of Poly(I:C) into the cytoplasm of A549 cells and the presence of functional 
intracellular RNA sensing in our A549 cells. Transfection of 5’ppp-dsRNA did not induce expression of 
IFNB1 or CXCL10, even at high doses (Figure 3.2.1D), despite possessing both a short dsRNA region 
and a 5’ triphosphate group. Contrastingly, stimulation of A549 cells with triphosphate hairpin RNA 
(3p-hpRNA) was successful at activating transcription of CXCL10 at higher doses (0.5 and 1 μg), 
although IFNB1 was still not detectable above background levels (Figure 3.2.1E). 
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Based on these data, transfection with 1 μg Poly(I:C) and 3p-hpRNA was used to further examine 
activation of RIG-I by synthetic RNAs. 
 
Figure 3.2.2: A549 cells generate an immune response when stimulated by synthetic RNAs 
A) Sequence of 5’pppRNA. B) Lowest free energy structure of 3p-hpRNA, predicted by RNAStructure v6.2 
(http://rna.urmc.rochester.edu/RNAstructure.html). qPCR to measure transcription of indicated genes in A549 
WT cells both not transfected (Mock) and 6h post-stimulation with C) 1 μg Poly(I:C) (n=2, data representative 
of >3 experimental replicates), D) 1, 2 and 5 μg 5’ppp dsRNA (n=2, data representative of one experimental 
replicate) and E) 0.01, 0.1, 0.5 and 1 μg 3p-hpRNA (n=2, all data representative of one experimental replicate). 
3.2.3. A549 cells generate an immune response when infected with 
respiratory RNA viruses, SeV and IAV  
After successful stimulation of A549 cells with synthetic RNAs, the response of the cells to infection 
with known RIG-I-activating respiratory RNA viruses was measured.  
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Sendai virus (SeV) and Influenza A virus (IAV) were chosen as stimulation models due to their 
specificity activating RIG-I over other PRR and their physiological relevance in the cell type chosen. 
The Cantell strain of SeV was used as it is a potent activator of RIG-I, due to high levels of defective 
interfering RNAs consisting of copyback genomes, induced by continuous passage at high 
multiplicity281,282. The strain of Influenza A virus used, A/Puerto Rico/8/1934, is a mouse adapted 
H1N1 virus known to activate both RIG-I and TLR3 in A549 cells345.  
As the Cantell strain of SeV doesn’t result in a productive infection due to the generation of 
defective interfering (DI) particles with copy-back genomes rather than intact viral genomes281, 
multiplicity of infection (MOI) could not be used as a measure of virus concentration, so dilution of 
virus stock was used. To determine the optimal concentration of SeV for infection studies, A549 cells 
were infected with varying dilutions of the SeV stock for 6 hours (Figure 3.2.3A). Infection at all 
dilutions resulted in induction of high levels of IFNB1 and CXCL10 transcripts, with the 1:100 dilution 
being the most potent stimulator. However, as there were only small increases in transcription of 
IFNB1 and CXCL10 at higher concentrations above 1:300, a 1:300 dilution was chosen for further use. 
Following infection with IAV PR8, qPCR analysis showed a 200,000-fold increase in transcription of 
NS1 (Figure 3.2.2B), an early and abundantly expressed IAV gene. Despite this, transcription of both 
IFNB1 and CXCL10 was not detected above background levels by 6 hours post infection (Figure 
3.2.2C). This is likely due to the known immunosuppressive functions of the NS1 protein itself, which 
inhibits virus induced activation of both IRF3 and NF-κB, including directly disrupting RIG-I signalling 
by binding to dsRNA, TRIM25 and Riplet244,362–364. Because of this, a virus with a reduced its capacity 
to antagonise RIG-I signalling caused by Lysine (K) to Alanine (A) mutations at positions 38 and 41 of 
NS1, abrogating its binding to dsRNA to prevent it from sequestration away from RIG-I362,365, was 
used. In response to infection of A549 cells with the NS1 R38A mutant virus, transcription of CXCL10 
increased slightly (less than 5-fold) compared to PR8 WT infection. However, in response to infection 
with the double mutant virus NS1 R38A K41A (R+K), CXCL10 transcription was over 30-fold higher 
than in resting cells (Figure 3.2.3C). Transcription of IFNB1 was still not detected, as was seen with 




Figure 3.2.3: A549 cells generate an immune response when stimulated by RNA viruses 
qPCR to study transcription of indicated genes in A549 WT cells during A) infection with SeV for 6 hours at the 
indicated dilution (n=2, data representative of 2 experimental replicates), B) and C) infection with IAV PR8 WT 
and indicated NS1 mutants at MOI 5 for 6 hours (n=2, data representative of >3 experimental replicates), C) 
IFNB1 and CXCL10 in NI cells and after 6 hour infection with IAV PR8 WT, NS1 R38A and NS1 R38A K41A 
mutants at MOI 5 (n=2, data representative of one experimental replicate). 
3.2.4 A549 cells as a model to study ZIKV infection 
Zika virus (ZIKV) is an Arborvirus, spread by the bite of an infected mosquito. Because of this, initial 
infection generally occurs in skin epithelial cells, meaning that A549 cells are not the most 
physiologically relevant model for studying early responses to ZIKV infection. The majority of the 
pathology associated with severe ZIKV infection, such as congenital microcephaly and Guillian Barre 
syndrome, is related to infection of astrocytes in the central nervous system, so many studies of ZIKV 
infection use U251 cells, a human glioblastoma astrocytoma cell line366,367. 
Previous data suggests that RIG-I plays a role in sensing ZIKV infection in physiologically relevant cell 
lines such as U251368–370. To confirm that RIG-I senses RNA virus infection U251 cells, they were 
infected with SeV and IAV R+K and the transcription of IFNB1 and CXCL10 was measured by qPCR 
(Figure 3.2.4A and B). 50-fold induction of IFNB1 transcription and over 200-fold induction of CXCL10 
transcription was seen in response to infection with both SeV IAV R+K. Consequently, ZIKV infection 
was used as additional infection model to study RIG-I signalling in A549 cells. 
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Previous studies have shown that ZIKV can infect A549 cells313,369,371,372. To confirm this, A549 WT 
cells were infected with ZIKV, transcription of the virus-encoded open reading frame (ORF) was 
measured by qPCR (Figure 3.2.4C), expression of the ZIKV E protein was confirmed by Western 
blotting (Figure 3.2.4D) and replication of ZIKV was determined by a one-step growth curve (Figure 
3.2.4E). ZIKV infections were done together with Dr. Nerea Irigoyen and Charlotte Lefevre 
(University of Cambridge), who completed all RNA extraction, Western blotting and growth curve 
analyses. Detection of increasing levels of ZIKV ORF transcript and E protein through the time course 
confirmed successful infection and increasing levels of plaque forming units over the time course 
confirmed that ZIKV can infect and productively replicate in A549 cells.  
Finally, transcription of IFNB1 and CXCL10 was also measured in ZIKV infected A549 cells (Figure 
3.2.4F). Although delayed compared to infection with SeV or IAV R+K (Figure 3.2.3A and C), 
transcription of both genes was detectable above background levels by 16 hours post infection. This 
confirmed both A549 cells could sense and mount an immune response to ZIKV infection and that 
despite measuring immune readout at later time points, we were still capturing the initial RIG-I 




Figure 3.2.4: A549 cells are a suitable model to study innate immune sensing of ZIKV  
qPCR to measure transcription of indicated genes in U251 WT cells during infection with A) SeV at 1:300 
dilution and B) IAV R+K at MOI 5 (both n=2, data representative of 1 experimental repeat). C) qPCR to measure 
ZIKV PE243 ORF transcription during infection of A549 WT cells with ZIKV PE243 at MOI 3 (n=3).  D) Western 
blotting analysis of infection of A549 cells with ZIKV PE234 at MOI 3 (blot carried out by Dr. Nerea Irigoyen and 
Charlotte Lefevre). E) ZIKV PE243 growth curve generated by titration and plaque assay of ZIKV infection of 
A549 WT cells (n=3, data representative of 3 experimental replicates, generated by Dr. Nerea Irigoyen and 
Charlotte Lefevre). F) qPCR to measure transcription of indicated genes during  infection of A549 WT cells with 
ZIKV PE243 at MOI 3 (n=2, data representative of >3 experimental replicates). 
3.3 Characterising the signalling response of A549 cells to synthetic 
RNAs and RNA viruses 
To better understand the immune response in A549 cells stimulated by synthetic RNAs and RNA 
viruses was carried out.  
The transcriptional response of stimulated cells was studied in more detail by measuring the 
expression of a wider panel of immune genes by qPCR. In addition to IFNB1, transcription of IFN-I 
gene IFNA2 was also measured because whilst IFNB1 transcription requires co-ordinated binding of 
both IRF3 and NF-κB to its promoter, IFNα genes can be activated by binding of either IRF3 or NF-
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κB373. To counteract that fact that IFNB1 is often only expressed by a small subset of cells358,359, 
transcription of IFN-I dependent genes ISG15 and ISG54 was also measured. In addition to occurring 
in an IFN-I-dependent manner, transcription of ISG54 is directly activated by IRF3 independent of 
IFN-I activity. Activation of IFN-III was determined by measuring transcription of IFNL1. NF-κB activity 
was examined by studying transcription of NFKBIA, TNFA and IL6. NFKBIA is used here as a technical 
readout of NF-κB activity, transcribed only as a direct result of the activity of NF-κB, whereas TNFA 
and IL6 are functional NF-κB-responsive cytokines. Additionally, transcription of the chemokine 
CXCL10 was further validated using ELISA to measure secretion of CXCL10 into the supernatant of 
stimulated cells.  
Many proteins in the RIG-I signalling pathway, including TBK1, IRF3 and IκBα, are activated by 
phosphorylation. Both Western blotting and phos-flow analyses, using antibodies specific for the 
phosphorylated forms of the individual proteins, were used to detect their activation. Western 
blotting analysis indicates the level of accumulation of the phosphorylated form of the protein, and 
phos-flow indicates the percentage of cells expressing the phospho-form of IRF3. 
3.3.1 Stimulation of RIG-I by synthetic RNAs activates Type I IFN, 
chemokines and ISGs  
Stimulation with synthetic RNAs was done as previously described, transcription of an extended 
gene panel was examined by qPCR and activation of signalling proteins measured by Western 
blotting and phos-flow. 
After stimulation with 3p-hpRNA, transcription of IFN-I dependent genes ISG15 and ISG54 was 
robustly induced (Figure 3.3.1A), as seen previously with CXCL10. As with IFNB1, transcription of IFN-
I gene IFNA2 was undetectable, which contradicts previous studies374. However, this may well be 
because the fact that IFN-I genes are only expressed by a small subset of cells is exacerbated by low 
levels of transfection efficiency in A549 cells, making their transcription undetectable. Poly(I:C) 
transfection resulted in a 30-fold increase in transcription of IFN-I gene IFNB1, but not IFNA2. 
Additionally, transcription of IFN-I-dependent genes ISG15 and ISG54 was also detected. Neither 
synthetic RNA induced robust transcription of IFN-III or NF-κB-dependent genes IFNL1 and NFKBIA, 
despite the literature suggesting both that IFNλ is critical to the antiviral response to respiratory 
viruses, acting potently on epithelial cells375–377 and that NF-κB is activated downstream of RIG-I 
stimulation by synthetic RNAs378. This also contradicts previous studies showing transcription of IFN-
III-dependent genes IL28 and IL29 after stimulation of HepG2 cells with 3p-hpRNA and Poly(I:C)379. 
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Transcription of TNFA and IL6 was not measured because NFKBIA transcription was not detectable 
above background levels.  
The transcription of CXCL10 in response to stimulation with both synthetic RNAs transfection was 
supported by ELISA analysis (Figure 3.3.1B), which showed substantial secretion of CXCL10 by 24 
hours post stimulation. 
Examination of signalling protein phosphorylation in A549 cells stimulated by 3p-hpRNA and 
Poly(I:C) by Western blotting showed phosphorylation of both TBK1 and IRF3 after 6 hours (Figure 
3.3.1C), however this was much stronger with Poly(I:C) than with 3p-hpRNA. Despite this, 
examination of IRF3 phosphorylation by phos-flow showed no detectable increase in cells expressing 
phosphorylated IRF3 after 6 hours of Poly(I:C) stimulation (Figure 3.3.1D). This is likely due to a lower 
sensitivity level of the phos-flow assay compared to Western blotting, compounded by the relatively 
low transfection efficiency of A549 cells. Phosphorylation of IκBα was barely detected by Western 
blotting, consistent with the lack of detectable NFKBIA transcription. However, this may also be 
because, in the absence of proteasome inhibitors such as MG-132, IκBα is degraded quickly once 




Figure 3.3.1: Synthetic RNAs activate IRF3-dependent pathways, but not NF-κB dependent 
A) qPCR to measure transcription of indicated genes 6 hours post-stimulation of A549 WT cells with 1 μg 3p-
hpRNA and 1 μg Poly(I:C) (n=2, data representative of >3 independent assays). B) ELISA to measure CXCL10 
secretion 24 hours post-stimulation of A549 WT cells with 1 μg 3p-hpRNA and 1 μg Poly(I:C) (n=2, data 
representative of >3 experimental replicates). C) Western blotting analysis of lysates from A549 WT cells 
stimulated with 5 μg 3p-hpRNA or Poly(I:C) (data representative of one experimental replicate). D) Phos-flow 
analysis of expression of phospho-IRF3 (Ser396) and active caspase 3 in A549 WT cells 6 hours post-stimulation 
with 2 μg Poly(I:C) (n=1, data representative of 1 experimental repeat). 
3.3.2. Infection of A549 cells with SeV activates IRF3 and NF-κB, driving 
expression of IFN, chemokines and NF-κB stimulated genes 
The signalling outcomes of SeV infection of A549 cells were examined by qPCR, ELISA, Western 
blotting and phos-flow (Figure 3.4.2).  
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SeV infection resulted in increasing transcription of IFN-I and IFN-III genes (IFNB1 and IFNL1), IRF-
activated ISG15 and ISG54, the chemokine CXCL10 and NF-κB-driven genes NFKBIA, TNFA and IL6 
through the 6 hour time course (Figure 3.3.2A). Of the genes tested, only IFNA2 transcripts were not 
detectable above background levels, conversely to a previous studies showing transcription of IFNα 
genes in murine fibroblasts and lung tissue after infection with SeV, albeit to approximately 100-fold 
lower level than IFNβ transcripts383,384. Compared to the transcriptional response to synthetic RNAs, 
expression of all transcripts was more robust during SeV infection. Additionally, significant 
upregulation of IFNL1 (4000-fold) and NFKBIA (600-fold), not seen with synthetic RNAs, was evident 
by 6 hours post infection with SeV. Although TNFA transcription was modestly upregulated by 6 
hours post infection, IL6 transcription was barely detectable above background levels.   
Detection of CXCL10 secretion by ELISA during SeV infection of A549 cells confirmed CXCL10 
transcription data, with detectable levels of CXCL10 by 6 hours post infection and much higher levels 
of accumulation at 24 hours (Figure 3.3.2B). 
Western blotting of A549 cells during SeV infection (Figure 3.3.2C) detected visible phosphorylation 
of IRF3, TBK1 and IκBα, with stronger bands suggesting higher levels of phosphorylation, or 
phosphorylation in a higher proportion of cells than seen during stimulation with synthetic RNAs. 
Visible phosphorylation of IκBα, seen most strongly in the presence of MG-132 is in line with the 
robust transcription of NFKBIA and TNFA seen during SeV infection, but not stimulation with 
synthetic RNAs. Unchanged total (unphosphorylated) protein expression levels through the infection 
time course confirm that the increase of phosphorylated protein during infection was not due to a 
change in total protein levels.  
Phosphorylation of IRF3 during SeV infection was also detected by phos-flow analysis in 
approximately a third of A549 WT cells (Figure 3.3.2D). Without staining of cells with antibody 
against SeV or dsRNA, so we cannot confirm whether infection fully correlates with IRF3 
phosphorylation. It is possible that only a small percentage of A549 WT cells were successfully 
infected; that only a small proportion of infected cells expressed phosphorylated IRF3; or that we 






Figure 3.3.2: SeV infection drives activation of IRF3- and NF-κB-dependent pathways 
A) qPCR to measure transcription of indicated genes in response to infection of A549 WT cells with SeV at 
1:300 dilution (n=2, data representative of >3 independent assays). B) ELISA to measure CXCL10 secretion in 
response to infection of A549 cells with SeV at 1:300 dilution dilution (n=2, data representative of >3 
independent assays). C) Western blotting to detect phosphorylation of signalling pathway components in 
response to infection with SeV at 1:300 dilution with and without the presence of 10 μM MG-132 (3+) (data 
representative of >3 independent assays). D) Phos-flow analysis of A549 WT cells expressing phospho-IRF3 
(Ser396) and active caspase 3 in response to 6 hour infection with SeV at a 1:300 dilution (data representative 
of 3 independent assays). 
3.3.3. Infection of A549 cells with IAV R+K results in potent IRF3 activation, 
resulting in IFN, chemokine and ISG expression 
To compare the stimulation profile of SeV with another respiratory RNA virus, A549 WT cells were 
infected with IAV PR8 NS1 R38A K41A (R+K) and the immune response was analysed by qPCR (Figure 
3.3.3A) and Western blotting (Figure 3.3.3B). 
Transcription of IFN-I gene IFNB1, chemokine CXCL10 and ISGs ISG15 and ISG54 was robustly 
induced during IAV infection, however IFN-III and NF-κB dependent genes IFNL1 and NFKBIA 
transcripts were not detectable above background levels, as with IFNA2. This transcription profile 
induced by IAV R+K infection is more like that seen with A549 cells stimulated with synthetic RNAs 
(Figure 3.3.1A), than to SeV infected A549 cells (Figure 3.3.2A).  
Western blotting analysis of IAV R+K-infected A549 cells detected high levels of phosphorylation of 
IRF3 and TBK1, increasing through the time course (Figure 3.3.3B), as seen during SeV infection 
(Figure 3.3.2C). Evidence of IκBα phosphorylation was less clear, appearing to peak at two hours post 
infection, with consistently reduced levels seen until eight hours post infection. This mirrors the 
levels of NFKBIA transcription seen during IAV R+K infection (Figure 3.3.3A), possibly suggesting that 
the peak of IκBα phosphorylation and NFKBIA transcription may be before 2 hours post infection, 




Figure 3.3.3: IAV R+K infection drives activation of IRF3-, but not NF-κB-dependent pathways  
A) qPCR to measure transcription of indicated genes in response to infection of A549 cells with IAV PR8 R+K at 
MOI 5 (n=2, data representative of >3 independent assays). B) Western blotting to detect phosphorylation of 
signalling pathway components in response to infection with IAV R+K at MOI 5 for the indicated time in hours 
(data representative of >3 independent assays). Data generated by Rahul Singh. 
 
3.3.4. Infection of A549 cells with ZIKV PE243 drives transcription of Type I 
and III IFN, ISGs and NF-κB dependent genes  
Expression of an expanded panel of immune genes was also measured by qPCR during a ZIKV 
infection time course (Figure 3.3.4). At 16 and 24 hours post infection, ZIKV induced transcription of 
IFN-I and III genes IFNB1 and IFNL1 and IFN-I-dependent genes ISG15 and ISG54, but not NF-κB-
dependent genes NFKBIA, TNFA or IL6. At 48 hours post infection, a robust increase in transcription 
of IFNA2 and TNFA was detected, although transcripts from other NF-κB-dependent genes NFKBIA 
and IL6 are barely detectable above background levels. Transcription of CXCL10, known to be 
strongly associated with the microcephaly phenotype during ZIKV infection385, was detected from 16 




Figure 3.3.4: ZIKV PE243 infection drives transcription of IRF3- and NF-κB-dependent genes 
qPCR to measure transcription of indicated genes in response to infection of A549 cells with ZIKV PE243 at 
MOI 3 (n=3, data representative of >3 independent assays). Infections done in collaboration with Dr. Nerea 
Irigoyen and Charlotte Lefevre. 
3.4. RIG-I is required for immune activation of A549 cells by synthetic 
RNAs and RNA viruses  
3.4.1 RIG-I is an ISG, upregulated during immune stimulation 
RIG-I was undetectable by Western blotting in resting A549 cells (Figure 3.2.1A). However, like many 
other PRR, RIG-I is an immune stimulated gene (ISG), expressed at a low level in resting cells and 
upregulated in response to IFN-I, to amplify immune signalling66,67. To confirm that RIG-I is 
upregulated by an IFN-I response in A549 cells, its transcription was analysed by qPCR (Figure 3.4.1A) 
and protein expression by Western blotting (Figure 3.3.1B).  
During SeV infection of A549 cells, previously shown to rapidly to activate an IFN-I response, 
transcription of  IFNB1 was detected at 6 hours post infection. This early wave of IFN-I activation was 
followed by a strong upregulation of DDX58 (the gene name for RIG-I) transcription, detectable by 6 
hours post infection but much stronger by 24 hours post infection. Western blotting of RIG-I protein 
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levels in untreated, IFNα stimulated and SeV infected A549 cells showed that RIG-I, undetectable in 
resting cells, was much more abundant after stimulation with both IFNα and SeV. Both of these data 
are both consistent with RIG-I behaving as an ISG in A549 cells. 
 
Figure 3.4.1: RIG-I is an ISG that is upregulated by Type I IFN and SeV infection 
A) qPCR of IFNB1 and DDX58 (RIG-I) transcription after 0, 6, 24 hours SeV infection at 1:300 dilution (n=2, 
representative of one experimental replicate). B) Western blotting analysis of RIG-I expression in cells left 
unstimulated, stimulated with IFNα at 100 U/mL and infected with SeV at a 1:300 dilution, both for 24 hours 
(data shown is representative of >3 experimental replicates). 
3.4.2 Generation of RIG-I deficient A549 cells  
As the tested synthetic RNAs and RNA viruses are known RIG-I ligands, we hypothesised that 
response to stimulation seen in A549 cells was dependent RIG-I. To assess this, a RIG-I knock out cell 
line was generated by CRISPR/Cas9 in A549 WT cells (described in Chapter 2.2).  
Figure 3.4.2A shows the position of the sgRNA that was successfully used to generate the knock-out 
cell line, targeting exon one of RIG-I after the start codon. RIG-I protein expression in potential RIG-I 
knockout (-/-) clonal cell lines was tested by Western blotting after stimulation with IFNα for 24 
hours. If negative, loss of expression was confirmed by Sanger sequencing of genomic DNA extracted 
from putative knockout cells. The region around the sgRNA target site was cloned into an expression 
vector and 20 amplicons from each clone was sequenced to look for the mutations introduced by 
the Cas9 endonuclease. All mutated sequences were translated using EXPASY, to check for presence 
a premature STOP codon. For the clone taken forward for all future experiments, all translations 
generated from the sequencing of 20 amplicons showed mutations that introduced a premature 
STOP codon, shown in Figure 3.4.2B. 
The selected RIG-I -/- cells showed no detectable expression of the RIG-I protein by western blotting, 
even after stimulation with 100 U/mL IFNα for 24h, a condition in which RIG-I is clearly visible in 
A549 WT cells (Figure 3.2.1C). Western blotting analysis of other RIG-I signalling proteins confirmed 
comparative expression levels of TBK1, IRF3 and MAVS in WT and RIG-I -/- cells (Figure 3.4.2D), 
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ensuring that any phenotype seen in downstream experiments was due to loss of the targeted 
protein only.  
 
Figure 3.4.2: Generation and characterisation of a RIG-I -/- cell line 
A) Schematic of location of small guide RNA targeting RIG-I for CRISPR  (Exons indicated by blue boxes and 
introns by black lines. Start codon (ATG) position indicated by green arrow and location of target sequence of 
sgRNA by red arrow). B) ExPASY translation of A549 WT and RIG-I -/- sequences. Western blot analysis of C) 
A549 WT and RIG-I -/- cells with and without 24h stimulation with 100 U/mL IFNα ( data representative of >3 
independent assays) and D) RIG-I signalling pathway components in A549 WT and RIG-I -/- cells (data 
representative of 2 independent assays). 
3.4.3. A549 RIG-I -/- cells respond to various receptor stimuli 
To verify that the newly generated RIG-I -/- cells were not deficient in other innate immune sensing 
pathways, their ability to respond to DNA, IFN-I and LPS was tested.  
A549 WT and RIG-I -/- cells were stimulated with 2 μg of herring testes (ht)DNA (Figure 3.3.5A), a 
known immuno-stimulatory DNA388–390. Neither A549 WT nor RIG-I -/- cells showed more than a 5-
fold increase in IFNB1 or CXCL10 transcription when analysed by qPCR. This lack of response is likely 
due to the fact that A549 cells downregulate STING expression, preventing them sensing DNA341–343, 
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which is common in cancer cell lines to allow them to remain undetected by the immune system 391–
393.  
Stimulation of WT and RIG-I -/- cells with IFNα resulted in significant induction of CXCL10 
transcription in both WT and RIG-I -/- cells (Figure 3.3.5B). The levels of CXCL10 transcripts were 
significantly lower in RIG-I -/- cells than WT, possibly due to the clonal nature of the RIG-I-deficient 
cells, but it is still expressed almost 100 times more than in unstimulated cells, confirming that RIG-I 
-/- cells have functional interferon α receptor (IFNAR) signalling. LPS treatment of cells resulted in a 
small induction of both IFNB1 and CXCL10 transcription after 6 hours, even in the absence of RIG-I 
(Figure 3.3.5C). RIG-I deficient cells transcribed IFNB1 at levels twice that of WT, but the converse 
with true of CXCL10 transcription.  
These results demonstrate that RIG-I -/- cells can induce an immune response to RIG-I-independent 
stimuli, suggesting that any phenotype seen when RIG-I -/- cells are stimulated with RIG-I ligands is 
due to loss of RIG-I expression rather than other abnormalities in this cell line. 
 
Figure 3.4.3: A549 RIG-I -/- cells have immune signalling capacity 
qPCR to measure transcription of indicated genes after stimulation of A549 WT and RIG-I -/- cells with A) 2 μg 
htDNA (n=2, data representative of 2 independent assays), B) 100 U/mL IFNα (n=2, data representative of 1 
independent assay ) and C) 1 μg LPS (n=2, data representative of 2 independent assays). 
3.4.4. Stimulation of A549 cells by synthetic RNAs is dependent on RIG-I  
To study the role of RIG-I in the sensing of synthetic RNAs in A549 cells, WT and RIG-I -/- cells were 
transfected with 3p-hpRNA and Poly(I:C) and transcription of genes previously seen to be 
upregulated in WT cells (Figure 3.3.1A) was measured by qPCR. 
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For both 3p-hpRNA (Figure 3.4.4A) and Poly(I:C) (Figure 3.4.4B), transcription of all genes in A549 WT 
cells was as previously seen. However, transcription of all genes was undetectable above 
background levels in RIG-I -/- cells. This shows that in A549 cells, sensing of both RNA species in is 
entirely dependent on RIG-I, without any contribution from other RNA sensing PRRs like MDA5 or 
TLR3. This was expected for 3p-hpRNA, which is designed to be a specific agonist of RIG-I. However, 
it was more surprising for HMW Poly(I:C), which is thought to be a more potent activator of MDA5, a 
sensor of longer double stranded RNAs with no 5’ modifications, like Poly(I:C). 
 
Figure 3.4.4: Stimulation of A549 cells by synthetic RNAs is dependent on RIG-I  
qPCR to measure transcription of indicated genes in response to stimulation of A549 WT and RIG-I -/- with A) 1 
μg 3p-hpRNA and B) 1 μg Poly(I:C) (for all data shown, n=2 and  data are representative of >3 independent 
experimental replicates). 
 
3.4.5. Stimulation of A549 cells by SeV and IAV R+K is dependent on RIG-I  
Due to the complex structure of viruses, they often encode ligands for multiple PRRs. Subsequently, 
many viruses have evolved to avoid detection by encoding inhibitors to block the signalling of these 
receptors. Because of this, we examined the contribution of RIG-I to the sensing of SeV and IAV in 
A549 cells. 
In WT cells, infection with both SeV (Figure 3.4.5A) and IAV R+K (Figure 3.4.5B) resulted in similar 
patterns of transcription to what we saw previously (Figure 3.3.2A and 3.3.3A). As with synthetic 
RNAs, transcription of all genes in RIG-I -/- cells was barely detectable above background levels, 
confirming that RIG-I is the major sensor of SeV and IAV in A549 cells. 
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To corroborate this, the percentage of WT and RIG-I -/- cells expressing phosphorylated IRF3 and 
activated caspase 3 was analysed using phos-flow after infection with SeV. Approximately 20% of 
A549 WT cells infected with SeV for 6 hours were positive for phosphorylated IRF3. However, only 
0.2% of RIG-I -/- cells expressed phosphorylated IRF3, indicating this activation is dependent on RIG-
I. Almost none of either cell line, expressed activated caspase 3, suggesting RIG-I doesn’t initiate 




Figure 3.4.5: Stimulation  of A549 cells by SeV and IAV R+K is dependent on RIG-I  
qPCR to measure transcription of indicated genes in A549 WT and RIG-I -/- cells infected with A) SeV at 1:300 
dilution (n=2, data representative of >3 independent assays) and B) IAV PR8 NS1 R+K at MOI 3 (n=2, data 
representative of 3 independent assays). C) Dot plot and corresponding graphs of intracellular phosflow 
staining of pIRF3 (Ser396) and active caspase 3 in A549 WT and RIG-I -/- cells infected with SeV at 1:300 
dilution (n=1, WT data representative of 3 independent assay, RIG-I -/- data from one experimental replicate). 
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3.4.6. Stimulation of A549 cells by ZIKV is dependent on RIG-I  
To examine the extent to which RIG-I is responsible for sensing ZIKV in A549 cells, A549 WT and RIG-I 
-/- cells were infected with ZIKV PE243 and qPCR was used to measure transcription of immune 
genes shown to be activated in A549 WT cells (Figure 3.4.6A).  
At 16 and 24 hours post infection, transcription of IFNB1, IFNL1, CXCL10, ISG15 and ISG54, but not 
IFNA2, TNFA or IL6, was significantly induced. For all transcribed genes, this was dependent on RIG-I, 
with expression in RIG-I -/- cells barely detectable above background levels. This reinforces previous 
data showing RIG-I plays a dominant role in the induction of ZIKV-driven transcription394. By 48 hours 
post infection, transcription IFNA2, TNFA and IL6 in WT cells is detectable. However, they are also 
transcribed to the same level in RIG-I -/- cells, with significant induction of IFNL1 transcription also 
seen in RIG-I -/- cells at this later time point. This suggests that up to 24-hours, signalling is 
dependent on RIG-I, but by 48 hours a wave of RIG-I-independent immune signalling has been 
activated. 
Growth curve analysis of ZIKV replication (Figure 3.4.6B) showed similar levels of virus present at 16 
and 24 hours post infection in WT and RIG-I -/- cells, with only 1.5 times more virus present in WT 
cells at 24 hours. However, at 48 hours post infection there was 5 times the amount of virus present 
in RIG-I-knockout cells compared to WT. This is likely because the lack of a RIG-I-driven IFN-I 
response in knockout cells prevents the inhibition of viral replication seen in WT cells. 
The RIG-I-specific nature of early ZIKV-driven immunity in A549 cells strengthens the use of ZIKV as a 




Figure 3.4.6: Stimulation of A549 cells by ZIKV is dependent on RIG-I at early time points  
A) qPCR to measure transcription of indicated genes in A549 WT and RIG-I -/- cells infected with ZIKV PE243 at 
MOI 3 (n=3, data representative of >3 experimental repeats). B) ZIKV PE243 growth curve generated by 
titration and plaque assay, done by Dr. Nerea Irigoyen and Charlotte Lefevre. (n=3, data representative of 3 
experimental repeats). 
3.5. Discussion 
Sensing of RNA by RIG-I has been studied extensively, with synthetic RNAs, RNA viruses and gain or 
loss of function systems used to stimulate RIG-I in a variety of model cell lines, primary cells, and in 
vivo models. The signalling outputs of RIG-I stimulation have been characterised in multiple ways 
including gene expression quantification, cell signalling analysis and in vivo cellular immunity studies.  
Despite this large body of work, there are still many unanswered questions about most aspects of 
RIG-I signalling; from the features of RIG-I ligands and the identity of signalling and regulatory 
proteins involved in the pathway, to the outputs of RIG-I activation. Through the work in this 
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chapter, we determined and optimised the tools and assays required to investigate RIG-I signalling 
outcomes and characterise the RIG-I-dependent immune response generated. Generation of this 
system has allowed us to explore the RIG-I signalling complex and how it is regulated. 
3.5.1 A549 as a model system to study RIG-I signalling  
A549 cells were chosen as a tractable model to study RIG-I signalling and we established successful 
stimulation models with two synthetic RNAs, 3p-hpRNA and Poly(I:C), and three RNA viruses, SeV, 
IAV R+K and ZIKV PE243. all of which induced a measurable anti-viral innate immune response in 
these cells.  
Synthetic RNAs were chosen as they specifically activate RIG-I without the unwanted activation of 
other PRRs, which can occur when a single stimulus contains multiple ligands in complex with the 
RNA species, as is the case for viruses91. This specific activation of RIG-I without being recognised by 
other PRR is possible because the features of RNAs that activate RIG-I have been extensively studied 
and relatively well characterised83,89,90,95,354. Stimulation with of RIG-I by 3p-hpRNA and Poly(I:C) in 
A549 cells generates a measurable immune response, despite the relatively low transfection 
efficiency that affected our ability to monitor intracellular signalling with these ligands.  
RNA viruses were chosen as a model to study RIG-I signalling due to the biological significance of 
their sensing; IFN-I and IFN-III production during virus infection, essential to driving downstream 
immunity, is critically dependent on the detection of the virus by intracellular RNA sensors. Three 
viruses were chosen as RIG-I stimulation models: Sendai, Influenza and Zika, as their sensing has 
previously been shown to be RIG-I-dependent282,345,394. Infection of A549 cells with SeV and ZIKV, and 
use of an IAV mutant virus, results in activation of a measurable immune response, allowing us to 
study how viruses are sensed by RIG-I. 
3.5.2 There is variation between the immune gene expression profile in 
response to different RIG-I ligands 
Closer examination of the immune signalling response in A549 cells by qPCR, Western blotting 
analysis and ELISA showed that both the magnitude and the breadth of the immune response 
differed between the ligands. Stimulation with all ligands induced TBK1 and IRF3 activation resulting 
in IFN-I and chemokine production, whereas only SeV infection activated NF-κB and downstream 
inflammatory responses.  
As 3p-hpRNA is a relatively newly developed synthetic RNA, the response it induces is yet to be 
comprehensively characterised. Early studies show it stimulates activation of IFN-I and chemokine 
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responses374,379,395–397, mirroring what we see during stimulation of A549 cells. Induction of IFN-III 
and NF-κB-dependent responses by 3p-hpRNA, which we did not see, was detected in some but not 
all these studies, possibly due to differences in the response between cell types. Alternatively, this 
may be because their expression may meet the threshold of detection in some studies but not 
others, depending on the cell type, transfection method or analysis method. As we saw, the lack of a 
measurable immune response to the similar RNA 5’ppp-dsRNA has been previously shown in HEK 
cells91, although other studies have successfully used 5’ppp-dsRNA to stimulate RIG-I90,343. Possibly 
5’ppp-dsRNA may be a weaker ligand than 3p-hpRNA if RIG-I is preferentially activated by regions of 
secondary structure such as pan-handles than perfectly complementary dsRNA duplexes. 
Alternatively, it may be less efficiently transfected into A549 cells than 3p-hpRNA, or may be 
degraded upon entry into the host cell prior to being sensed by RIG-I. 
The activation of IFN-I and chemokine responses by Poly(I:C) seen in A549 also mirrored other 
studies398–402. However, from the transcriptional output of A549 cells we did not observe Poly(I:C)-
induced NF-κB activation, which has been relatively consistently documented previously, 
demonstrated by both phosphorylation of IκBα and transcription of IL6 and TNFA398,400,402–406. In 
some of these earlier studies, activation of NF-κB by Poly(I:C) was proven to be dependent on TLR3, 
which we have shown does not contribute to sensing of Poly(I:C) in our A549 cells, as no Poly(I:C)-
driven stimulation is present in RIG-I-deficient cells. This is supported by a study that showed that 
treatment of cells with extracellular Poly(I:C) resulted in TLR3-mediated activation of IFN-I and the 
NF-κB-dependent gene IL-8, but transfection of Poly(I:C) in the same cells activated RIG-I/MAVS-
dependent IFN-I activation, without IL-8 co-activation349. This suggests that NF-κB activation by 
Poly(I:C) seen in previous studies is likely to be mediated by TLR3 activation, supporting our lack of 
RIG-I-driven NF-κB activation in response to Poly(I:C). 
Infection of A549 cells with SeV resulted in activation of IFN-I, IFN-III, chemokines, and NF-κB-
dependent responses, with the highest levels of IFN-I and chemokine transcription of any 
stimulation method, mirroring what has been seen in previous studies301,407–412. Interestingly, SeV is 
the only stimulation method tested that activated NF-κB-dependent responses in A549 cells.  
One possibility as to why differing expression profiles are detected for different stimuli is that the 
responses are controlled by an activation threshold controls. For example, ligands like 3p-hpRNA and 
Poly(I:C), which induced minimal transcription of NF-κB dependent genes and no detectable IκBα 
phosphorylation, also tended to induce lower levels of IFNB1 and CXCL10 transcription than seen 
with SeV, which also activates NF-κB. Therefore, the threshold level of RIG-I activation that results in 
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NF-κB activation may be higher than the threshold for IRF3 activation. This threshold may depend on 
the activation status of a RIG-I signalling complex, varying in relation to the elements of a specific 
ligand; how many activated molecules of RIG-I there are in a single cell; or to how many stimulated 
cells there are in a population. For example, complexes containing fewer activated RIG-I CARD 
domains may only signal to activate IRF3 and not NF-κB. It is not known whether a single RIG-I 
signalling complex can activate both IRF3 and NF-κB, or whether each signalling complex drives 
either IRF3- or NF-κB-activation. It is likely rarer that both IRF3 and NF-κB are activated 
simultaneously in a single cell than just one of them, but we know this does occur as their co-
operative binding to promoters is required for transcription of genes like IFNB1, which does occur in 
a small subset of cells. Alternatively, RIG-I may be able to differentiate between ligands, signalling 
via a distinct pathway to initiate different responses to different ligands, although this has not been 
shown before. 
IAV PR8 WT infection of A549 cells didn’t activate an immune response, likely due to the 
immunosuppressive functions of the IAV NS1 protein362,363. IFN-I, IFN-III and chemokine production 
have been detected during infection with IAV PR8 WT and WSN WT strains in previous studies, but 
generally at later time points than we used for our assays413–418. This is reinforced by the fact that 
infection with the IAV NS1 R38A K41A mutant virus did induce activation of IFN-I and chemokine 
responses, but not NF-κB or IFN-III-dependent responses. The mutation of residues R38 and K41 
abrogates the ability of NS1 to bind dsRNA, preventing is ability to shield viral RNAs from recognition 
by RIG-I365,419,420. Previously demonstrated activation of NF-κB by IAV infection only occurred at later 
time points like 12 hours post infection, with minimal transcription of NF-κB-dependent genes TNFA 
and IL6 by 4 hours post infection413, which agrees with our data showing no transcription of NF- κB-
dependent genes after 6 hours. Similarly to what we showed mutations in NS1 in the WSN strain of 
IAV has also been shown to result in higher levels of IFN-I, IFN-III and NF-κB dependent gene 
transcription than seen with WSN WT 416. Our demonstrated lack of IFNL1 transcription contradicts 
what has been previously shown, with IFN-III is known to be important in the antiviral response to 
infection with IAV and other RNA viruses in epithelial cells376,377,421. This is likely caused by a lack of 
NF-κB activation, as transcription of IFN-III gene IFNL1 is predominantly activated by the binding of 
NF-κB binding sites in the promoter422, whereas IFNβ expression predominantly depends on the 
binding of IRF3 and 7 to its promoter373. The lack of NF-κB activation by IAV infection may be due to 
the antagonism of their activation by other IAV proteins, or alternative functions of NS1 not 
abrogated by the mutations. 
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ZIKV PE243 infection activated IFN-I and IFN-III responses and chemokine secretion, but not NF-κB. 
This supports previous data, including some studies in A549 cells, showing that ZIKV strongly infects 
A549 cells371, resulting in activation of IFN-I, IFN-I-dependent genes, and chemokines, with 
significantly less transcription of NF-κB-dependent genes IL-6 and IL-8 369,372,423. Our finding of ZIKV-
driven IFN-III activation is novel, as no previous studies have described activation of IFN-III by ZIKV 
infection. 
In addition to induction of differing immune expression profiles by different ligands, the magnitude 
of the response detected varied significantly between the ligands. SeV infection was the most potent 
inducer of immune gene transcription and chemokine secretion and resulted in the highest levels of 
phospho-IRF3, -TBK1 and -IκBα. This is likely because of the high proportion of dysfunctional DI-virus 
particles produced by the Cantell strain of SeV, which are both potent activators of RIG-I and 
diminish the effectivity of SeV-encoded proteins known to inhibit the innate immune response408. 
The magnitude of induction of IFN and chemokines with IAV and ZIKV was significantly lower than 
with SeV infection, likely because both viruses encode proteins that are designed to antagonise the 
immune response to avoid detection. A stronger response to IAV and ZIKV infection than to 
synthetic RNA transfection is likely because infection with both viruses deliver RNA-ligands of RIG-I 
into more cells than occurs during transfection of synthetic RNAs, resulting in more activated RIG-I 
signalling complexes. 
Although differing responses have undoubtedly been seen before across studies with many synthetic 
RNAs and viruses, as well as during examination of the minimal essential RIG-I ligand in vivo91, the 
reason for this remains unknown. 
3.5.3 The response to synthetic RNAs and RNA viruses in A549 cells was 
entirely dependent on RIG-I 
The contribution of RIG-I and other PRRs to the sensing of these stimuli was determined using RIG-I -
/- cells. For the synthetic RNAs and RNA viruses examined, all measurable immune response was lost 
in RIG-I -/- cells. This shows that the first wave of signalling in A549 cells in response to these stimuli 
is entirely dependent on RIG-I and rules out the possibility that the varying ranges of signalling 
outcomes for different ligands was due to the contribution of other PRR. 
Clean stimulation of RIG-I by the commercial ‘RIG-I ligand’ 3p-hpRNA was anticipated, based on its 
molecular characteristics. 3p-hpRNA is composed solely of known features of RIG-I ligands: an 
uncapped 5’ triphosphate group and regions of double-stranded RNA, in the form of panhandle or 
hairpin structures formed by self-annealing of the single stranded RNA, without any known features 
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that activate other PRR83,354. Previously, 5’ blunt ended dsRNA structures were reported to be the 
most potent RIG-I activators89,90, however in our hands measurable RIG-I signalling was not activated 
by the blunt-ended dsRNA 5’ppp-dsRNA, suggesting a preference for panhandle or hairpin structures 
formed by partially complementary single stranded RNAs like 3p-hpRNA. This is supported by 
Linehan et al. who, during analysis of the components of the minimal RIG-I ligand, suggest that RNA 
ligands with a stem loop “provide simplicity, structural stability, and resistance to nucleases while 
presenting a single duplex terminus that fits precisely into the RNA binding pocket of RIG-I”, which is 
not the case for dsRNA duplexes91.  
Surprisingly, RIG-I was also specifically activated by Poly(I:C) in our A549 cells, despite it not 
containing 5’ tri-or di-phosphate modifications. This disputes the idea that 5’ modifications are 
essential for RIG-I activation and is supported by previous studies that found RIG-I is activated by 
dsRNAs without a 5’phosphate group, albeit to a lesser extent than those with91,95. There is still much 
debate around how varied the RNA structures that successfully activate RIG-I can be. A lack of one 
preferential feature can has been proposed to be compensated for by the presence of another, 
enabled by the plasticity of the RNA binding domain of RIG-I93. Despite this, mono-phosphorylated 
RNA ends are thought to be selectively discriminated against by RIG-I, possibly even blocking the 
signalling of RIG-I101. 
Although generally thought of as a more potent ligand of MDA595, multiple studies implicate RIG-I as 
the major sensor of transfected high molecular weight (HMW) Poly(I:C), especially in epithelial and 
fibroblast cell types167,349–353. Lengths of Poly(I:C) below 2 kilobase-pairs (kbp) preferentially activate 
RIG-I over MDA5, with the reverse being true for full length undigested Poly(I:C)95. The two distinct 
mechanisms for binding of RNA by RIG-I, both preferentially binding 5’triphosphate blunt RNA ends 
and binding dsRNA internally, may allow for activation of RIG-I by RNAs without 5’phosphate 
groups353,424. Additionally, although Poly(I:C) is supposed to mimic long double-stranded RNA, it is in 
fact extensively branched and contains some single stranded segments and overhangs that may be 
responsible for activation of RIG-I107,425. Poly(I:C) used in these studies was advertised to be 1.5-8 kbp 
in length426, although we did not investigate its structure in more detail. 
Despite studies showing RIG-I contributes to the sensing of Poly(I:C), the lack of contribution of 
MDA5 was surprising. One potential explanation for this is that MDA5 is expressed at very low levels 
in these A549 cells. Opposing this, previous studies have shown MDA5 activation by Poly(I:C) in A549 
cells427–430 and upregulation of MDA5 expression in response to stimulation with VSV and Poly(I:C)427–
429. However, as previously discussed there can be differences between batches of commonly used 
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mammalian cell lines and a previous study examining the levels of RIG-I and MDA5 mRNAs in resting 
A549 cells by qPCR showed that the level of MDA5 mRNA is significantly lower than that of RIG-I431, 
reinforcing the fact that in our cells MDA5 was undetectable by western blotting in A549 cells, even 
after treatment with IFNα. From this, we suggest that MDA5 is not playing any role in the sensing of 
RNAs in A549 cells in our system.  
Our data suggests that TLR3, despite being known to be potently activated by extracellular and 
endosomal Poly(I:C)432, does not contribute to the sensing of transfected Poly(I:C) in A549 cells. This 
is supported by previous studies showing an intact immune response to Poly(I:C) in TLR3 deficient 
embryonic fibroblast cells, but not MAVS-deficient A549 cells or mice167,433–435. Like MDA5, TLR3 also 
has a low basal expression level in resting A549 cells, undetectable by Western blotting and with 
only very low levels of mRNA compared to RIG-I431. Perhaps, as its expression has been shown to be 
upregulated in response to IFN-I, Poly(I:C) transfection and IAV infection in A549 cells405,436, TLR3 
may contribute to later waves of immune signalling, but it does not contribute to the first wave of 
signalling in response to Poly(I:C) in our A549 cells. 
Studies with RIG-I -/- mice have shown the importance of RIG-I in the sensing of multiple RNA viruses 
such as Sendai, Vesicular Stomatitis Virus (VSV) and Newcastle Disease Virus (NDV) in most cell 
types. Only in plasmacytoid dendritic cells was RIG-I dispensable for IFN-I and interleukin production 
in response to infection with Newcastle disease virus, where TLR7 and 9 were required437. Although 
virus infection often results in the simultaneous activation of multiple PRRs, infection of A549 cells 
with SeV, IAV R+K and ZIKV activated RIG-I alone. The RIG-I specificity shown by SeV was expected as 
the DI particles produced by the Cantell strain potently activate RIG-I, but do not generate the long 
dsRNAs generally sensed by MDA5 and TLR397.   
Surprisingly, infection with IAV R+K also specifically activated RIG-I. As well as RIG-I, TLR3 is thought 
to be required for the pro-inflammatory response and maximum IFN induction by IAV infection, 
especially in lung epithelial cells432,438–441. However, previous studies have shown IAV-driven immune 
signalling to be solely RIG-I dependent95 and it is known that like SeV, natural IAV infection results in 
production of DI-RNAs essential for RIG-I driven early activation of IFN-I in IAV infected cells301. As 
described for Poly(I:C), we suggest that the absence of IAV-induced TLR3-dependent signalling is 
likely due to its low expression in A549 cells, although it also could be inhibited by the remaining 
immunosuppressive functions of the mutant NS1 protein, or other IAV proteins known to antagonise 
immune responses442. The absence of signalling by TLR3 , likely accounts for the lack of pro-
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inflammatory signalling seen after IAV infection of A549 cells, as this has been shown to mediate NF-
κB, but not IRF-3 dependent gene activation during IAV infection of human lung epithelium440.  
Up to 24 hours post infection, ZIKV-induced antiviral transcription was entirely dependent on RIG-I, 
although at 48 hours post-infection a second wave of RIG-I-independent signalling was activated.  
Recent studies have shown that RIG-I is the primary sensor of ZIKV infection, with MDA5 and TLR3 
both dispensable despite upregulation of TLR3 by early ZIKV infection313,368,369. This supports what 
had previously been inferred from the sensing of other flaviviruses such as Dengue102,443–445 and is 
further reinforced by the targeting of MAVS and IKKε by ZIKV-encoded proteins NS4A and NS5 to 
inhibit RIG-I signalling370,446. The cGAS-STING pathway has also been implicated in ZIKV sensing311,318, 
but this is unlikely to be playing a role in our system as A549 cells do not express STING thus can’t 
respond to stimulation with DNA343. The wave of RIG-I-independent signalling seen at later time 
points is likely to be activated by the other PRRs detecting the high levels of viral material in cells or 
the damage caused by virus infection. The activation of IFNα by ZIKV in a RIG-I-independent manner 
has previously been shown during Dengue infection, where its transcription is induced to prolong 
and increase expression of IFN-I, exacerbating the immune response447.   
The absence of functional MDA5 and TLR3 in A549 cells provides us with a ‘clean’ system to study 
the RIG-I signalling pathway and its outcomes. However, the main limitation of this system is that we 
could not use primary cells to best mimic the immune response that would happen in a physiological 
setting. Despite this, the system we have developed has allowed us to study specific RIG-I activation 
and the downstream signalling in detail, addressing previous inconsistencies. 
3.6 Conclusion 
In this chapter we have developed a system to study RIG-I-signalling in human cells.  Optimisation of  
stimulation methods and techniques examining the RIG-I-driven immune-response, resulted in a 
system where treatment of A549 cells with synthetic RNAs 3p-hpRNA and Poly(I:C) and RNA viruses 
SeV, IAV R+K and ZIKV generates a measurable innate immune response. All stimulation methods 
activated the TBK1/IRF3 signalling axis, resulting in transcription of IFN-I, IFN-I-dependent genes, and 
chemokines. SeV and ZIKV infection also activated IFN-III, and SeV alone activated NF-κB and 
downstream pro-inflammatory responses. Generation of RIG-I deficient cells allowed us to 
demonstrate that all signalling outcomes activated by all of the tested ligands were dependent on 
RIG-I, suggesting that they all specifically stimulate RIG-I in A549 cells. The development and 
characterisation of this system has given us a platform from which to address conflicting data from 
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previous studies surrounding the requirement for various downstream signalling proteins and the 
regulation of the RIG-I signalling pathway by LUBAC.   
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Chapter Four: Characterising the RIG-I 
signalling pathway 
4.1 Introduction 
Upon binding non-self RNA, RIG-I activates downstream signalling through the adaptor protein 
MAVS. Through the recruitment of many downstream signalling proteins, this triggers a cascade that 
activates IRF3 and NF-κB to induce expression of IFN and pro-inflammatory mediators. Although the 
signalling pathway downstream of RIG-I is better characterised than many other PRR, there is still 
much debate about which proteins are definitively required for the RIG-I driven immune response, 
the mechanism by which they act, and whether this differs depending on conditions or ligand. 
Before studying the role of LUBAC in RIG-I signalling, we wanted to better characterise what proteins 
are involved in the signalling complex in our system. LUBAC is known to conjugate M1-Ub chains to 
signalling complex proteins to enable efficient recruitment of downstream signalling proteins, thus 
controlling the composition of the signalling complex and the outcome of signalling. Therefore, this 
exploration of the signalling complex will be vital to help us understand how LUBAC functions to 
regulate it. 
Using knockout A549 cell lines, we tested the role of MAVS, NEMO, TBK1, IKKε, the TANK-NAP1-
SINTBAD complex, RIP1 and optineurin in RIG-I signalling. We found MAVS and NEMO, a known 
target of M1-Ub chains, to be essential for both IRF3- and NF-κB-driven responses. TBK1 and IKKε 
were shown to function redundantly to activate IRF3 in response to all ligands but play no role in NF-
κB activation. The role of the TANK-NAP1-SINTBAD complex, RIP1 and optineurin in RIG-I signalling 
remain unclear, with possible functions for RIP1 and optineurin in IRF3 activation, and potential 
redundant functions of all three proteins or protein complexes in the recruitment of TBK1 and IKKε 
to the signalling complex. 
4.2 MAVS is the central adaptor protein of the RIG-I signalling 
pathway 
The adaptor protein MAVS functions directly downstream of RIG-I activation. Upon recognition of 
viral RNA, RIG-I oligomerises its CARD domain, in a ubiquitin-dependent and -independent fashion. 
The CARD domain is then recruited to MAVS, which in turn oligomerises its CARD domains in a prion-
like fashion73, becoming a scaffold for sequential recruitment of a cascade of immune signalling 
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proteins. This cascade is thought to begin with recruitment of TRAFs 2, 5, and 6 to MAVS135,138,448, 
and ultimately results in the activation of IRF3 and NF-κB.  
4.2.1 MAVS is required for transcription downstream of RIG-I activation by 
SeV and 3p-hpRNA, but not Poly(I:C) 
To confirm the requirement of MAVS for RIG-I-driven immune gene transcription, A549 MAVS -/- 
cells were purchased from Invivogen. Upon analysis by Western blotting (Figure 4.2.1A), MAVS -/- 
cells were found to express a truncated form of the MAVS protein, with a molecular mass of 30 kDa 
compared to 70 kDa in WT cells. 
qPCR was used to analyse transcription of IFNB1 and CXCL10 in A549 WT and MAVS -/- cells 
stimulated by transfection with 3p-hpRNA (Figure 4.2.1B) and Poly(I:C) (Figure 4.2.1C) and infection 
with SeV (Figure 4.2.1D). Transcription of both IFNB1 and CXCL10 was entirely dependent on MAVS 
during stimulation of RIG-I with both 3p-hpRNA and SeV. However, in response to transfection with 
Poly(I:C), expression of IFNB1 and CXCL10 transcripts was three times higher MAVS -/- cells 
compared to WT.  
This may be due to differential protein expression between clonal cell lines, even derived from the 
same cell original cell line, which has been described previously in A549 cells449. The WT and MAVS -
/- cells in this experiment are from different batches, with the WT cells coming from the lab of 
Henning Walczak (University of Cologne) and the MAVS -/- cells from Invivogen. TLR3 is the only 
known sensor of Poly(I:C) that does not signal through the adaptor proteins MAVS, instead using 
TRIF346,450,451. Therefore, we suggest that the MAVS -/- cell line expresses higher levels of TLR3 than 
WT cells, which senses Poly(I:C) in endosomes of transfected cells. To investigate this possibility, WT 
and MAVS -/- cells were treated with extracellular, non-transfected, Poly(I:C), which can only be 
detected by TLR3, and transcription was measured by qPCR (Figure 4.2.1E). Again, MAVS -/- cells 
showed much higher levels of CXCL10 transcripts than WT suggesting that MAVS -/- cells express 
higher levels of TLR3, and possibly other components unique to the TLR3 signalling complex. 
From this we conclude that MAVS is required for RIG-I-driven signalling in response to both 3p-
hpRNA and SeV, which specifically activate RIG-I, but not Poly(I:C), whose activation in MAVS -/- cells 
is not RIG-I-specific. To confirm that MAVS was required for activation of both IRF3 and NF-κB by 
RIG-I, transcription further genes would have to be analysed by qPCR, although based on these 




Figure 4.2.1 MAVS is required for RIG-I-driven immune signalling following stimulation with synthetic RNAs 
and RNA viruses 
A) Western blotting analysis of A549 WT and MAVS -/- cells. qPCR to measure transcription of indicated genes 
in A549 WT and MAVS -/- cells in response to B) transfection with 1 μg 3p-hpRNA, C) transfection with 1 μg 
Poly(I:C), D) SeV infection at 1:300 dilution and E) external treatment with 1 μg Poly(I:C) (for all qPCR, n=2 and 
data is representative of 2 experimental repeats). 
4.3 NEMO is required for activation of both IRF3 and NF-κB during 
RIG-I signalling 
The adaptor protein NEMO is found in many PRR signalling pathways and has also been implicated in 
RIG-I signalling, where it acts upstream of TBK1 and IKKε to activate both the IRF3/7 and NF-κB 
signalling pathways143,149. To investigate the role of NEMO in RIG-I signalling, we used A549 cells 
deficient in NEMO, and NEMO -/- cells reconstituted with TAP-NEMO expression, both a kind gift 
from Henning Walczak (University of Cologne). 
4.3.1 NEMO is required for transcription of IFN-I-dependent genes during 
stimulation of RIG-I with synthetic RNAs 
Western blotting analysis of WT, NEMO -/- and NEMO -/- + TAP-NEMO (TAP-NEMO) cells (Figure 
4.3.1A) confirmed loss of NEMO expression in knockout cells, and re-expression of endogenous 
levels of NEMO in the TAP-NEMO cell line.  
To test whether NEMO is required for the synthetic RNA-driven IRF3-dependent immune response, 
A549 WT and NEMO -/- cells were stimulated with 3p-hpRNA and Poly(I:C) and transcription of 
immune genes was examined by qPCR. During both 3p-hpRNA (Figure 4.3.1B) and Poly(I:C) (Figure 
4.3.1C) stimulation, increased transcription was seen in WT cells but was barely detectable above 
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background levels in NEMO -/- cells, showing that expression of NEMO was required for 
transcription of all tested genes. 
 
Figure 4.3.1: NEMO is required for synthetic RNA-driven activation of IRF3- and NF-κB-dependent pathways  
A) Western blot analysis of A549 WT and NEMO -/- cells. qPCR to analyse transcription of indicated genes in 
A549 WT and NEMO -/- cells stimulated with B) 1 μg 3p-hpRNA and C) 1 μg Poly(I:C) (for both, n=2 and data is 
representative of 3 experimental repeats). 
4.3.2 NEMO is required for activation of both IRF3- and NF-κB-dependent 
responses to SeV infection 
To assess whether NEMO is also required for RIG-I-driven antiviral responses, the effect of NEMO 
expression on SeV-driven IRF3 and NF-κB-dependent signalling was examined.  
During SeV infection, expression of IFN-dependent transcripts IFNB1, IFNL1, CXCL10, ISG15 and 
ISG54 was barely detectable above background levels in NEMO -/- cells, despite high levels of 
transcripts being found in WT cells (Figure 4.3.2A). NFKBIA, the only NF-κB-dependent gene whose 
transcription was strongly induced by SeV infection in WT cells, was also not transcribed above 
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background levels in NEMO -/- cells. Together, these data show that NEMO is essential for 
transcription of both IRF3 and NF-κB-dependent genes during RIG-I activation. qPCR analysis of the 
transcription in SeV infected A549 WT, NEMO -/- and TAP-NEMO cells (Figure 4.3.2C), demonstrates 
that re-expression of NEMO cells rescues the transcription of immune genes to near WT levels, 
confirming the requirement of NEMO.  
Western blotting analysis of SeV infected A549 WT and NEMO -/- cells (Figure 4.3.2C) showed that 
NEMO was required for phosphorylation of IRF3 at serine residues 386 and 396. Conversely, NEMO 
appears not to be required for phosphorylation of TBK1 or IκBα. Having said this, NEMO does appear 
to be required for the degradation of total IκBα, which only occurred in WT cells during SeV 
infection.  
Because in the absence of NEMO, TBK1 is still activated by RIG-I signalling, but IRF3 is not, we posit 
that NEMO may be involved in the recruitment of IRF3 to the RIG-I signalling complex, bringing it 
into proximity to TBK1 to enable activation. NEMO also appears to be required for NF-κB activation 
and subsequent transcription, because although cells lacking NEMO still express phospho-IκBα, they 





Figure 4.3.2: NEMO is required for SeV-driven activation of IRF3- and NF-κB-dependent pathways  
qPCR analysis of transcription of indicated genes in A) A549 WT and NEMO -/- cells infected with SeV at 1:300 
dilution (n=2, data representative of 3 experimental repeats) and B) SeV infection of A549 WT, NEMO -/- and 
NEMO -/- + TAP-NEMO at 1:300 dilution (n=2, data representative of 2 experimental repeats). C) Western blot 
analysis of signalling protein activation in A549 WT and NEMO -/- cells infected with SeV at 1:300 dilution blot 
in the presence (+) or absence of 10 μM MG-132 (data representative of 2 experimental repeats).  
4.4 TBK1 and IKKε function redundantly to activate IRF3 during RIG-I 
signalling in A549 cells 
Our previous experiments have shown that stimulation of A549 cells with both synthetic RNAs and 
RNA viruses results in phosphorylation of TBK1 at Serine 172 (Figures 3.3.1C, 3.3.2C and 3.3.3B), a 
modification known to strongly promote TBK1 activity452. Consequently, we predicted that, as has 
been shown in signalling pathways in many model systems, TBK1 was required for the 




TBK1, alongside IKKα, β and ε, is part of the Inhibitor of Nuclear Factor Kappa-B Kinase (IKK) 
subfamily of Serine-Threonine protein kinases. IKKα and IKKβ form the canonical IKK complex to 
activate NF-κB, whereas TBK1 and IKKε form the non-canonical IKK complex171. TBK1 and IKKε were 
initially implicated in NF-κB activation, evident during overexpression of the two proteins172,453–455. 
However, this was later disputed and the non-canonical IKK complex was found to be required for 
the phosphorylation of IR 21,151,152 F3. Furthermore, TBK1 and IKKε are also responsible for 
restricting cell death outcomes downstream of TNF activation333,456. TBK1 exhibits functional 
redundancy with IKKε, but the proteins have differing expression patterns; TBK1 is constitutively 
expressed in many cell types, but basal IKKε expression is only detectable in specific cell types, such 
as pancreas, thymus and spleen170. Despite low basal levels, IKKε expression has been shown to be 
rapidly and dramatically upregulated in response to cytokines and microbial products171,172, triggered 
by both NF-κB and STAT3 binding sites in its promoter457,458. This capacity for rapid upregulation 
enables IKKε to contribute to signalling, even in cell types where its expression is very low. In non-
immune cells, IKKε was reported to be predominantly involved in phosphorylation of STAT proteins 
after initiation of the Type I IFN response173, but has also been shown to phosphorylate IRF3 and 
IRF7 downstream of viral RNA sensors143,459. 
4.4.1 TBK1 and IKKε function redundantly in the RIG-I response to 
synthetic RNAs 
We set out to assess the relative contributions of TBK1 and IKKε to RIG-I signalling using A549 WT, 
TBK1 -/-, IKKε -/- and TBK1/IKKε -/- cells (a gift from Henning Walczak, University of Cologne, 
Germany). These cell lines were stimulated with 3p-hpRNA (Figure 4.4.1A) and Poly(I:C) (Figure 
4.4.1B) and transcription of immune genes was analysed by qPCR. In TBK1 and IKKε single knockout 
cells, the level of transcription of all genes was as, or more than, seen in WT cells. However, cells 
lacking both TBK1 and IKKε expression had significantly reduced CXCL10 and ISG54 transcription 
during stimulation with both 3p-hpRNA and Poly(I:C). Low expression of IFNB1, IFNL1 and ISG15, 




Figure 4.4.1: TBK1 and IKKε act redundantly during RIG-I stimulation by synthetic RNAs 
qPCR to measure expression of indicated genes during stimulation of A549 WT, TBK1 -/-, IKKε -/- and 
TBK1/IKKε -/- cells by transfection of A) 1 μg 3p-hpRNA and B) 1 μg Poly(I:C) (for both, n=2 and data is 
representative of 3 experimental repeats). 
 
4.4.2 TBK1 and IKKε function redundantly in the IRF3-dependent response 
to SeV infection, but are not required for the NF-κB dependent response 
Infection of TBK1 and IKKε deficient cells with SeV enabled us to investigate involvement of TBK1 
and IKKε in both IRF3 and NF-κB activation downstream of RIG-I, due to the broader measurable 
immune response induced.  
Analysis of transcription by qPCR (Figure 4.4.2A) showed that loss of either TBK1 or IKKε resulted in 
either no significant change or a significant increase in transcription of all genes, as seen with 3p-
hpRNA and Poly(I:C). In a much clearer picture than during synthetic RNA stimulation, in cells lacking 
both TBK1 and IKKε the transcription of IFNB1, IFNL1, CXCL10, ISG16 and ISG54 was undetectable 
above background levels. This confirms that the contribution of either one of TBK1 or IKKε is 
essential for activation of an IFN-I and IFN-III-driven transcriptional response, as previously 
reported167,460. Conversely, transcription of NFKBIA and TNFA in cells lacking both TBK1 and IKKε was 
not significantly different from WT or single knockout cell lines, demonstrating that TBK1 and IKKε 
do not contribute to RIG-I-driven NF-κB activation in A549 cells.  
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The requirement of either TBK1 or IKKε for efficient chemokine production was confirmed by ELISA 
analysis of CXCL10 secretion from A549 WT, TBK1 -/-, IKKε -/- and TBK1/IKKε -/- cells infected with 
SeV (Figure 4.4.2B). Unlike with qPCR analysis, ELISA showed that TBK1 -/- and IKKε -/- cells have an 
intermediate phenotype, secreting about two thirds the level of CXCL10 secretion seen in WT cells. 
Across 2 experimental replicates, TBK1 -/- cells showed consistently lower levels of CXCL10 secretion 
than IKKε, in line with observations that TBK1 plays the predominant role in IRF3 activation in non-
immune cells. A549 cells deficient in both TBK1 and IKKε secreted little or no CXCL10 after infection. 
To further analyse the role of TBK1 and IKKε in the activation of IRF3 and NF-κB, Western blotting 
analysis of TBK1, IRF3 and IκBα phosphorylation in these cell lines was done during SeV infection 
(Figure 4.4.2C). In WT cells, levels of phosphorylated IRF3 and TBK1 increased through the 6-hour 
infection time course, whereas the level of phospho(p)-IκBα was highest at 3 hours post infection 
and lost at later time points, consistent with it being quickly degraded by the proteosome post-
phosphorylation. In TBK1 -/- cells, levels of phospho-IRF3 and phospho-IκBα are consistent with 
what is seen in WT cells, with TBK1 phosphorylation absent. Levels of phospho-IRF3 and phospho-
IκBα in IKKε -/- cells are similar to both WT and TBK1 -/- cells, however increased levels of phospho-
TBK1 were detected. This is suggestive of increased TBK1 activation to compensate for loss of IKKε 
expression, in line with their redundancy. IRF3 phosphorylation is undetectable in cells lacking both 
TBK1 and IKKε, supporting the requirement for either TBK1 or IKKε in IRF3 activation, IκBα 
phosphorylation is unchanged or higher than seen in WT and single knockout cell lines. This is 
consistent with the qPCR data for showing the unaffected transcription of NFKBIA in these cells 
(Figure 4.4.2A), confirming that TBK1 and IKKε are not required for NF-κB activation.  
IKKε phosphorylation was still undetectable by Western blotting after 6 hours of infection, even in 
TBK1 -/- cells, and there was no visible upregulation of total IKKε protein levels (data not shown). 
However, after a longer SeV infection time course and a 24 hour IFNα treatment, conditions 
previously shown to upregulate known ISG RIG-I (Figure 3.4.1B), phospho-IKKε was detected by 
Western blotting in TBK1-deficient cells but not WT cells (Figure 4.4.2D), with expression is much 
stronger after stimulation with IFNα. Upregulation of IKKε only in TBK1 -/- cells suggests loss of TBK1 




Figure 4.4.2: TBK1 and IKKε act redundantly during stimulation of RIG-I by SeV 
Infection of A549 WT, TBK1 -/-, IKKε -/- and TBK1/IKKε -/- cells with SeV at 1:300 dilution and A) qPCR to 
analyse transcription of indicated genes (n=2, data representative of >3 experimental repeats), B) ELISA to 
analyse CXCL10 secretion (n=2, data representative of 2 experimental repeats), C) Western blotting analysis of 
signalling protein activation (data representative of 2 experimental repeats) and D) Western blotting analysis 
of IKKε phosphorylation during infection with SeV at 1:300 dilution and treatment with 100 U/mL IFNα. 
4.5 How are TBK1 and IKKε recruited to the RIG-I signalling pathway 
Activation of TBK1 and IKKε is known to occurs by trans-autophosphorylation when the proteins are 
at a high concentration in signalling complexes161,452, but there is debate surrounding about how 
TBK1 and IKKε are recruited to the RIG-I signalling pathway. TRAF proteins, the TANK/NAP1/SINTBAD 
complex, RIP1 and Optineurin have all been implicated in its recruitment to the mitochondrial MAVS 
complexes. To study their contribution to TBK1 and IKKε recruitment, we have used A549 cell lines 
deficient in TANK/NAP1/SINTBAD, RIPK1 and Optineurin.  
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4.5.1 TANK/NAP1/SINTBAD are not essential for recruitment of TBK1 and 
IKKε to the RIG-I signalling complex during stimulation with synthetic 
RNAs 
The TANK, NAP1 and SINTBAD proteins, identified through their shared TBK1-binding 
domains453,461,462, have been previously implicated in TBK1 recruitment to the RIG-I signalling 
complex462–465, as well as TBK1 and IKKε recruitment to the TNF-RSC466. Using A549 cells deficient in 
TANK, NAP1 and SINTBAD (TKO), a kind gift from the lab of Henning Walczak (University of Cologne), 
we examined the requirement of this protein complex in TBK1 and IKKε recruitment to the RIG-I-
RSC. 
Western blotting analysis of TANK protein expression in WT and TKO cells (Figure 4.5.1A) confirmed 
loss of TANK expression in the knockout cells, but antibodies against NAP1 and SINTBAD were 
unsuccessful in detecting proteins in either WT or TKO cells. Therefore, to verify that the TKO cells 
behave previously shown, with reduced levels of TBK1 phosphorylation during TNFα stimulation333, 
WT and TKO cells were stimulated with TNFα and the phosphorylation of IRF3, TBK1 and IκBα was 
analysed by Western blotting (Figure 5.4.1B). In cells lacking TANK, NAP1 and SINTBAD, TBK1 
phosphorylation was significantly reduced compared to WT cells, confirming reduced recruitment of 
TBK1 to the TNF signalling complex in TKO cells, and increased in IκBα phosphorylation was also 
seen, mimicking the previous study333. Because, unlike in RIG-I signalling, TBK1 doesn’t drive IFN-I 
induction downstream of TNF, the lack of IRF3 phosphorylation seen was expected. This highlights 
the different roles of TBK1 and IKKε between the two pathways, possibly mediated by differential 
recruitment mechanisms to the respective signalling complexes.  
After functional verification of the TKO cells, qPCR analysis was used to assess the role of the 
TANK/NAP1/SINTBAD complex in RIG-I-induced transcription in response to stimulation with 3p-
hpRNA (Figure 4.5.1C) and Poly(I:C) (Figure 4.5.1D). Whilst transcription of CXCL10 in response to 
both RNAs was significantly lesser in TKO cells across multiple experimental repeats, this was not 
true of other IFN-I or IFN-I-stimulated genes. From this we cannot say whether the 
TANK/NAP1/SINTBAD complex is required for the recruitment of one of TBK1 or IKKε due to their 
functional redundancy, however it suggests that the complex is not essential for the recruitment of 




Figure 4.5.1: TANK/NAP1/SINTBAD are not essential for RIG-I-driven pathways downstream of activation by 
synthetic RNAs 
A) Western blotting of A549 WT and TANK/NAP1/SINTBAD -/- (TKO) cells and B) Western blotting analysis 
signalling protein phosphorylation in A549 WT and TKO cells stimulated with TNFα @ 200 ng/mL. qPCR 
analysis of transcription of indicated genes in A549 WT and TKO cells stimulated by C) 1 μg 3p-hpRNA and D) 1 
μg Poly(I:C) (both n=2, data representative of 3 experimental replicates).  
 
4.5.2 TANK/NAP1/SINTBAD are not essential for recruitment of TBK1 and 
IKKε to the RIG-I signalling complex during SeV infection 
To see if this is also the case during RNA virus infection, WT and TKO cells were infected with SeV, 
transcription of immune genes was measured by qPCR (Figure 4.5.2A) and activation of signalling 
proteins was measured by Western blotting (Figure 4.5.2B). Unlike seen with synthetic RNAs, during 
SeV infection there was no significant reduction in CXCL10 transcription in TKO cells. Results differed 
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slightly between experimental replicates, but generally there was a trend for either no significant 
change or an increase in transcription in cells lacking TANK, NAP1 and SINTBAD compared to WT for 
both IRF3 and NF-κB dependent genes. Western blotting during SeV infection supported this, with 
TKO cells expressing similar levels of phospho-IRF3 but elevated levels of both p-TBK1 and p-IκBα 
compared to WT.  
This data, as well as that seen with synthetic RNA stimulation, shows that the TANK/NAP1/SINTBAD 
complex is not essential for recruitment of both TBK1 and IKKε to the RIG-I signalling complex, but 
may play a role in the recruitment of one of the proteins. This is likely to be TBK1, as this has 
previously been shown151–153, whereas they have never been specifically implicated in IKKε 
recruitment previously. 
 
Figure 4.5.2: TANK/NAP1/SINTBAD are not essential for RIG-I-driven pathways downstream of activation by 
SeV 
SeV infection A549 WT and TKO cells at 1:300 dilution and A) qPCR analysis of transcription of indicated genes 
(n=2, data representative of >3 experimental replicates) and B) Western blotting analysis of signalling protein 
100 
 
phosphorylation. 0h and 1h samples were accidentally loaded in the wrong lanes, represented by a red 
double-headed arrow (data representative of 2 experimental repeats). 
 
4.5.3 The role of RIP1 in the RIG-I signalling pathway is unclear 
The role of the kinase RIP1 in RIG-I signalling is heavily contested. Some studies have shown that it is 
recruitment to the MAVS signalling complex alongside FADD and caspase 8, where RIP1 recruits 
TANK and NEMO to MAVS, a process required for maximum activation of NF-κB and IRF3 149,467–470, 
before it is cleaved by caspase 8 to inhibit IRF3 activation in a self-regulating loop. However, loss of 
RIP1 expression in MEFs was shown to have no effect on IFN-I production142, disputing this. To 
investigate the role of RIP1 in the RIG-I signalling in A549 cells, A549 RIP1 -/- cells, generated in the 
lab of Henning Walczak (University of Cologne), were stimulated by SeV infection. 
Loss of RIP1 protein expression in RIP1 -/- cells was confirmed by Western blotting analysis (Figure 
4.5.3A). A549 WT and RIP1 -/- cells were then analysed by qPCR to measure immune gene activation 
(Figure 4.5.3B). During SeV infection, RIP1 -/- cells showed significantly reduced transcription of 
IFNB1, consistent across 4 experimental repeats. However, the transcription of IFN-I-stimulated 
genes ISG15 and ISG54 was not consistently reduced in RIP1-deficient cells, with mixed outcomes 
across experimental repeats. Similarly, loss of RIP1 expression also did not significantly alter 
transcription of chemokine CXCL10, or NF-κB dependent genes NFKBIA.   
This is somewhat supported by Western blotting analysis of lysates from SeV infected WT and RIP1 -
/- cells (Figure 4.5.3C). Generally, deletion of RIP1 only minorly affected phosphorylation of signalling 
pathway components, with IκBα phosphorylation unaffected and higher levels of phosphorylated 
TBK1 were detected in RIP1 -/- cells at 2 and 4 hours post infection. However, IRF3 phosphorylation 
appeared to be delayed in RIP1 -/- cells. As RIP1 -/- cells show a defect in the activation of IRF3, 
which affects the transcription of IFN-I gene IFNB1, we suggest that RIP1 may play a role in 
activation of IRF3 during RIG-I signalling. However, unclear data around the transcription of ISGs 
means that more work would have to be done to confirm this. Both transcriptional and Western 
blotting data consistently suggests that RIP1 is not to be required for RIG-I-dependent activation of 





Figure 4.5.3: RIP1 may play a role in RIG-I-driven IRF3 activation by SeV 
A) Western blot analysis of A549 WT and RIP1 -/- cells. SeV infection of A549 WT and RIP1 -/- cells at 1:300 
dilution and A) qPCR analysis of transcription of indicated genes (n=2, data representative of >3 experimental 




4.5.4 Optineurin appears not to be required in the RIG-I response to SeV 
infection 
Optineurin (OPTN) is a NEMO-related, Golgi localised protein known to bind to ubiquitinated 
proteins. It has been shown to regulate many cellular processes, including immune, inflammatory 
and antiviral signalling, generally occurring through suppression of NF-κB activation by mimicking 
NEMO471–474, or activation of IFN-I through its interaction with TBK1162,475,476. Optineurin has also 
been implicated in the RLR-driven antiviral response, interacting with ubiquitinated TBK1 to initiate 
its trans-autophosphorylation, resulting in IRF3 phosphorylation and IFN-I activation162–164. However, 
this appears to be cell-type specific and has been opposed, with Optineurin also suggested to be a 
negative regulator of RIG-I-driven IFN-I activation477. Interestingly, OPTN can bind TBK1 but not IKKε, 
supporting suggestions that the two redundant proteins may be recruited differently155,156. OPTN has 
also been shown to interact with the LUBAC complex during RNA virus infection157.  
To explore its role in RIG-I signalling in A549 cells, optineurin deficient A549 cells (OPTN -/-), a kind 
gift from the lab of Henning Walczak (University of Cologne) were infected with SeV. From a single 
experimental replicate, qPCR data shows that expression of IFNB1 was significantly less in OPTN -/- 
cells, but expression of CXCL10 was significantly more (Figure 4.5.4A), meaning that we do not have 
enough data to conclude anything around the role of optineurin in RIG-I signalling in A549 cells. 
 
Figure 4.5.4: Optineurin is not essential for RIG-I-driven pathways downstream of activation by SeV 
A) SeV infection of A549 WT and OPTN -/- cells at 1:300 dilution and qPCR analysis of transcription of indicated 
genes (n=2, data representative of one experimental replicate). 
4.6 Discussion 
Much of the data surrounding the requirement of individual signalling proteins for RIG-I-driven IFN-I 
and NF-κB activation is conflicting, suggesting that this may be context dependent. Because we have 
demonstrated that we have a system to study RIG-I signalling that is not interfered with by other 
RNA sensors, with RIG-I-deficient A549 cells showing no signalling response to all tested RNAs and 
103 
 
viruses, we believe we have a clean system to assess the contribution of proteins to signalling in 
A549 cells. Therefore, before examining how LUBAC and M1 ubiquitin chains regulate the RIG-I 
signalling pathway, we set out to further define the composition of the RIG-I signalling complex in 
our system. Through the work in this chapter, we used knockout cell lines to test the requirement of 
various signalling proteins, some of which are known to be modified by LUBAC, for the activation of 
both IRF3 and NF-κB. Such data will then allow us to identify where LUBAC fits into the signalling 
pathway, what both LUBAC and M1-Ub chains are binding to, and how it contributes to RIG-I 
signalling outputs. 
4.6.1 Limitations of experimental system 
Throughout this project, protein function was studied using CRISPR knockout cells, predominantly 
A549. Although this system has many benefits over some techniques such as protein overexpression 
or incomplete knockdown studies, various limitations prevail. 
Limitations of using cancer cell lines are derived from the fact that cancer is driven by genetic 
alterations, which can dysregulate signalling pathways. For example, A549 cells have downregulated 
STING to inhibit the DNA sensing pathway, helping them remain undetected by the immune 
system341–343. However, in this instance, as A549 cells have an intact RIG-I-driven RNA sensing 
pathway but appear to have downregulated other RNA sensors like MDA5 and TLR3431, this enabled 
us to have a clean system to study RIG-I signalling without interference from other PRR. Use of 
primary cells would provide more relevance to the data, although they are not as tractable for 
genetic manipulation to study the function of individual proteins within signalling pathways. Cell 
lines enable fine manipulation of cellular functions and tend to generate more reproducible data, as 
they aren’t as reactive to small changes in culture conditions as primary cells, and their features do 
not change as much with serial passaging. However, as cancer cell lines are often resistant to cell 
death, another mechanism developed to inhibit their destruction by the immune system, limiting 
their usefulness for studying regulation of cell death pathways, as was done in this project. 
The use of CRISPR techniques to study protein function also comes with limitations. Although recent 
advances in CRISPR technology have enabled its accurate and target-specific use to knockout 
expression of an individual protein, off-target effects of CRISPR can still occur478. This can result in 
incorrect attribution of phenotypes to target proteins protein, that are in fact the result of off-target 
genetic editing. Furthermore, once a population of CRISPR edited cells has been generated, studies 
must then use either the heterozygous pool of edited cells or clonal populations grown from 
individual edited cells. In this study, CRISPR-edited A549 cells from the heterogenous wild-type 
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population were grown as clonal populations, which were then characterised and used for functional 
studies. This was done as a homozygous clonal cell line ensures that expression of the target protein 
is entirely ablated, leading to reproducible results. However, if only a single CRISPR clone is then 
used to study protein function, variation between the individual clones, unrelated to the function of 
the target protein, can be misconstrued.  
A number of mechanisms can be used to address these limitations. To mitigate against off-target 
effects, whole genome sequencing can be done in CRISPR-edited cells, although this is expensive and 
time consuming. Clonal variation can be countered by the use of multiple knockout clones to explore 
target protein function. Additionally, single cell sorting and clonal expansion from the wild-type 
population of cells would enable CRISPR pools to be pools generated from a single wild-type clone, 
preventing clonal variability. To address both limitations, repetition of assays in knockout cells with 
the target protein re-expressed, either stably or transiently, to see if the phenotype seen in knockout 
cells was reversed, could be done. CRISPR-edited cells can also be validated by repeating previously 
published functional characterisation. 
Where possible in the scope of this study, some of the aforementioned measures were used to 
mitigate against limitations. Although predominantly knockout A549 cells were used for to explore 
the function of target proteins, CRISPR-edited HaCaT and MEF cells were also used to further explore 
phenotypes seen in A549 cells. For CRISPR knockout cell lines generated as part of the project, loss 
of protein expression was confirmed by Western blotting and the presence and location of the 
mutation introduced by editing was confirmed by sequencing of the genomic DNA of the knockout 
clone. Unfortunately for both cell lines generated during this project, only one successful knockout 
clonal cell line was generated, so multiple clones could not be used for functional characterisation. 
These cells were further characterised by functional assays to ensure non-targeted signalling 
pathways remained intact. For CRISPR knockout cell lines used in the project that were kind gifts 
from collaborators, loss of protein expression was also confirmed by Western blotting. Where 
possible, functional confirmation of the cell line was also done by repeating a relevant assay 
previously published using the specific cell line, for example when A549 WT and A549 
TANK/NAP1/SINTBAD -/- cells were stimulated with TNFα (Figure 4.5.1B) to confirm reduced TBK1 
phosphorylation in triple knockout cells. Functional characterisation of knockout cells stably re-
expressing both HOIP and NEMO confirmed that re-expression of the target protein reversed the 




4.6.2 Requirement for MAVS and NEMO in RIG-I signalling  
Much of the controversy surrounding the specific role of many proteins in RIG-I signalling is likely 
due to the use of many different cell types and even species in prior studies, between which we 
would expect a level of variation. Because of this, we did not assume anything about the 
composition of the RIG-I signalling complex in our system. Instead, we examined RIG-I signalling 
outcomes in a range of knockout cell lines to ascertain the relative contribution of each protein to 
the signalling outputs.  
We confirmed the requirement of MAVS, the central adaptor protein of both the RIG-I and MDA5 
signalling complexes, for activation of IFN-I and chemokine responses. This was expected as the role 
of MAVS in the RIG-I signalling complex is well described, with MAVS forming the basis for 
recruitment of signalling proteins that activate IRF3 and NF-κB434,479. In our system, we did not 
examine the mechanism by which MAVS activated signalling outcomes, although previous data 
suggests that the activation of the resultant signalling cascades is mediated by the recruitment of 
TRAF proteins to MAVS at the mitochondrial outer membrane135,143.  
Secondly, consistent with previous studies describing its role in both branches of RIG-I signalling149, 
we showed that NEMO is required for the activation of both IRF and NF-κB-dependent signalling 
responses. Previously, NEMO-mediated activation of both branches of signalling has been shown to 
occur through recruitment of the IKK complex, which then phosphorylates IκBα to activate NF-κB, 
and TBK1 to enable IRF3 activation143,480. Our data somewhat disputes this, showing that TBK1, but 
not IRF3, was activated in the absence of NEMO. This instead supports a previously proposed NEMO-
independent mechanism of TBK1 and IKKε activation by MAVS and TRAF proteins143. However, as 
NEMO is required for IRF3 activation, we propose that NEMO recruits active TBK1 to the RIG-I 
signalling complex, bringing it into proximity with IRF3. In addition to this, whilst NEMO was required 
for the transcription of NF-κB-dependent genes and the required degradation of IκBα, NEMO was 
not required for the prior phosphorylation of IκBα. Degradation of IκBα is initiated by its N-terminal 
phosphorylation by IKKβ, which recruits the E3 ligase SCF-βTrCP that conjugates K48-ubiquitin chains 
to IκBα, targeting the protein for selective degradation by the 26S proteosome481. As 
phosphorylation but not degradation of IκBα does not occur in cells lacking NEMO, possibly NEMO is 
involved in the recruitment of the UBC4/5 E2 and SCF-βTrCP E3 ligase to IκBα at the RIG-I signalling 
complex, something that has previously been attributed to IKKβ482.  
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4.6.3 The role of TBK1 and IKKε in IRF3 activation in non-immune cells 
Activation of IRF3 occurs occur through direct phosphorylation at Serine 386 by both TBK1 and 
IKKε69,173,460,483,484. We have shown that TBK1 and IKKε function redundantly to phosphorylate IRF3 
and activate IFN-I dependent signalling downstream of RIG-I, suggesting that they are both recruited 
to the RIG-I signalling complex in this system.  
Previously, TBK1 has been shown to be the major mediator of IRF3 activation in non-immune cells, 
with IKKε considered dispensable for IFN-I induction, likely due to its low expression167,169,460,485. 
Disputes around the role of IKKε in IRF3 activation likely stem from differential expression of IKKε 
between non-immune cell types. However, as IKKε is upregulated as quickly as 1 hour during 
infection with RNA virus SeV in embryonic fibroblasts and A549 cells169,486, it can contribute to 
signalling in cells where it is undetectable in the absence of stimulation. In our system, IKKε fully 
activates IRF3 in the absence of TBK1, supporting this. This in turn disputes previous studies showing 
that the requirement for IKKε in non-immune cells is either less significant or delayed compared to 
TBK1169,173,487,488.  
We have also shown that TBK1 and IKKε are not required for the activation of NF-κB by RIG-I in A549 
cells, supporting the majority of previous reports showing that TBK1 and IKKε play no role in NF-κB, 
or MAPK activation143,167,169,488. Interestingly, this differs from STING signalling, where TBK1 and IKKε 
function redundantly to activate NF-κB through activation of the IKK complex, despite the fact that 
TBK1 alone has been implicated in activation of IRF3146,488. We do not know why or how TBK1 is 
able to perform different functions downstream of different immune receptors, although it is also 
seen in TNFR signalling, where activated TBK1 phosphorylates RIP1 to prevent cell death 
activation333,456. The differing roles for TBK1 and IKKε in different immune signalling pathways shows 
that there is much we still do not know about the rules governing the recruitment, activation and 
regulation of TBK1 and IKKε, or the functional consequences of this. 
4.6.4 The mechanism of recruitment and activation of TBK1 and IKKε at the 
RIG-I signalling complex in A549 cells remains unclear 
Having already highlighted the importance of both TBK1 and IKKε for RIG-I-mediated IRF3 activation, 
understanding their recruitment to the signalling complex was important. Recruitment to activated 
signalling complex generally occurs through pre-association with multiple different adaptor 
proteins490, although the mechanism by which TBK1 and IKKε are recruited to MAVS remains 
unclear, with TRAF proteins, the TANK/NAP1/SINTBAD complex and optineurin all previously 
suggested to facilitate this process143,149,151,162,163,462,491. Despite attempts to examine the contribution 
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of the TANK/NAP1/SINTBAD complex, RIP1 and Optineurin to recruitment and activation of TBK1 
and IKKε to RIG-I signalling in A549 cells, we remain unable to conclusively describe the mechanism 
by which this occurs. 
Our data indicated that none of TANK, NAP1 and SINTBAD, RIP1 or optineurin were solely required 
for the recruitment of both TBK1 and IKKε to the RIG-I signalling complex. For TANK, NAP1 and 
SINTBAD, this disputes previous studies demonstrating their individual requirement for RIG-I-driven 
IFN induction in HEK293T and HeLa cells, mediated by the recruitment of TBK1 and IKKε151–153. 
However, others have shown that HEK293T cells lacking all three components have unimpaired IFN-I 
induction in response to RNA virus infection143. Our detection of a small defect in IRF3 
phosphorylation in cells lacking this complex may suggest they do play a role in the recruitment of 
either or both TBK1 and IKKε, albeit redundantly.  
Optineurin, which shares the TBK1 interaction domain found in TANK, NAP1 and SINTBAD, was 
identified as a TBK1 binding partner by yeast 2-hybrid screens155,156. However, its role in RIG-I has 
been much disputed, as it was initially described to initiate the trans-activation of TBK1 after RIG-I 
activation162,163,491, but more recently has been shown to dampen RIG-I-driven NF-κB and IRF3 
activation157,158. As signalling outcomes in response to loss of optineurin expression vary between 
cell lines, this is likely to be cell-type specific. As well as TBK1 recruitment, optineurin has also been 
implicated in its activation, binding to ubiquitinated TBK1 to promote its trans-autophosphorylation 
in OPTN-TBK1 complexes found at the Golgi158,162,164. Our data neither confirms or rules out a role for 
optineurin in RIG-I-mediated TBK1 recruitment and activation.  
Furthermore, our data points to a requirement for RIP1 in the activation of IRF3 and IFN-I 
transcription, but not TBK1 activation or ISG transcription by RIG-I. The requirement of RIP1 for IFN 
induction supports previous studies showing that it acts as a signalling enhancer for IFN-induction 
during RIG-I signalling, recruited to MAVS complexes during RNA virus infection467,470,492. However, 
the reason why RIP1 was not required for the transcription of ISGs is unclear. This inconsistent 
phenotype and the conflicting literature surrounding the role of RIP1 in RIG-I signalling may be 
caused by how RIP1-mediated negative regulation of RIG-I signalling, where its cleavage by caspase 8 
results in inhibition of signalling142,492. Despite this, our data suggests that RIP1 may play a role in the 
recruitment of activated TBK1 to the signalling complex, which is further supported by the fact 
thatRIP1 is not required for activation of NF-κB, a process that is also independent of TBK1 and IKKε.  
The importance of TRAF proteins in RIG-I signalling is well characterised, with roles in activation of 
IRF3 and NF-κB previously described135,137,138,140,141, both requiring the generation of K63-linked 
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ubiquitin chains144–147. However, some level of redundancy between TRAF2, 3 and 5 for IFN-I 
activation is evident135,142,143. Despite this, attempts were made to examine the role of TRAF proteins 
in RIG-I signalling using TRAF2-deficient A549 cells generated in the lab of Henning Walczak 
(University of Cologne). However, multiple attempts to grow up the cells from multiple batches of 
frozen stocks failed, possibly suggesting that loss of TRAF2 is toxic to these cells.  
As there was no clear phenotype in any of our adaptor protein knockout cell lines, as was seen in 
cells lacking both TBK1 and IKKε, we suggest that TBK1 and IKKε are likely recruited to RIG-I by 
different mechanisms. In systems where TBK1 and IKKε function redundantly, unless a single adaptor 
protein or protein complex is solely required for the recruitment of both proteins, the phenotype 
seen in cells lacking that adaptor would be masked, as a lack of recruitment of either protein would 
be compensated for by the activity of the other. The redundant function of TBK1 and IKKε in our 
system suggests that they are recruited to the RIG-I signalling complex by different mechanisms, 
explaining the modest phenotypes seen in cells lacking TANK/NAP1/SINTBAD, RIP1 and OPTN. 
Previous data also suggests this is the case, with studies showing that optineurin binds TBK1 but not 
IKKε155,156, and that IKKε but not TBK1 can be recruited directly to MAVS via K63 chains conjugated to 
MAVS159. This is further supported by visualisation of IKKε and TBK1 in distinct subcellular locations 
during RNA virus infection486.  
The biological significance of the differing mechanisms for recruitment of TBK1 and IKKε to other 
signalling pathways may relate to the roles of the proteins within each specific signalling pathway. 
The substrate specificity of TBK1 is at least partially determined by proximity493, suggesting that its 
function is decided by the other proteins in the signalling complex. However, it may also be 
determined by the adaptor protein that recruits TBK1/IKKε to the signalling complex. For example, in 
TNF-receptor signalling, TBK1 is predominantly recruited by the TANK/NAP1/SINTBAD complex and 
acts to phosphorylate RIPK1, but not IRF3, despite the fact that it is phosphorylated at the same 
residue to become active333,494,495, resulting in differing signalling outcomes than if IRF3 was 
activated. During intracellular DNA sensing, STING directly recruits TBK1 through a specific 
interaction between the C-terminal tail of STING and the kinase domain of TBK1496. TBK1 then not 
only directly activates IRF3, but also activates NF-κB redundantly with IKKε146,489, not seen during 
RIG-I signalling. Using distinct mechanisms of recruitment of TBK1 and IKKε would be advantageous 
as it would make it more difficult for viruses to inhibit the activation of IRF3, requiring the 
antagonism of multiple mechanisms to prevent TBK1 recruitment to signalling complexes. 
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Although many different mechanisms of TBK1 recruitment have been proposed and are evident in 
different signalling pathways, one unifying factor is the ubiquitin binding capacity of the adaptor 
proteins, including NEMO, SINTBAD, NAP1 and OPTN496–498. Ubiquitin chains form a recruitment 
platform for TBK1 in many signalling pathways and their presence at the RIG-I signalling complex 
could enable recruitment of multiple of these adaptor proteins, supporting our suggestion for 
redundant methods of TBK1 and IKKε recruitment. Together with our data, this supports a role for 
any or all of the TANK/NAP1/SINTBAD complex, RIP1 and optineurin in the recruitment of TBK1/ IKKε 
to MAVS during RIG-I signalling.  
4.6.5 How a better insight into the RIG-I signalling complex helps us study 
the contribution of LUBAC to RIG-I signalling 
As well as adding new information about how RIG-I signalling functions, the work in this chapter has 
laid the foundations for examining how LUBAC and M1 ubiquitin chains interact with the rest of the 
RIG-I signalling complex, and how this contributes to signalling outcomes. The ‘clean’ system of RIG-I 
activation that we have allows us to confidently assign functional roles for each of these proteins. By 
generating and analysing LUBAC-knockout cell lines and comparing the phenotypes with those from 
this chapter, we will be able to determine where LUBAC fits in the pathway and to use a rational 
approach to find LUBAC binding partners and the targets of M1-linked ubiquitin chains.  
Several of the proteins we studied have already been well characterised to interact with LUBAC, 
both downstream of RIG-I and in other immune signalling complexes. NEMO binds both LUBAC and 
M1-Ub chains, with the recruitment of NEMO to the RIG-I signalling complex previously shown to 
rely on its binding to ubiquitin chains synthesised by both TRAF proteins and LUBAC135,143. 
Additionally, optineurin’s previously described role in dampening RIG-I-driven NF-κB and IRF3 
activation is facilitated by its interaction with LUBAC, sequestering LUBAC from signalling 
complexes157,158. Outside of RNA sensing, LUBAC is well characterised to interact with NEMO and 
RIP1 at the TNF-RSC 500–502, both of which we suggest are involved in RIG-I signalling. This knowledge 
we have gained about how proteins known to interact with LUBAC function within RIG-I signalling is 
vital for helping us define how LUBAC contributes to the signalling complex and its outcomes. 
4.7 Conclusion 
Through the generation of a ‘clean’ system for RIG-I activation, we have been able to use knockout 
cell lines to determine the specific function of several proteins in RIG-I signalling. Based on this and 
previous literature, we propose a mechanism by which RIG-I drives activation of both IRF3 (Figure 
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4.7.1) and NF-κB (Figure 4.7.2). We have shown that in A549 cells, regardless of the ligand that is 
used to stimulate RIG-I, activation of NF-κB requires the presence of both MAVS and NEMO, but not 
TBK1, IKKε, TANK/NAP1/SINTBAD, RIP1 or Optineurin. Activation of IRF3 and the resultant IFN-I 
signalling required expression of MAVS, NEMO and either TBK1 or IKKε. The mechanism by which 
TBK1 and IKKε are recruited to the complex remains inconclusive, although we suggest that the 
TANK/NAP1/SINTBAD complex, RIP1 and optineurin may play a role, although both proteins appear 
not to be recruited by the same mechanism. Better characterisation of the RIG-I signalling pathway 
in our system gives us a platform from which to examine how LUBAC and M1-ubiquitin chains 
regulate it.  
 
Figure 4.7.1: Schematic of the mechanism of IRF3 activation by RIG-I  
1. RIG-I binds to RNA with 5’ppp and regions of double-stranded secondary structure 
2. This alongside ubiquitination of RIG-I CARD domains by Riplet and TRIM25 activates RIG-I CARD, 
which is recruited to MAVS at the mitochondrial outer membrane 
3. Activation of MAVS by RIG-I (and a wealth of other modifications) causes oligomerization of MAVS via 
the CARD domain 




5. NEMO is recruited by binding K63 ubiquitin chains 
6. Pre-activated TBK1 and IKKε are recruited to the signalling complex via distinct mechanisms, likely 
involving the TANK/NAP1/SINTBAD complex, RIP1 and optineurin, or direct recruitment of IKK ε to 
ubiquitinated MAVS  
7. IRF3 is recruited to the signalling complex, and once in proximity with activated TBK1/IKKε, is 





Figure 4.7.2: Schematic of the mechanism of NF-κB activation by RIG-I  
1. RIG-I binds to RNA with 5’ppp and regions of double-stranded secondary structure 
2. This alongside ubiquitination of RIG-I CARD domains by Riplet and TRIM25 activates RIG-I CARD, 
which is recruited to MAVS at the mitochondrial outer membrane 
3. Activation of MAVS by RIG-I (and a wealth of other modifications) causes oligomerization of MAVS via 
the CARD domain 
4. TRAF proteins are recruited to MAVS, where they add K63 ubiquitin chains to the CARD domain of 
MAVS oligomers 




6. NEMO is recruited by binding K63 ubiquitin chains on MAVS 
7. NEMO recruits the E3 ligase SCF-βTrCP and the proteasomal degradation machinery to the signalling 
complex, where it ubiquitinates IκBα, inducing its degradation by the 26S proteosome 






Chapter Five: HOIP is required for RIG-
I-driven immune responses 
5.1 Introduction 
LUBAC is critical to regulating many signalling pathways, including those involved in development, 
immune responses to infection and cell death activation503. In these pathways, it is well 
characterised to drive activation of NF-κB and induction of pro-inflammatory mediators, as well as 
restrict the activation of a multitude of cell death pathways. In RNA sensing pathways, LUBAC is 
required for activation of NF-κB and IFN by both TLR3 and MDA5432,504, controlling virus levels and 
preventing cell death by forming a crucial part of the TLR3 signalling complex. However, previous 
studies exploring the role of HOIP in RIG-I signalling have yielded highly conflicting conclusions, with 
results suggesting that HOIP is required for, restricts, or has no effect on RIG-I-driven immune 
responses213,432,504–506. Data surrounding the influence of HOIP on virus infection and RIG-I-driven cell 
death is also inconsistent. 
In this chapter, we studied the role of HOIP in RIG-I signalling, examining how it regulates the RIG-I 
signalling pathway and its outcomes, as well as monitoring its effects on the kinetics of virus 
infection and RIG-I-driven cell death. To address this, we used A549 cells deficient in HOIP, and cells 
stably expressing either a tagged WT or catalytic mutant of HOIP. Cells were stimulated with 
synthetic RNAs, 3p-hpRNA and Poly(I:C), and RNA viruses, SeV, IAV R+K and ZIKV PE243. The effect of 
HOIP on RIG-I-driven antiviral signalling was analysed by multiple techniques: qPCR to measure 
transcription of genes previously shown to activated by RIG-I in response to the chosen ligand; 
Western blotting and phos-flow to assess at the activation of signalling pathway components; and 
ELISA to measure secretion of chemokines. qPCR and Western blotting were also used to measure 
viral gene transcription and protein expression, which alongside growth curve analyses quantifying 
viral replication, formed a picture of the effect of HOIP on virus infection kinetics. Cell death was 
measured using flow cytometry analysis of caspase 3 activation and a Nucleocounter vitality assay. 
We demonstrate that HOIP is required for efficient RIG-I-driven transcription, signalling pathway 
activation and chemokine secretion, for all tested methods of RIG-I activation. Despite this, and its 
apparent influence on viral transcription, HOIP appeared to have minimal effect on viral protein 
expression or virus replication and did not affect to RIG-I-driven cell death, which was not detected 
in this system.  
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5.2 Determining the best system to study the role of HOIP in RIG-I 
signalling 
5.2.1 Overexpression of LUBAC components in HEK does not affect the 
immune response to SeV 
Many studies exploring LUBACs role in signalling pathways have utilised exogenous protein 
expression techniques. First used to demonstrate LUBACs role in immune signalling, overexpression 
of HOIP and either HOIL or SHARPIN was shown to enhance TNF- and CD40-mediated NF-κB 
activation507,508. However, overexpression of HOIP and HOIL-1 during RIG-I activation has been 
shown to reduce IFN-I and NF-κB activation213,505,509, indicating that LUBAC may negatively 
regulate RIG-I signalling. 
In an attempt to replicate these previous studies, LUBAC components HOIP and HOIL were 
overexpressed in HEK 293T cells for 24 hours, followed by a 16-hour infection with SeV. Western 
blotting confirmed the presence of overexpressed HOIP and HOIL-1 in these cells (Figure 5.2.1A), 
known to be sufficient to generate M1-Ub chains510. However, qPCR analysis detected no 
significant effect of HOIP or HOIL overexpression on transcription of IFNB1 or CXCL10 (Figure 5.2.1B). 
Transcription of both genes was reduced during overexpression of HOIP and HOIL-1, but this also 
occurred after transfection with an empty expression plasmid, suggesting their reduced transcription 
was likely caused by the burden of DNA plasmid expression on the cells, rather than the proteins 
themselves. Generally, expression of HOIP and HOIL together lead to an increase of IFNB1 and 
CXCL10 transcription after SeV infection, but this was not consistent across the two genes, or 
experimental repeats, unlike previously described507,508. These inconclusive findings, as well as the 
conflicting literature, suggest that overexpression systems are not a good model to study the role of 




Figure 5.2.1: Reproducing previous LUBAC-overexpression experiments in HEK293T cells 
A) Western blotting of HEK293T cells transfected with an empty pcDNA4 plasmid (EV), and either 0.5 or 1 μg 
overexpression plasmids with V5 tagged HOIP and HOIL-1 (data representative of 2 independent assays). B) 
qPCR to measure transcription of IFNB1 and CXCL10 in HEK293T cells after 24 hours of transfection with the 
plasmids and a subsequent 16-hour infection with SeV at a 1:100 dilution (n=2, data representative of 2 
independent assays). 
5.2.2 Use of HOIP-deficient A549 cells to study the role of LUBAC in RIG-I 
signalling 
Instead, HOIP-deficient (HOIP -/-) A549 cells generated using a lentiviral CRISPR system in the lab of 
Henning Walczak (University of Cologne)334, were used to study the role of HOIP in RIG-I signalling. 
To demonstrate that any phenotype seen in HOIP -/- cells was due to loss of HOIP expression alone, 
knockout cells were reconstituted by lentiviral expression of a TAP-tagged HOIP construct (TAP-
HOIP-WT), resulting in stable expression of TAP-HOIP. 
Expression of LUBAC components was analysed by Western blotting in WT, HOIP -/- and TAP-HOIP-
WT cells (Figure 5.2.2), confirming that HOIP could be detected in WT cells, its expression was lost in 
HOIP -/- cells, and TAP-HOIP-WT cells were found to express higher than WT levels of HOIP. Unlike 
previous studies213,503,505,506, loss of HOIP expression in HOIP -/- did not result in reduced levels 
of HOIL-1 or SHARPIN but conversely, over-expression of HOIP in TAP-HOIP-WT cells did result in 
higher HOIL-1 and SHARPIN expression. This may be due to more HOIP enabling increased 
incorporation of HOIL and SHARPIN into LUBAC complexes, as has been previously 
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described338,510. As HOIL and SHARPIN transcription was not examined, we cannot say whether 
this increase at the protein level was due to increased transcription, or increased protein stability.  
 
Figure 5.2.2: Characterisation of A549 HOIP -/- and +TAP-HOIP-WT cells 
Western blotting to show presence of LUBAC components in resting A549 WT, HOIP -/- and TAP-HOIP-WT cells 
(data representative of 2 independent assays). 
5.3 HOIP is required for RIG-I-driven transcription of antiviral genes  
5.3.1 HOIP is required for efficient transcription of IFN-I, ISGs and 
chemokines in response to 3p-hpRNA and Poly(I:C) stimulation 
The only synthetic RNA previously used in studies exploring the role of HOIP in RNA sensing is 
Poly(I:C)432,504. Although MDA5 and TLR3 were implicated the sensing of Poly(I:C) in these studies, 
collectively they demonstrated that HOIP is required for Poly(I:C) driven signalling, with loss of HOIP 
expression resulting in reduced NF-κB, IFN-I and chemokine activation. To examine the requirement 
of HOIP for synthetic RNA-induced RIG-I-driven immune gene transcription in our system, A549 WT, 
HOIP -/- and TAP-HOIP-WT cells were stimulated by transfection of 3p-hpRNA and Poly(I:C) and 
transcription was measured by qPCR.  
When stimulated with 3p-hpRNA, HOIP -/- cells showed significantly reduced transcription of CXC10, 
ISG15 and ISG54 in comparison to WT cells (Figure 5.3.1A). Re-expression of HOIP in knockout cells 
rescued the transcription of both IFNB1 and CXCL10, with TAP-HOIP-WT cells expressing higher 
levels of both genes than WT cells (Figure 5.3.1B), suggesting that elevated levels of HOIP enhanced 
RIG-I activation. This conflicts with data from HEK293T overexpression experiments (Figure 5.2.1B) 
but is consistently true for stable HOIP overexpression in A549 cells with multiple stimulation 
methods. 
Stimulation of A549 WT and HOIP -/- cells with Poly(I:C) yielded similar results, with transcription of 
IFNB1, IFNL1, CXCL10 and ISG15 significantly lower in HOIP-deficient cells (Figure 5.3.1C). Although 
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ISG54 transcription was more variable, HOIP -/- cells consistently expressed similar or higher levels 
of ISG54 transcripts than WT cells, a phenotype only seen with Poly(I:C) and one which we cannot 
explain. Again, stable re-expression of HOIP resulted in similar or higher levels of transcription of 
both IFNB1 and CXCL10 than in WT cells (Figure 5.3.1D). 
These data demonstrate that HOIP is required for the efficient RIG-I-driven transcription of IFN-I, 
IFN-III and ISGs after stimulation with synthetic RNAs. 
 
Figure 5.3.1: RIG-I-driven expression of immune genes in response to synthetic RNAs is dependent on HOIP 
qPCR to measure transcription of indicated genes in response to stimulation with A) 1 μg 3p-hpRNA in A549 
WT and HOIP -/- cells (n=2, data is representative of >3 independent assays), B) 1 μg 3p-hpRNA in A549 WT, 
HOIP -/- and HOIP -/- + TAP-HOIP-WT (TAP-HOIP-WT) cells (n=2, data representative of 2 independent assays), 
C) 1 μg Poly(I:C) in A549 WT and HOIP -/- cells (n=2, data is representative of >3 independent assays) and D) 1 
μg Poly(I:C) in A549 WT, HOIP -/- and TAP-HOIP-WT cells (n=2, data representative of 2 independent assays). 
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5.3.2 HOIP is required for efficient transcription of IFN-I, IFN-III, NF-κB-
dependent genes and chemokines in response to SeV infection 
As viruses like SeV are capable of activating a broader measurable immune response, the effect of 
HOIP on RNA virus-driven transcription was also studied. Only one previous study has explored the 
role of HOIP during SeV infection213, but multiple studies have used other RNA viruses such as VSV 
and IAV135,505. In this previous study, knockdown of HOIP in MEF cells had little effect on SeV-
driven IFNβ expression, although did increase the ubiquitination of RIG-I and its consequent binding 
to TRIM25213.  
In our system, SeV-induced transcription of IFN-I and IFN-III, ISGs, chemokines and NF-κB-dependent 
genes was reduced in HOIP -/- cells (Figure 5.3.2A), with the reduction even more marked than that 
seen with synthetic RNAs. Again, re-expression of HOIP resulted in similar or higher levels of IFNB1 
and CXCL10 transcription than seen in WT cells (Figure 5.3.3B).  
 
Figure 5.3.2: RIG-I-driven expression of immune genes in response to SeV infection is dependent on HOIP 
qPCR to measure transcription of indicated genes in A) A549 WT and HOIP -/- and B) A549 WT, HOIP -/- and 




5.3.3 HOIP is required for efficient transcription of IFN-I, ISGs and 
chemokines in response to IAV R+K infection 
The role of HOIP during infection with the replication competent RNA virus IAV, was also studied. 
HOIP has previously been shown to be required for the IAV-driven response in A549 cells and in vivo, 
with loss of HOIP in alveolar stem cells shown to result in in reduced transcription of Ifnb1, Il6 and 
Mcp1 compared to WT stem cells during IAV WSN infection506.  
Here, A549 WT and HOIP -/- cells were infected with IAV PR8 NS1 R+K and transcription was 
measured using qPCR (Figure 5.3.3A). The robust upregulation of IFNB1, CXCL10, ISG15 and ISG54, 
seen in WT cells was significantly reduced in HOIP -/- cells in several experiments (Figure 5.3.3A). 
However, the data was not always consistent, with differing signalling outcomes shown in Figure 
5.3.3B. To understand the cause of this variation, transcription of early expressed IAV gene NS1 was 
measured for each experiment (Figure 5.3.3B). When NS1 transcripts were less abundant in HOIP -/- 
cells, they also expressed much lower levels of IFNB1 and CXCL10 transcripts, whereas when NS1 
transcripts were much higher in HOIP -/- cells than WT, transcription of IFNB1 and CXCL10 was 
unaltered by loss of HOIP expression. Varied signalling outcomes is likely caused by uneven infection 
kinetics between replicate experiments, captured by NS1 transcriptional data. Induction of IFN-I and 
chemokine transcription in these cells correlates with the level of viral RNA in the cells, but despite 
this viral RNA does appear to induce a less potent immune response in HOIP -/- cells. 
To explore whether variable NS1 transcription was due to unequal infection between cell lines, 
attempts were made to measure replication of IAV NS1 R+K in WT and HOIP -/- cells by plaque assay. 
However, IAV R+K did not replicate in A549 cells, possibly because the mutant virus is incapable of 
suppressing the RIG-I-driven immune response in these cells (Figure 5.3.3C). Because of this, IAV PR8 
was used, which did replicate at low levels in both A549 WT and HOIP -/- cells (Figure 5.3.3D). In this 
assay, loss of HOIP had no effect on viral replication, possibly because the RIG-I-driven immune 
response is already impeded by the IAV NS1 protein in WT cells, so the reduction in RIG-I-driven 
transcription seen in HOIP -/- cells would have no effect, or because the cells were infected at too 




Figure 5.3.3: HOIP may contribute to innate immune sensing of IAV 
qPCR to measure transcription of indicated genes in A549 WT and HOIP -/- cells during IAV R+K infection at 
MOI 3 A) (n=2, data representative of >3 independent assays) and B) (n=2, two datasets shown are examples 
of variability of results). C and D) Replication of IAV NS1 R+K and PR8 WT, growth curves analysis generated by 
titration of lysates on Vero cells followed by plaque assay. (n=2, data representative of 2 experimental 
repeats). 
 
5.3.4 HOIP is required for efficient transcription of IFN-I, IFN-III, ISGs and 
chemokines during to ZIKV infection 
Because the data generated by IAV infection was inconsistent, we used ZIKV infection to study the 
impact of HOIP on the infection kinetics of and immune response to a replicating RNA virus in our 
system.   
A549 WT and HOIP -/- cells were infected with ZIKV and the transcription of genes previously 
upregulated at 16 and 24 hours post ZIKV infection (Figure 3.3.4) were analysed by qPCR. As the 
transcription of most genes was RIG-I-independent by 48 hours post infection (Figure 3.4.6A), cells 
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were only infected for 24 hours. Transcription of all genes was significantly reduced in HOIP -/- cells 
at both 16 and 24-hours post infection, with transcription of IFNB1, IFNL1, CXCL10 and ISG54 in HOIP 
-/- cells barely detectable above background levels. ISG15 was still strongly expressed in the absence 
of HOIP, but still significantly less than in WT cells, together showing that HOIP is required for the 
RIG-I-driven transcriptional response to ZIKV. 
As with IAV, ZIKV transcription was measured by qPCR. Figure 5.3.4B shows the location of the 
primer pairs targeted to both the ORF (open reading frame) region and 3’UTR (untranslated region) 
of the ZIKV genome, mapped against the polyprotein and mature proteins. Transcription of both 
regions of the ORF and 3’UTR was not significantly different between WT and HOIP -/- cells at 16 
hours post infection but was transcribed to a much higher level WT cells by 24 hours (Figure 5.3.4C), 
mimicking what was seen most frequently during IAV infection (Figure 5.3.3B). The level of ORF 
transcripts was significantly lower than UTR transcripts, likely due to the degradation of the ZIKV 
RNA by cellular exonucleases512, from which the 3’UTR is protected due to secondary RNA 
pseudoknot structures that accumulate during infection513. Conversely, expression of the ZIKV 
protein analysed by Western blotting was consistent between WT and HOIP -/- cells at all time 
points (Figure 5.3.4D). Similarly, a single-step analysis of ZIKV replication using a plaque assay 
showed that HOIP expression did not affect ZIKV replication (Figure 5.3.4E).  
From this we suggest that measuring transcription is a poor technique to study viral infection, as 
measures of viral protein expression and replication show consistency between the cell lines and 




Figure 5.3.4: RIG-I-driven expression of immune genes in response to ZIKV infection is dependent on HOIP 
A) qPCR to measure transcription of indicated genes during ZIKV PE243 infection A549 WT and HOIP -/- cells at 
MOI 3 (n=3, data representative of 3 experimental repeats). B) Schematic representation of location of primers 
targeting ZIKV polyprotein region for qPCR. C) qPCR to measure transcription of ZIKV ORF and 3’UTR during 
ZIKV PE243 infection A549 WT and HOIP -/- cells at MOI 3 (n=2, data representative of 2 independent assays). 
D) Western blotting analysis of ZIKV E protein during infection A549 WT and HOIP -/- cells with ZIKV PE243 at 
MOI 3, done by Dr Nerea Irigoyen and Charlotte Lefevre (data representative of 2 independent assays). E) ZIKV 
PE243 growth curve generated by titration and plaque assay, done by Dr Nerea Irigoyen and Charlotte Lefevre. 
(n=2, data representative of 2 experimental repeats). 
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5.4 HOIP is required for activation of RIG-I signalling pathway 
components  
We have found HOIP to be required for efficient transcription of all studied genes. Transcription of 
these genes requires activation of both IRF3 and NF-κB, suggesting that HOIP regulates both of their 
activation. To investigate this, we measured the activation of signalling pathway components TBK1, 
IRF3 and IκBα, all of which undergo phosphorylation during IRF3 and NF-κB activation, by both 
Western blotting and flow cytometry. 
5.4.1 Western blotting analysis and phos-flow are not sensitive enough to 
provide insight into the role of HOIP in signalling pathway activation 
during stimulation with synthetic RNAs 
Only once has the requirement of HOIP for synthetic RNA-driven signalling protein phosphorylation 
been demonstrated432, with siRNA knockdown of HOIP in HaCaT cells stimulated with extracellular 
Poly(I:C) resulting in reduced TLR3-mediated phosphorylation of IRF3, IκBα and MAPK proteins ERK 
and JNK. In this study, we examined signalling protein phosphorylation in A549 WT and HOIP -/- cells 
stimulated by 3p-hpRNA and transfected Poly(I:C) by Western blotting (Figure 5.4.1). 
Transfection of A549 WT cells with 3p-hpRNA and Poly(I:C) resulted in detectable phosphorylation of 
TBK1 and IRF3, but the weak expression of phospho-proteins, especially with 3p-hpRNA stimulation, 
means that we were unable to reliably differentiate between phosphorylation levels in WT and 
HOIP-/- cells. Phos-flow analysis could not be used to study the role of HOIP during stimulation with 
synthetic RNA ligands because, as previously shown (Figure 3.3.1D), there was no detectable 
increase in A549 WT cells expressing phosphorylated IRF3 after 6-hour stimulation with Poly(I:C). To 
be able to examine the effect of HOIP on activation of signalling pathway components during 
stimulation with synthetic RNAs, different model cell lines, further transfection optimisation or more 




Figure 5.4.1: Stimulation with synthetic RNAs is too weak to quantify using Western blotting 
A) Western blotting analysis of signalling protein phosphorylation during stimulation of A549 WT and HOIP -/- 
with 5 μg 3p-hpRNA and Poly(I:C) (data representative of one assay).  
 
5.4.2 HOIP increases activation of TBK1, IRF3 and IκBα in response to SeV 
infection 
Previous studies exploring the role of HOIP in RNA virus-induced signalling protein activation 
generally acknowledge that HOIP is required. siRNA HOIP knockdown in A549 resulted in reduced 
IRF3 phosphorylation in response to IAV WSN infection506. Similarly, during VSV infection in U2OS 
cells and TRAF-deficient MEFs, HOIP knockdown resulted in reduced IRF3 and IκBα 
phosphorylation135, although no phenotype was seen with shRNA knockdown of HOIP in WT MEFs.  
SeV is a more potent stimulator of RIG-I than the synthetic RNAs in our system, therefore the 
resulting higher levels of phosphorylated signalling proteins produced allowed the role of HOIP in 
signalling pathway activation to be analysed by both Western blotting and phos-flow. During SeV 
infection, lower levels of phospho-IRF3, -TBK1 and -IκBα in were detected in HOIP -/- cells compared 
to WT (Figure 5.4.2A). This is supported by phos-flow analysis of SeV infection, which also showed 
reduced IRF3 phosphorylation in HOIP-deficient cells, with twice the number of phospho-IRF3-
expressing WT cells than HOIP -/- cells by 6 hours post-infection (Figure 5.4.2B).  
This data demonstrates that HOIP is required for efficient activation of both the TBK1-IRF3 arm and 





Figure 5.4.2: HOIP is required for activation of signalling pathway components in response to Sendai virus 
Infection of A549 WT and HOIP -/- cells with SeV at 1:300 dilution and A) Western blotting analysis of signalling 
protein phosphorylation in the presence and absence of 10 μM MG-132 (data representative of >3 
independent assays) and B) Phos-flow analysis of cells expressing phospho-IRF3 and active caspase 3 (n=1, 
data representative of 3 independent assays). 
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5.5 HOIP is required for RIG-I-driven chemokine secretion in 
response to synthetic RNA ligands and SeV infection 
Multiple earlier studies show the requirement of HOIP for efficient RNA-induced secretion of 
chemokines and IFN-I135,432,505. In HaCaT and HeLa cells stimulated with extracellular Poly(I:C), 
reduction or loss of HOIP expression resulted in reduced TLR3-driven CCL5, TNFα and IL-8 
secretion432. Similarly, HOIP knockdown in MEF cells resulted in reduced secretion of IFNβ, IL-6 and 
CXCL10 in response to VSV ifnection135, also seen during IAV infection of HOIP-deficient A549 
cells505. Conversely, knockdown of HOIP in MEF cells had no effect on IFNβ secretion during SeV 
infection213. 
ELISA analysis of CXCL10 secretion in A549 WT and HOIP -/- cells was used to validate our previous 
data showing that HOIP is required for efficient transcription of the chemokine CXCL10 in response 
to synthetic RNAs and RNA viruses. In A549 WT, HOIP -/- and TAP-HOIP-WT cells stimulated with 3p-
hpRNA (Figure 5.5A), Poly(I:C) (Figure 5.5B), HOIP -/- cells had secreted significantly less CXCL10 than 
WT after 24 hours. This is even more pronounced during SeV infection (Figure 5.5C), with CXCL10 
secretion was almost undetectable by the assay in HOIP -/- cells after 6 hours and significantly 
reduced at 24 hours. Secretion of CXCL10 in TAP-HOIP-WT cells was even higher than that seen in 
WT cells at 24 hours post stimulation with all stimulation methods, as seen with CXCL10 
transcription.  
This confirms that, as previously described135,432,506, secretion of CXCL10 in response to RIG-I 
activation is dependent on HOIP. Additionally, the use of longer infection and stimulation time 
points in ELISA assays confirms that loss of HOIP expression prevents, rather than just delays, RIG-I-




Figure 5.5.1: HOIP is required for CXCL10 secretion during stimulation with synthetic RNAs and SeV  
ELISA to measure CXCL10 secretion in A549 WT, HOIP -/- and TAP-HOIP-WT cells during stimulation with A) 1 
μg 3p-hpRNA (n=2, representative of 3 independent assays), 1 μg Poly(I:C) (n=2, representative of 3 
independent assays) and C) SeV infection at 1:300 dilution (n=2, representative of >3 independent assays). 
5.6 HOIP is also required for a RIG-I-driven antiviral immune 
response in HaCaT cells 
5.6.1 HOIP is required for RIG-I driven transcription in HaCaT cells in 
response to synthetic RNAs and RNA viruses 
To validate our findings that HOIP is required for RIG-I-driven transcription of antiviral genes and 
signalling protein phosphorylation, experiments were repeated in a second model cell line. The 
HaCaT cell line was generated from spontaneously transformed aneuploid immortal keratinocyte 
cells, derived from adult human skin. Like A549 cells, they are a physiologically relevant cell line to 
study the initial sensing of virus infection as many non-respiratory viruses enter the body through 
infection of skin cells. HaCaT cells deficient in HOIP were generated by Lentiviral CRISPR/Cas9 
technology in the lab of Henning Walczak (University of Cologne). 
Transcription of IFNB1, IFNL1 and CXCL10 was measured by qPCR in HaCaT WT and HOIP -/- cells 
after 6-hour stimulation with Poly(I:C) (Figure 5.6.1A) and infection with SeV (Figure 5.6.1B). Poly(I:C) 
induced robust of transcription of all genes in WT cells, but transcription was barely detectable 
above background levels in HOIP -/- cells, mimicking what was seen in A549 cells. SeV infection of 
HOIP -/- cells resulted in lower levels of IFNB1 and CXCL10 transcription than WT cells, but this was 
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only significant for IFNB1, although the data is of lower quality data than with A549 cells. Western 
blotting analysis of SeV-infected HaCaT WT and HOIP -/- cells (Figure 5.6.1B) detected reduced levels 
of phospho-IRF3 in HOIP -/- cells compared to WT, for all time points, as seen in A549 cells. Overall, 
these data reinforce conclusions from experiments in A549 cells, showing that HOIP is required for 
the RIG-I-mediated immune response 
 
Figure 5.6.1: HOIP is required for RIG-I signalling in HaCaT cells after stimulation with Poly(I:C) and SeV 
infection 
Western blotting analysis of expression of A) LUBAC components and B) RIG-I signalling pathway components 
in HaCaT WT and HOIP -/- cells. qPCR to measure transcription of IFNB1, IFNL1 and CXCL10 in HaCaT WT and 
HOIP -/- cells in response to 6-hour stimulation with C) 1 μg Poly(I:C) and D) SeV at 1:300 dilution (both n=2, 
data representative of 3 independent assays). 
5.7 Catalytic activity of HOIP is only partially required for its role in 
RIG-I signalling 
Although we have demonstrated that HOIP is required for an efficient RIG-I mediated immune 
response to RNA and RNA viruses, we have not yet examined whether its contribution to RIG-I 
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signalling should be attributed this to the ability of HOIP to generate M1-linked ubiquitin chains or 
an alternative function.  
The requirement for the HOIPs E3 ligase activity for its role in NF-κB activation has been well 
characterised in multiple systems, using mutants lacking or inactivating the catalytic RBR domain514–
517. Ligase activity is also required for recruitment of TBK1 and IKKε to the TNF receptor signalling 
complex and the subsequent prevention of TNF-driven cell death333,516. As seen with full deletion of 
HOIP, the mutation of HOIP at cysteine 879 in mice, abrogating its catalytic activity, results in 
embryonic lethality335,518. This is due to the requirement for the E3 ligase activity of HOIP for 
prevention TNF-driven endothelial cell death, allowing maintenance of blood vessel integrity during 
development. The only systems in which a catalytic-independent function of HOIP has been shown is 
in B and T cells, where the E3 ligase activity of HOIP is required for canonical TNF-driven NF-κB and 
ERK activation, but not for B and T cell receptor mediated NF-κB and ERK activation519,520.  
5.7.1 Mutation of residue C885 inactivates the catalytic activity of HOIP 
The analogous mutation in human HOIP, of the residue cysteine 885 located within the second RING 
domain of the active site of HOIP (Figure 5.7.1A), also results in loss of E3 ligase activity521. To 
determine the contribution of HOIP’s E3 ligase activity and thus the contribution of M1-Ub chains to 
RIG-I signalling, we compared the RIG-I-driven immune response in A549 HOIP -/- cells stably 
expressing TAP-HOIP-C885S (TAP-HOIP-C885S cells) to that seen in WT, HOIP -/- and TAP-HOIP-WT 
cells.  
First, Western blotting analysis of LUBAC expression in WT, HOIP -/-, TAP-HOIP-WT and TAP-HOIP-
C885S cells (Figure 5.7.1B), showed similar levels of HOIP expression between TAP-HOIP-WT and 
TAP-HOIP-C885S cells, both higher than seen in A549 WT cells. As seen before with TAP-HOIP-WT 
cells, increased HOIP expression in TAP-HOIP-C885S cells resulted in higher levels of HOIL-1 and 
SHARPIN than in WT cells, also suggesting that the mutation did not disrupt LUBAC complex 
formation. Additionally, expression of signalling proteins IRF3, TBK1 and MAVS were consistent 
across the 4 cell lines (Figure 5.7.1C).  
Due both to the incredibly low abundance of M1-linked ubiquitin chains in cells even after 
stimulation and lack of a good antibody, we were unable to demonstrate the presence of M1-Ub 
chains by Western blotting. Therefore, to prove that TAP-HOIP-C885S cells behaved as expected for 
cells lacking M1-Ub chains, the effect of loss of ligase activity, previously shown to be required for 
recruitment of NEMO and TBK1 and to the TNF-RSC and prevention of RIP1 phosphorylation333, was 
examined. TAP-HOIP-WT and TAP-HOIP-C885S cells were stimulated with TNFα and phosphorylation 
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of TBK1, IκBα and RIP1 was measured by Western blotting analysis (Figure 5.7.1D). As previously 
described, TNFα stimulation resulted in phosphorylation of TBK1 in TAP-HOIP-WT cells, increasing in 
abundance through the 60-minute time course, with levels of phospho-TBK1 much lower in TAP-
HOIP-C885S cells, consistent with the reported role of LUBAC333. TNFα stimulation of TAP-HOIP-WT 
cells also resulted in early phosphorylation of IκBα, detected at 5 minutes post-stimulation but 
rapidly degraded by the proteasome after phosphorylation preventing detection after 15 or 30 
minutes, detectable again after 60 minutes indicating a cyclical nature of phosphorylation and 
degradation. As with TBK1, phosphorylation of IκBα was reduced in TAP-HOIP-C885S cells at both 5 
and 60-minutes post infection, supporting studies showing the requirement of the E3 ligase activity 
for NF-κB activation514–516. Finally, phosphorylation of RIP1, a modification that prevents cell death 
through the TNF-RSC-II522,523, is present to higher levels in TAP-HOIP-C885S cells than TAP-HOIP-WT, 
expected due to the protective role of the E3 ligase activity of HOIP against cell death516. From these 
observations, we were satisfied that TAP-HOIP-C885S cells are incapable of producing M1-linked 




Figure 5.7.1: Characterisation of TAP-HOIP-WT and TAP-HOIP-C885S cells 
A) Schematic of HOIP with position of mutation indicated (adapted from Gyrd Hansen et al., 2021). Western 
blotting analysis of B) expression of LUBAC components in A549 WT, HOIP -/-, TAP-HOIP-WT and TAP-HOIP-
C885S cells, C) expression of RIG-I signalling pathway components in A549 WT, HOIP -/-, TAP-HOIP-WT and 
TAP-HOIP-C885S cells and D) phosphorylation of signalling proteins during TNFα stimulation A549 TAP-HOIP-
WT and TAP-HOIP-C885S at 200 ng/mL (data representative of one experimental replicate). 
 
5.7.2 Expression of immune genes is only partially dependent on the 
catalytic activity of HOIP 
The requirement of the E3 ligase activity of LUBAC for RIG-I signalling outcomes has not previously 
been studied. We examined its role in RIG-I driven transcription by qPCR analysis of WT, HOIP -/-, 
TAP-HOIP-WT and TAP-HOIP-C885S cells transfected with 3p-hpRNA and Poly(I:C) and infected with 
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SeV (Figure 5.7.2A, B and C respectively). In general, transcription of both IRF3- and NF-κB-
dependent genes was significantly lower in TAP-HOIP-C885S cells than TAP-HOIP-WT cells, 
suggesting that loss of the catalytic activity of HOIP has a detrimental effect on the role of HOIP in 
RIG-I signalling. The most notable exception to this is ISG54, which was transcribed to significantly 
higher levels in TAP-HOIP-C885S cells than TAP-HOIP-WT. However, transcription of all tested genes 
was also significantly higher in TAP-HOIP-C885S cells than seen in HOIP -/- cells, showing HOIP is 
capable of regulation RIG-I-driven transcription in the absence of M1-linked ubiquitin chains. 
Together this data suggests that the M1-Ub chains produced by HOIP are partially responsible for its 
role in RIG-I signalling, but that HOIP also drives signalling by another mechanism, as seen in T and B 
cell receptor-mediated NF-κB activation519,524. 
 
Figure 5.7.2: Expression of immune genes in response to synthetic RNAs and SeV infection is only partially 
dependent on the catalytic activity of HOIP 
qPCR to measure transcription of indicated genes in WT, HOIP -/-, TAP-HOIP-WT and TAP-HOIP-C885S cells in 
response to stimulation with A) 1 μg 3p-hpRNA in A549 WT and HOIP -/- cells (n=2, data is representative of >3 
independent assays), B) 1 μg Poly(I:C) (n=2, data is representative of >3 independent assays) and C) infection 
with SeV at 1:300 dilution (n=2, data representative of 3 independent assays). 
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5.7.3 Phosphorylation of IRF3, TBK1 and IκBα is not dependent on the 
catalytic activity of HOIP 
Previously, the catalytic activity of HOIP has been shown to be required for RIG-I-driven signalling 
protein activation, with WT but not a catalytically inactive HOIP mutant able to rescue VSV-induced 
IRF3 dimerization135. This study also reported a functional redundancy between the E3 ligase activity 
of HOIP RBR domain and TRAF2 RING domain in RIG-I signalling.  
To examine this in our system, TAP-HOIP-WT and TAP-HOIP-C885S cells were infected with SeV and 
phosphorylation of IRF3, TBK1 and IκBα was measured by Western blotting (Figure 5.7.3). The 
phosphorylation of IRF3 and TBK1 in TAP-HOIP-WT cells mimicked that previously seen in A549 WT 
cells (Figure 3.3.2), as did detection of phospho-IκBα in the presence of proteasome inhibitor MG-
132 at 4 hours post-infection. However, phosphorylation of all three proteins appeared unaffected 
by mutation of HOIP, suggesting loss of M1-linked ubiquitin chains had no effect on signalling 
protein activation, disputing the earlier study135. This also somewhat contradicts our transcriptional 
data showing that expression of the mutant HOIP only partially rescues transcription of immune 
genes compared to expression of WT HOIP. This may suggest that IRF3 phosphorylation is not 
dependent on M1-linked chains but dimerization or nuclear translation of IRF3 is, or more likely may 
be accounted for by the sensitivity threshold of the two assays, with qPCR much better at detecting 




Figure 5.7.3: Phosphorylation of signalling proteins during SeV infection appears not to be dependent on the 
catalytic activity of HOIP 
Western blotting analysis of A549 TAP-HOIP-WT and TAP-HOIP-C885S cells infected with SeV at 1:300 dilution 
with and without 10 μM MG-132 (data representative of 2 experimental replicates). 
 
5.7.4 Chemokine expression is only partially dependent on the catalytic 
activity of HOIP 
Because CXCL10 transcription in response to SeV infection was partially reduced by mutation of the 
HOIP ligase domain (Figure 5.7.2C), secretion of CXCL10 was analysed by ELISA at 6 and 24 hours 
post infection with SeV (Figure 5.7.4). After 6 hours, TAP-HOIP-C885S cells had secreted significantly 
more CXCL10 than TAP-HOIP-WT cells. However, by 24-hours post infection, the phenotype more 
closely mimicked what was seen for transcription with the cells expressing mutant HOIP secreting an 
intermediate amount of CXCL10, between what was seen in HOIP -/- cells and in TAP-HOIP-WT cells. 
This change in secretion dynamics across the infection time course was consistent over three 
experimental replicates, which is consistent with a role of M1 chains in signal amplification.  
 
Figure 5.7.4: CXCL10 secretion in response to SeV infection is only partially dependent on the catalytic 
activity of HOIP 
ELISA to measure secretion of CXCL10 in A549 WT, HOIP -/-, TAP-HOIP-WT and TAP-HOIP-C885S cells infected 
with SeV at 1:300 dilution (n=2, data representative of 3 independent assays). 
5.8 The LUBAC complex functions as a scaffold during RIG-I signalling 
5.8.1 LUBAC components co-IP with NEMO and SHARPIN during SeV 
infection 
As our data indicates a M1-linked ubiquitin chain-independent function of HOIP in RIG-I signalling, 
we hypothesised that the HOIP or the LUBAC complex may act as a scaffold, binding to and enabling 
efficient recruitment of other proteins to the signalling complex. Co-immunoprecipitation studies 
were used to test whether the HOIP binds to other proteins known to be involved in RIG-I signalling, 
analysed by Western blotting. In TNF signalling, presence of LUBAC leads to enhanced and sustained 
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recruitment of NEMO to the TNF-RSC, a process that requires the enzymatic activity of LUBAC501. 
This, alongside our demonstration that HOIP and NEMO are required for IRF3 and NF-κB activation 
downstream of RIG-I, meant that we chose to do these co-immunoprecipitation studies in A549 cells 
expressing TAP-HOIP-WT and TAP-NEMO. As Western blotting analysis is a targeted approach for 
finding binding partners, candidate proteins known to interact with LUBAC in other signalling 
complexes, such as NEMO and RIP1 in the TNF-RSC338,507, were examined. 
As a proof of principle of the assay, TAP-HOIP and -NEMO were immunoprecipitated in cells that 
were stimulated with TNFα (Figure 5.8.1A), as they are known to interact in the TNF-RSC338,507. 
Western blotting analysis showed that HOIP co-immunoprecipitated with NEMO in TAP-NEMO cells 
at 5 minutes post-stimulation, but not in unstimulated cells or 15 minutes after stimulation. In TAP-
HOIP cells, both RIP1 and TRAF2 were found to interact with HOIP after 5 and 15 minutes of TNFα 
stimulation, but not in unstimulated cells. This was as expected, as TRAF2 is also known to be 
required for TNF-RSC-driven signalling and showed that co-immunoprecipitation is an effective 
method to study interactions of HOIP and NEMO in signalling complexes in this system. 
Consequently, co-immunoprecipitation techniques were used to analyse the RIG-I signalling complex 
during SeV infection. As RIG-I is expressed at such low levels in resting A549 cells, A549 TAP-NEMO 
and TAP-HOIP-WT cells were pre-stimulated with IFNα for 24 hours to increase the amount of RIG-I 
available to form signalling complexes, infected with SeV, and NEMO and HOIP were 
immunoprecipitated using Flag-M2 beads (Figure 5.8.1B). Western blotting analysis detected binding 
of HOIP, SHARPIN and TBK1 to TAP-NEMO during SeV infection. Binding of HOIP was only detected 
at 3 hours post infection, but for TBK1 and SHARPIN, a very low level of binding was detected in the 
absence of infection, but this binding was enhanced in the presence of infection. Apparent binding in 
the absence of infection is likely due to the proteins ‘sticking’ to the antibody beads, despite 
extensive washing. TBK1 also co-immunoprecipitated with TAP-HOIP during SeV infection, with some 
background binding in the absence of infection, but much higher levels detected at 3- and 6-hours 
post-infection.  
Unlike in the TNF-RSC (Figure 5.8.1A), we did not detect binding of HOIP to RIP1 during SeV 
infection, suggesting it does not form part of the RIG-I signalling complex and is not bound or 
modified by LUBAC during RIG-I signalling. This is supported by our data using RIP1 knockout cells, 
which showed that, unlike in TNF signalling525,526, RIP1 appeared not to be essential for the RIG-I-
driven immune response, so may not be present in this signalling complex. Conversely, binding of 
TRAF2 to TAP-HOIP was also not detected during SeV infection, despite its previously reported role 
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alongside LUBAC in the RIG-I-RSC135. Because HOIL-1 is the same molecular weight as the antibody 
heavy chain, we were unable to study it’s binding to NEMO in this experiment, as it could not be 
detected by Western blotting. Use of light-chain only secondary antibodies to overcome this was 
attempted, but their reduced sensitivity meant that we did not detect binding of other proteins. 
Despite this, from these data we conclude that LUBAC is present in the RIG-I signalling complex, 
binding to both NEMO and TBK1, both of which we have shown are required for the RIG-I mediated 
immune response.  
 
Figure 5.8.1: LUBAC co-IPs with NEMO and TBK1 during SeV infection 
Western blotting analysis of Flag-M2 immunoprecipitation (IP) of TAP-NEMO and TAP-HOIP in A549 NEMO -/- 
+ TAP-NEMO and A549 HOIP -/- + TAP-HOIP-WT cells respectively after A) treatment with 500 ng/mL TNFα and 
B) infection with SeV at 1:300 dilution (for both, data is representative of 2 independent assays). 
5.9 HOIP does not play a role in preventing RIG-I-driven cell death in 
A549 cells 
When LUBAC was first discovered to play a role in TNF signalling, it was identified as a modulator of 
cell death pathways, as loss of LUBAC activity resulted in a loss of the TNF-driven pro-inflammatory 
phenotype and sensitisation of cells to TNF-driven cell death, predominantly by programmed 
necrotic death pathway necroptosis338,527,528. More recently, loss of LUBAC activity has also been 
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shown to result in RLR- and TLR3-driven cell death, occurring through either apoptosis during VSV 
infection and Poly(I:C) stimulation, or activation of necroptosis during SeV infection432,505,529.  In vivo, 
enhanced lung injury was seen during IAV infection of mice with an alveolar epithelium-specific HOIP 
deletion506, as was seen during Poly(I:C) treatment of SHARPIN deficient mice432. Conversely, LUBAC-
mediated ubiquitination of IRF was shown to be required for activation of the RLR-induced IRF3-
mediated pathway of apoptosis (RIPA) during late stages of SeV infection530.  
5.9.1 RIG-I-driven cell death is not activated in A549 cells lacking HOIP 
To see if HOIP is playing a role in RIG-I-driven cell death in our model, we studied whether HOIP -/- 
cells were sensitised to cell death after stimulation with our RIG-I ligands. SeV infection of both A549 
WT and HOIP -/- resulted in no visible cytopathic effects (CPE) (Figure 5.9.1A), whereas treatment of 
the same cells with staurosporine, a potent inducer of caspase-dependent and -independent 
apoptosis531,532, became apoptotic in morphology (not shown). Similarly, no visible morphological 
changes were observed in either A549 WT or HOIP -/- cells after treatment with 3p-hpRNA or 
Poly(I:C), or infection with IAV R+K (not shown). Some visible cell death was seen at later time points 
of ZIKV infection, although this was not quantified and only occurred at time points where signalling 
outcomes were no longer RIG-I-specific, suggesting RIG-I was not driving this death. 
Despite no visible CPE, phos-flow and a vitality assay were used were used to quantify cell death 
during SeV infection. Phos-flow staining for activated caspase 3 was to identify cells undergoing 
programmed apoptosis as caspase 3 is an effector caspase activated by cleavage by an initiator 
caspase during both intrinsic and extrinsic cell apoptosis533. After 6 hours of SeV infection, there was 
no notable increase in the number of either WT or HOIP -/- cells expressing activated caspase 3 
(Figure 5.9.1B).  
This was further verified using a vitality assay, which detects changes in the intracellular level of 
reduced thiols as a measure of apoptosis activation, as depletion of reduced thiol GSH is an early 
hallmark of apoptosis progression. Resting and infected cells were stained with a VB-48™ dye, to 
quantify the amount of free thiols, and propidium iodide (PI), which accumulates in cells with 
permeabilised membranes. Stained cells were analysed using a NC-250 vitality assay programme, 
and a fluorescence intensity plot showing the distribution of thiol levels and PI in individual cells was 
generated. Staining of resting healthy cells was used to devise a gating strategy, which was then 
used to assign cells as healthy (high VB-48 and low PI), apoptotic (low VB-48 and low PI) and dead 
(high PI), (Figure 5.9.1C). A549 WT and HOIP -/- cells were infected with SeV or stimulated with 
staurosporine and categorised using the same gating parameters as the control cells (also Figure 
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5.9.1C). The percentage of healthy, early apoptotic and necrotic cells was compared between WT 
and HOIP -/- (Figure 5.9.1D). In the absence of stimulation, approximately 90% of both cell lines 
were healthy. Staurosporine stimulation of cells resulted in 40-50% of cells taking up PI and only 30-
40% of the cells remaining healthy, both relatively consistent between WT and HOIP -/- cells across 
the two time points. After a 6-hour infection with SeV, 80-90% of both WT and HOIP -/- cells 
remained healthy. This reinforces the phos-flow data, confirming that SeV infection is not inducing 




Figure 5.9.1: RIG-I does not drive cell death in A549 cells, even in the absence of HOIP 
A549 WT and HOIP -/- cells infected with SeV at 1:300 dilution, A) Images taken at 10x magnification and B) 
phos-flow to look at % of cells with activates caspase 3 (n=1, data representative of >3 independent assays). 
Nucleocounter NC-250 Vitality Assay of A549 WT and HOIP -/- cells treated with 2 μM Staurosporine (STS) or 
infected with SeV at 1:300 dilution, C) images of dot plots generated during vitality assay where upper left and 
right quadrants represent necroptotic cells (PI positive), lower left represents apoptotic cells (PI negative, VB-
48 negative) and the lower right quadrant represents healthy cells (PI negative, VB-48 positive) and D) stacked 




Through the work in this chapter, we aimed to study how the E3 ligase component of LUBAC HOIP 
regulates RIG-I signalling. Our work using cell lines deficient in HOIP and cells expressing wild-type 
and a catalytic dead mutant of HOIP goes some way to addresses previous inconsistencies in the 
literature surrounding the role of HOIP in RIG-I signalling and suggests that HOIP positively regulates 
RIG-I-driven immune activation in a similar way to other signalling pathways like TNF, NOD2 and 
TLR3.  
5.10.1 Addressing previously conflicting studies showing opposing roles for 
HOIP in the regulation of RNA sensing. 
We have shown that in A549 cells, HOIP is required for efficient RIG-I-driven activation of IRF3 and 
NF-κB and the resultant immune gene transcription and chemokine secretion. Previous data 
surrounding this topic is conflicting, some of which is supported by our results. 
HOIP was previously shown to be required for RIG-I signalling during infection with IAV WSN, where 
knockdown of HOIP in A549 cells resulted in reduced IRF3 and NF-κB activation, and loss of HOIP 
expression in the alveolar epithelium of mice inhibited the IFN-I and inflammatory-driven immune 
response534. Similarly, HOIP was required for VSV-driven IFN-I activation in U2OS cells, but only 
played a modest role in the activation of IRF3- and NF-κB-dependent pathways, due to its functional 
redundancy with TRAF proteins135. However, other studies were less clear cut, with HOIP knockout 
having minimal effect on IFN-I activation, but HOIP overexpression reducing IFN-I induction, both in 
MEF cells infected with SeV 213. Additionally, HOIP was shown to assists Hepatitis B-mediated 
restriction of IFN-I activity when RIG-I is activated by pre-genomic RNA535. This conflicting literature 
may suggest that the role of HOIP in RIG-I signalling is cell-type dependent, as both studies indicating 
either a redundant or non-existent role for HOIP in RIG-I-mediated signalling were done using MEF 
cells135,213. However, it may also highlight the importance of using clean knockout systems to study 
the role of LUBAC, as both studies also relied on knock-down systems, where evidence of residual 
HOIP expression after knockdown was visible213. 
Our data supports what is known about the regulation of other RNA sensing pathways by HOIP. In 
TLR3 signalling, recruitment of HOIP results in efficient activation of IRF3 and NF-κB, as well as 
cytokine signalling, seen in both HaCaT and HeLa cells432. This is also supported by data showing that 
small molecule inhibitors of HOIP called HOIPINs inhibit the TLR3-dependent response to Poly(I:C)536. 
By using a clean knockout system to show that HOIP is required for efficient RIG-I signalling, we 
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provide clear evidence that that HOIP has a consistent function between different RNA sensing 
pathways. 
In addition to in other RNA sensing pathways, our data showing the requirement of HOIP for 
immune activation mimics what is seen in other immune signalling pathways, strengthening our 
findings. M1-ubiqutin chains generated by HOIP are required for the activation of NF-κB, MAP kinase 
cascades and pro-inflammatory gene transcription by TNFR1, IL-1, NOD1 and 2 and other TLRs, 
through enabling the efficient recruitment of RIPK and IRAK proteins501,518,537–540. HOIP also drives 
IRF-dependent defences to intracellular bacteria, through enabling recruitment of TBK1/IKKε to the 
bacteria541. Outside of RIG-I signalling, no previous studies show negative regulation of immune 
activation by HOIP. 
From our study, we concluded that overexpression systems, a technique that has been used to 
generate much of the data surrounding LUBAC and RIG-I, are poorly suited to studying the role of E3 
ligases like HOIP or HOIL-1. Previous studies using this system showed that overexpression of HOIP 
and HOIL-1 reduced IFN-I, and NF-κB activation in response to both SeV infection and overexpression 
of many components of the RIG-I signalling complex213,505,542. These findings contradict much of the 
data that has been generated using cells lacking expression of either HOIP or HOIL-1.  
The main issue with using overexpression systems to study LUBAC is that it almost certainly disrupts 
the tight regulation of LUBAC that occurs in physiological systems, critical to appropriate LUBAC 
function, with “inappropriate regulation of Met1-Ub giving rise to severe and potentially fatal 
pathologies”503. This tight regulation is achieved by stable complex formation of LUBAC with de-
ubiquitinases (DUBs) OTULIN and CYLD, which cleave M1-Ub chains to tightly regulate the activity of 
LUBAC543,544. Loss of OTULIN results in accumulation of M1-linked ubiquitin chains, which is thought 
to interfere with LUBAC function by causing autoubiquitination545, highlighting the detrimental 
effects of hyperactive LUBAC. Additionally, overexpression of a catalytically active protein complex 
like LUBAC is likely to result in above-physiological levels of ubiquitin chain generation, which may 
lead to binding of ubiquitin chains to proteins that would not normally be targeted, potentially giving 
rise to a differing phenotype. Previous occurrence of this has been seen with HOIL-1 overexpression, 
which was shown to promote proteosome-mediated degradation of IRF3542, conflicting with both 
biochemical analyses showing IRF3 is not a substrate for HOIL-1 and studies showing HOIL-1-
deficiency in fibroblasts does not affect IRF3 stability213. Occurrence of either or both 
aforementioned processes may account for the differing phenotypes seen between overexpression 
and studies and those that use knock-out or knock-down techniques.  
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The importance of understanding how HOIP regulates signalling processes, and the biological 
implications of this are highlighted by the effect of mutations of HOIP, both in humans and in mice. 
Full HOIP -/- mice die during embryonic development, due to sensitisation to aberrant TNFR1-
mediated cell death activation516,519, as do mice expressing catalytically inactive HOIP518,546, and in 
mice with an endothelial deletion of HOIP516. However, mice with other cell-type specific deletions of 
HOIP are possible, as has been done in B cells and alveolar epithelium519,534, likely due to the 
importance of the endothelium in maintenance of the vascular architecture during 
embryogenesis516. In humans, mutations in HOIP result in immune dysregulation with complex 
clinical characteristics547,548, sharing phenotypes see in mice with either partial HOIL-1 -/- or full 
SHARPIN -/- mice338,504,508,511,549,550. These characteristics include immunodeficiency, likely due to 
impaired IFN, NF-κB and MAPK activation500,501, defective development of T and B cells519,551,552, and 
loss of dendritic cell homeostasis553, which leads to increased susceptibility to infection caused by an 
impaired antibody response547. Paradoxically, HOIP mutation also causes autoinflammation, thought 
to be driven by aberrant cell death activation or hyperactivation of monocytes causing excessive pro-
inflammatory cytokine production548. The two known clinical cases differ slightly in their 
manifestation, likely because only one of the mutations impairs the expression of HOIP, and 
therefore prevents formation of a stable LUBAC complex.  
5.10.2 A suggested two-step mechanism for the regulation of RIG-I 
signalling by LUBAC and M1-ubiqutin chains 
The mechanism by which LUBAC regulates RIG-I signalling has not yet been conclusively described, 
with differing mechanisms and conflicting outcomes suggested. However, through using multiple 
different methods to analyse the outputs of RIG-I signalling across a range of time points, we 
propose a dynamic model for RIG-I regulation by HOIP and M1 ubiquitin chains.  
We have shown that HOIP is required for efficient transcription of IFN-I, IFN-III, ISGs and 
chemokines, as well as NF-κB-dependent genes NFKBIA and TNFA, from which we can infer that  
HOIP regulates the RIG-I-signalling pathway at a point required for both IRF3 and NF-κB activation. 
We have also shown that that RIG-I, MAVS and NEMO, but not TBK1, IKKε, TANK/NAP1/SINTBAD, 
RIP1 or Optineurin, were required for both IRF3 and NF-κB activation during SeV infection. Also 
fitting with this, we showed that  LUBAC components HOIP and SHARPIN interact with known RIG-I 
signalling proteins NEMO and TBK1. In addition to this, we showed that the catalytic activity of HOIP 
is only partially required for its role in RIG-I signalling, with no defect in IRF3 and NF-κB activation 
and chemokine secretion at early time points in cells expressing a catalytically inactive mutant of 
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HOIP, but lower levels of transcription of both IFN-I and NF-κB-dependent genes and chemokine 
secretion at later time points.  
This requirement for the ligase activity of HOIP at later time points and the demonstrated 
interaction between LUBAC and RIG-I signalling proteins has allowed us to propose a model for 
HOIP-mediated regulation of RIG-I signalling. We suggest that HOIP, and possibly the other LUBAC 
proteins HOIL-1 and SHARPIN, are required for proper formation of the RIG-I signalling complex, 
probably acting as scaffold proteins. LUBAC then conjugates M1-linked ubiquitin chains to proteins 
in the signalling complex to amplify the signalling outputs, either by enhancing recruitment of other 
signalling proteins or stabilisation the active signalling complex to extend signalling. This is analogous 
to the suggested mechanism for TNF signalling regulation, where the enzymatic activity of HOIP is 
required for the enhanced and sustained recruitment of NEMO to the signalling complex, and the 
resultant downstream signalling501. This could be tested by using a fluorescently tagged M1-
ubiquitin-binding domain, such as GFP–UBAN (ubiquitin-binding in ABIN and NEMO), which would 
enable us to monitor the timing of the generation of M1-linked ubiquitin chains554.  
Until this study, the requirement of the ligase activity of HOIP for its regulation of RIG-I signalling 
was unclear. A ubiquitin-chain independent mechanism of downregulation of RIG-I signalling by 
LUBAC was proposed by Inn et al., as overexpression of RING mutants of both HOIL-1 and HOIP with 
no catalytic activity did not prevent the ability of the proteins to suppress SeV or RIG-I-induced IFN-I 
activation213. But conversely, the ligase activity of either TRAF2 or HOIP was shown to be required 
for IRF3 activation by RIG-I135. Our data does not agree directly with either of these studies, but 
together they do support our suggestion of a dual role for HOIP as a scaffold protein and producer of 
M1-ubiquitin chains.  
We cannot yet confirm the target of M1-linked ubiquitin chains in the RIG-I signalling complex, 
however the interaction of HOIP with NEMO and TBK1 provide possible targets to be further 
explored. Alongside TRIM25, NEMO has previously been proposed as a target for M1-Ub chains in 
the RIG-I complex213,505. However, the studies proposing these proteins as targets of M1-linked 
ubiquitination suggest that this is detrimental to RIG-I-driven immune signalling, which is 
inconsistent with our data. An additional study disputes this further, showing that only ubiquitin 
binding by NEMO and not ubiquitination of NEMO, was essential for MAVS signalling135.  
The targets of M1-linked ubiquitination are better characterised in other signalling pathways. In 
TNFR1 signalling, NEMO both binds to and is ubiquitinated by M1-Ub chains, both of which are 
required efficient IKKβ phosphorylation and downstream NF-κB activation338,501,528. RIP1 is also a 
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target for the conjugation of M1-linked ubiquitin chains in TNFR signalling, preventing formation of 
complex II and limiting the subsequent programmed cell death activation500–502. Alternatively, 
Emmerich et al have suggested that M1-Ub chains are conjugated directly onto K63-linked chains, 
forming M1/K63-hybrid ubiquitin chains during IL-1, TLR1, 2 and 3, TNFR1 and NOD1 signalling 518,555, 
allowing the recruitment of multiple protein complexes at the same location to facilitate 
downstream signalling. To speculate around the likelihood of these known targets of M1-linked 
ubiquitination to play the same role during RIG-I signalling, we considered the requirement for 
NEMO and RIP1 in RIG-I signalling. In our model NEMO, but not RIP1, is absolutely required for 
activation of both IRF3 and NF-κB by RIG-I, processes also both regulated by HOIP. It is also known 
that both NEMO and HOIP bind to K63-linked ubiquitin chains and each other135,505,518. Therefore, we 
propose that the most likely targets of M1-Ub chains in the RIG-I signalling complex are NEMO and 
the K63-linked ubiquitin chains generated by TRAFs, responsible for recruitment of NEMO.  
Our data on the role of M1-Ub chains in RIG-I signalling adds to the wealth of literature highlighting 
the importance of ubiquitin chains and E3 ligases in antiviral RIG-I signalling46,556,557, as well as the 
bank of knowledge for how M1-Ub ubiquitin chains regulate immune signalling pathways.  
5.10.3 HOIP does not act to restrict virus replication in our system 
In addition to regulating immune signalling outcomes, LUBAC has previously been shown to restrict 
virus infection. Our data with RNA viruses IAV PR8 and ZIKV PE243 showed that HOIP had no effect 
on either viral protein production or viral replication, however the use of a multi-step growth curve 
may have yielded a different result. This contradicts the only previous study of virus restriction by 
HOIP, which showed that loss of HOIP in the alveolar epithelium of mice resulted in higher viral titres 
during IAV infection506, but in vivo studies like this are done in the context of a whole organism with 
a complete immune system, so this is not directly comparable to our cell-based assays. 
HOIL-1 and SHARPIN have also been previously shown to affect virus replication, with expression of 
HOIL-1 beneficial for the replication of VSV in both MEF and HEK293 cells under certain conditions, 
but not for MNoV replication in BMDC213,504,509. The presence of SHARPIN also appeared to enhance 
VSV replication in MEF cells but had no effect on the IAV viral load in cpdm mice was 
unaffected432,505. Although significant, these phenotypes are strikingly mild compared to the impact 
of RIG-I on RNA virus replication, with viral yield during VSV infection 100-fold higher in cells lacking 
RIG-I437, which is surprising, considering how important HOIP is for RIG-I driven activation of IFN and 
pro-inflammatory antiviral signalling. Having said this, we did not detect this strikingly enhanced 
ZIKV replication in RIG-I -/- cells during preliminary growth curve experiments with ZIKV, so this may 
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well be a condition-specific phenomenon. To better understand the full impact of HOIP on virus 
replication, the virus replication needs to be more carefully analysed using single- and multi-step 
growth curves at both high and low MOI. 
5.10.4 Involvement of LUBAC in RIG-I-driven cell death 
A predominant feature of LUBACs regulation of other signalling pathways is that it controls a 
molecular switch between immune signalling and activation of programmed cell death pathways. 
We have showed that in our system, stimulation of RIG-I by synthetic RNAs and SeV did not drive cell 
death, irrespective of the presence of HOIP. The only cell death we observed was at late time points 
following ZIKV infection, but only at times where we have shown that immune signalling was no 
longer dependent on RIG-I, indicating that RIG-I does not drive this cell death.  
Previously, HOIP has been shown to protect against RIG-I-driven cell death, with loss of HOIP from 
alveolar epithelial cells in mice resulting in enhanced lung injury during infection with IAV WSN534. 
This supports what has been shown during TLR3 activation, where loss of HOIP expression in HaCaT 
and HeLa cells sensitised them to Poly(I:C)-induced apoptosis, characterised by increased caspase-8 
and -3 dependent cell death432. This was also shown in vivo, where an inducible HOIP knockout in 
primary murine keratinocytes (PMK) resulted in a lower viability after Poly(I:C) stimulation432. All of 
these findings are in contrast to work by Chattopadhyay et al., which shows that LUBAC drives M1-
linked ubiquitination of IRF3, resulting in its interaction with Bax and activating IRF3- and RIG-I-
dependent, TNF-independent cell death termed RIPA530,558–560. Notably, these studies describe a 
function of LUBAC that is very different to what occurs in other signalling pathways, where the 
presence of both LUBAC and/or M1-Ub chains prevents the receptor signalling complex from driving 
cell death432,502,523,561.  
HOIL-1 and SHARPIN have also been implicated regulating RIG-I-driven cell death. Mutation of 
SHARPIN in cpdm MEF and mice resulted in higher levels of cell death and increased caspase 3 
cleavage during infection with VSV, also seen during stimulation of TLR3 with Poly(I:C)432,505. 
Contrastingly, mice expressing a truncated version of HOIL-1 showed decreased lung injury during 
IAV WSN infection, suggesting full-length HOIL-1 enhanced cell death in this system534. However, 
although as true HOIL-1 -/- mice are not viable335,507, all data generated using these mice must be 
carefully considered. 
Finally, in addition to RIPA, another model of SeV-induced RIG-I-dependent cell death has also been 
proposed. In L929 cells, infection with SeV resulted induction of TNF-independent RIG-I-dependent 
necroptosis, at time points as early as 10 hours post infection529. We did not observe this, likely 
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because A549 cells do not express RIP3, making them necroptosis-incompetent. However, 
preliminary assays using A549 cells stably overexpressing RIP3 showed that SeV infection still did not 
result in any visible cell death, even in the presence of caspase inhibitor Z-VAD. 
Given that direct RIG-I-induced cell death was not observed in our cells, any future investigations of 
LUBAC’s possible regulation of RIG-I-induced death would have to be carried out in different cell 
systems. 
5.11 Conclusion 
By examining RIG-I signalling outcomes in WT and HOIP-deficient A549 cells, we have been able to 
demonstrate the requirement of HOIP for the efficient activation of signalling pathway components, 
transcription of IFN-I and antiviral genes, and secretion of chemokines in response to activation of 
RIG-I by both synthetic RNAs and RNA viruses. Using a ligase-dead mutant of HOIP, we showed that 
the catalytic activity of HOIP is only partially responsible for its function in RIG-I signalling, and that 
this appears to be more pronounced at later time points. Demonstration of the interaction of LUBAC 
components HOIP and SHARPIN with NEMO and TBK1 during SeV infection supports the 
incorporation of LUBAC into the RIG-I signalling complex. Together, this enables us to propose a 
mechanism by which HOIP/LUBAC is required for efficient formation of the RIG-I signalling complex, 
and the subsequent production and conjugation of M1 ubiquitin chains in the signalling complex acts 





Chapter Six: The role of accessory 
proteins HOIL-1 and SHARPIN in RIG-I 
signalling 
6.1 Introduction 
Previous studies exploring the role of LUBAC in RIG-I signalling, and in many other signalling 
pathways, have examined the role of a single LUBAC component and attributed the phenotype seen 
to the function LUBAC as a complex, or to M1-linked ubiquitin chains. However, recent studies have 
shown that aside from contributing to the generation of M1-Ub chains by stabilising HOIP, HOIL-1 
and SHARPIN also contribute independently to signalling outcomes, by regulating or directing the 
function of LUBAC562–566, as well as independently regulating signalling567,568. Because of this, we 
wanted to explore the individual contribution of all three LUBAC components to RIG-I signalling. 
Therefore, having shown that HOIP is required for the efficient activation of IRF3 and NF-κB-
dependent responses downstream of RIG-I, we next examined the effect of loss of HOIL-1 and 
SHARPIN expression on the immune response to synthetic RNAs 3p-hpRNA and Poly(I:C) and RNA 
viruses SeV and IAV R+K. As before, the outputs of RIG-I activation: signalling protein 
phosphorylation; immune gene transcription; and chemokine secretion, were analysed by Western 
blotting, qPCR and ELISA respectively. From this, we have demonstrated that HOIL-1 is required for 
RIG-I driven immune responses to both synthetic RNAs and RNA viruses, but that the role of 
SHARPIN is unclear. 
6.2 HOIL-1 is required for a RIG-I-driven immune response to 
synthetic RNAs and RNA viruses 
HOIL-1, like HOIP, is a member of the RING-in-between-RING family of E3 ligases. However, it was 
initially shown to have very limited activity in vitro and is incapable synthesising of M1-linked 
ubiquitin chains521. However, despite limited catalytic activity, HOIL-1 is required for the efficient 
generation of M1-Ub chains by HOIP, binding to release HOIP from the auto-inhibited confirmation it 
forms on its own515,521. Additionally, more recent studies have identified additional catalytic-
dependent roles for HOIL-1 in LUBAC signalling562,564,566,569. HOIL-1 also has LUBAC-independent 
functions, predominantly involving its ability to regulate protein degradation through conjugation of 
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K48 ubiquitin chains to proteins, linking HOIL-1 to regulation of antiviral signalling, cancer, cell death 
pathways and iron metabolism567. 
Previous reports of the impact of HOIL-1 on RIG-I signalling are conflicting, reporting both positive 
and negative regulation135,213,504,505,534. To study the role of HOIL-1 in the RIG-I-driven immune 
response, RIG-I was stimulated in WT and HOIL-1-deficient MEF cells. Generation HOIL-1-deficient 
A549 cells using CRISPR/Cas9 technology was attempted, but this was unsuccessful within the time 
frame of this project. Instead MEF TNF -/- HOIL-1 +/- and TNF -/- HOIL-1 -/- cells were stimulated 
with synthetic RNAs and RNA viruses and the immune response measured by qPCR and Western 
blotting. 
6.2.1 Characterisation of the immune response in MEF TNF -/- HOIL-1 +/- 
and HOIL-1 -/- cells 
MEF TNF -/- HOIL-1 +/- and MEF TNF -/- HOIL-1 -/- cells were generated by immortalisation of mouse 
embryonic fibroblasts (MEF) cells from a true HOIL-1 -/- mouse335.  Generation of just HOIL-1 -/- MEF 
cells is not possible as complete deletion of HOIL-1 in mice results in embryonic lethality, with 
embryos dying at day ten (E10) due to epithelial cell death in the yolk sack epithelium335,570. The 
additional deletion of TNF in these mice allows survival of embryos until day E16.5, enabling the 
generation of MEF cells. Because of this, the control “WT” MEF cells used in these experiments are a 
homozygous deletion for TNF and heterozygous for HOIL-1 (MEF TNF -/- HOIL-1 +/-) and the HOIL-1 
deficient cells are a homozygous deletion for both TNF and HOIL-1 (MEF TNF -/- HOIL-1 -/-). 
Apparent HOIL-1 -/- mice and MEF cells generated by Tokunaga et al507 have been used in previous 
HOIL-1 studies, however they retain expression of an N-terminal truncation of HOIL-1, retaining its 
ubiquitin and HOIP binding domains, shown in Figure 6.2.1A. 
Protein expression of LUBAC components and RIG-I signalling proteins was examined by Western 
blotting in MEF TNF -/- HOIL-1 +/- and HOIL-1 -/- cells (Figure 6.3.1B), confirming loss of HOIL-1 
expression in MEF TNF -/- HOIL-1 -/- cells. Expression of HOIP and SHARPIN appeared unaffected by 
loss of HOIL-1, as was expression of RIG-I signalling components IRF3, TBK1 and IκBα. 
As our previous studies were done in A549 cells, before examining the contribution of HOIL-1, 
stimulation of RIG-I in MEF cells was tested. qPCR after stimulation of MEF TNF -/- HOIL +/- cells with 
3p-hpRNA (Figure 6.2.1C) and Poly(I:C) (Figure 6.2.1D) showed similar levels of Cxcl10 transcription 
with both RNAs, but only Poly(I:C) transfection induced Ifnb1 transcription, as seen in A549 cells. 
MEF TNF -/- HOIL-1 +/- cells were also infected with varying dilutions of SeV (Figure 6.2.1E), resulting 
in transcription of both Ifnb1 and Cxcl10, which increased significantly more at higher 
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concentrations, up to 1:100. Therefore, a 1:100 dilution was used for all future SeV infection studies. 
Western blotting during SeV infection at 1:100 dilution also detected phosphorylation of IRF3, TBK1 
and IκBα (Figure 6.2.1F). Basal activation of IRF3 and TBK1 was detected in unstimulated cells, but 
this increased significantly with infection, with levels peaking at 6 hours post-infection. Finally, qPCR 
analysis of IAV R+K infection of MEF TNF -/- HOIL-1 +/- cells showed transcription of both Ifnb1 and 
Cxcl10, but not until 8 hours post-infection (Figure 6.2.1G). This is delayed compared to A549 cells, 
where significant levels of transcription were detected only 6 hours post infection with IAV R+K, 
likely due to the differing kinetics of virus infection in different cell types. 
These data show that stimulation with 3p-hpRNA, Poly(I:C), SeV and IAV R+K induces an immune 
response in MEF cells, allowing us to use these cells to investigate the impact of HOIL-1 on RIG-I-
signalling. As we did not generate RIG-I-deficient MEF cells to test the specificity of our stimulation 
methods, we cannot claim to know that they are RIG-I-specific in this cell line, especially Poly(I:C) 




6.2.1 Characterising the MEF TNF -/- HOIL-1 +/- cell line 
A) Schematic of expressed portion of in previously published “Tokunaga HOIL-1 -/-” mice (UBL = ubiquitin-like, 
NZF = nuclear protein localisation 4 (Npl4) zinc finger, ZnF = zinc finger, UBA = ubiquitin associated, RING = 
really interesting new gene and IBR = in-between-ring. B) Western blot analysis of MEF TNF -/- HOIL-1 +/- and 
TNF -/- HOIL-1 -/- cells. qPCR to measure transcription of indicated genes in MEF TNF -/- HOIL-1 +/-  cells after 
stimulation with C) 1 μg 3p-hpRNA (n=2, data representative of >3 independent assays), D) 1 μg Poly(I:C) (n=2, 
data representative of >3 independent assays), E) infection with SeV for 6 hours at varying dilutions (n=2, data 
from one independent assay) and G) infection with IAV R+K at MOI 5 (n=2, data representative of >3 
independent assays). F) Western blot analysis of MEF TNF -/- HOIL-1 +/- cells infected with SeV at 1:100 
dilution with and without 10 μM MG-132 (data representative of >3 independent assays). 
151 
 
6.2.2 The synthetic RNA-driven immune response is dependent on HOIL-1 
Following this confirmation that MEF cells are suitable as a model cell line to study the role of HOIL-1 
in RNA sensing, MEF TNF -/- HOIL-1 +/- and HOIL-1 -/- cells were transfected with 3p-hpRNA and 
Poly(I:C) and transcription of immune genes was measured by qPCR. Stimulation with 3p-hpRNA 
resulted in transcription of Cxcl10, Isg15, Isg56 (the murine homolog of human ISG54) and Il6 (Figure 
6.2.2.A), but not Ifnb1, Ifnl1 or Nfkbia (not shown). HOIL-1-deficient cells showed significantly 
reduced transcription of all genes except Isg15, whose transcription was only significantly reduced 4 
hours after stimulation. Transfection with Poly(I:C) yielded similar results (Figure 6.2.2B), with 
transcription of Ifnb1, Cxcl10, Isg15, Isg56 and Il6 all robustly induced in HOIL-1 +/- cells and 
expressed to a significantly lower level in HOIL-1 -/- cells.  This data shows that like HOIP, HOIL-1 is 
required for the RIG-I-driven transcription of immune genes in response to synthetic RNAs. 
 
Figure 6.2.2: Synthetic RNA-driven expression of immune genes is dependent on HOIL-1 
qPCR to measure transcription of indicated genes in MEF TNF -/- HOIL-1 +/- and TNF -/- HOIL-1 -/- cells 
stimulated with A) 1 μg 3p-hpRNA (n=2, data representative of 3 independent assays) and B) 1 μg Poly(I:C) 
(n=2, data representative of 3 independent assays). 
6.2.3 The antiviral transcriptional response to SeV infection is dependent 
on HOIL-1 
To see if HOIL-1 plays a similar role in RIG-I signalling in response to RNA virus infection, the 
response of HOIL-1 +/- and HOIL-1 -/- cells to infection SeV and IAV R+K was also measured by qPCR 
analysis (Figure 6.2.3A and B).  
SeV infection of HOIL-1 +/- cells resulted in a very similar transcriptional profile to A549 cells, except 
for Ifnl2/3, which is not transcribed in MEFs whereas its human homolog IFNL1 was in A549s. 
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Transcription of all genes was significantly reduced in HOIL-1 -/- cells at 4 hours post-infection, with 
Ifnb1, Cxcl10, Isg56 and Nfkbia also significantly reduced at 6 hours. As seen in A549 cells, infection 
of MEF HOIL +/- and HOIL -/- cells with IAV R+K resulted in variable levels of both Ifnb1 and Cxcl10 
transcription between experimental replicates (Figure 6.2.3B). This was apparently due to large 
variations in the response in HOIL-1 +/- cells between experiments, as transcription appeared 
consistent in HOIL-1 -/- cells. As also seen in A549 cells, this appeared to correlate with transcription 
of the NS1 protein being uneven between the two cell lines, preventing us from describing the role 
of HOIL-1 during IAV infection.  
Our data shows that loss of HOIL-1 results in reduced immune gene transcription in response to both 
synthetic RNAs and RNA viruses, meaning that even though the transcriptional phenotype seen in 





Figure 6.2.3: HOIL-1 is required for RNA virus-driven immune gene expression 
qPCR to measure transcription of indicated genes in MEF TNF HOIL-1 +/- and HOIL-1 -/- cells infected with A) 
SeV at 1:100 dilution (n=2, data representative of >3 independent assays) and B) IAV R+K at MOI 5 (n=2, data is 
representative of differing experimental results experienced). 
 
6.2.4 HOIL-1 is required for activation of RIG-I signalling proteins during 
SeV infection  
The role of HOIL-1 on signalling protein activation was then studied by Western blotting, measuring 
phosphorylation during SeV infection of MEF TNF -/- HOIL-1 +/- and HOIL-1 -/- cells (Figure 6.2.4). In 
cells lacking HOIL-1 expression, lower levels of phospho-IRF3, TBK1 and IκBα were detected, 




Figure 6.2.4: HOIL-1 is required for SeV-driven activation of signalling pathway components  
Western blot analysis of MEF TNF -/- HOIL-1 +/- and -/- cells infected with SeV at 1:100 dilution with 
(+) or without the presence of 10 μM MG-132 (data representative of >3 independent assays). 
6.3 SHARPIN is not required for a RIG-I driven immune response to 
synthetic RNAs or RNA virus infection 
SHARPIN is the third and most recently discovered component of LUBAC508,511, where it binds to and 
stabilises HOIP in its active confirmation, enabling efficient generation of M1-ubiquitin chains335,570. 
Before it was linked to LUBAC, SHARPIN was known to function in excitatory synapses in the brain, as 
well as in regulation of inflammation and immune development571,572. Interestingly, SHARPIN is the 
only component of LUBAC for which knockout mice are viable, named cpdm mice after their chronic 
proliferative dermatitis phenotype, caused by sensitisation of SHARPIN-deficient cells to TNF-driven 
apoptosis573. 
6.3.1 Generation of A549 SHARPIN -/- cells  
To study the role of SHARPIN in RIG-I signalling, SHARPIN-deficient A549 cells were generated using 
CRISPR/Cas9 technology. Figure 6.3.1A shows the location targeted by the sgRNA in exon 4 of 
SHARPIN, in relation to the start codon. Loss of SHARPIN expression was confirmed by Western 





Figure 6.3.1: Characterisation of SHARPIN -/- A549 cells 
A) Schematic of position of start ATG and small guide RNA used for CRISPR KO of SHARPIN in A549 cells, blue 
boxes represent exons and black line represents introns. B) Western blot analysis of LUBAC components in 
A549 WT and SHARPIN -/- cells. 
6.3.2 Mixed requirement of SHARPIN for a synthetic RNA-driven immune 
response in A549 cells  
To determine the requirement of SHARPIN for a synthetic RNA-driven immune response, A549 WT 
and SHARPIN -/- cells were transfected with 3p-hpRNA and Poly(I:C) and transcription of genes 
known to be induced in WT cells was measured by qPCR (Figure 6.3.2A and B). With both synthetic 
RNAs, loss of SHARPIN expression did not detrimentally affect transcription of either IFNB1 or 
CXCL10 but did result in significantly reduced transcription of both ISG15 and ISG54. This shows that 
the effect of SHARPIN on RNA-induced immune transcription is mixed, with a clear effect on ISGs, 





Figure 6.3.2: SHARPIN is not required for synthetic RNA-driven immune gene transcription in A549 cells 
qPCR to measure transcription of indicated genes in A549 WT and SHARPIN -/- cells stimulated with A) 1 μg 3p-
hpRNA (n=2, data representative of 2 independent assays) and B) 1 μg Poly(I:C) (n=2, data representative of 2 
independent assays). 
6.3.3 SHARPIN is not required for the SeV-driven immune response in A549 
cells 
Next, the effect of SHARPIN on an RNA virus-driven immune response was examined by measuring 
transcription, signalling protein phosphorylation and chemokine secretion in A549 WT and SHARPIN 
-/- cells infected with SeV. SHARPIN-deficient cells transcribed significantly higher levels of all tested 
genes in response to SeV infection, compared to WT (Figure 6.3.3A). Somewhat conversely, Western 
blotting analyses showed that loss of SHARPIN expression appeared to have no effect on 
phosphorylation of TBK1 or IκBα (Figure 6.3.3B), with SHARPIN -/- cells actually having slightly lower 
levels of phospho-IRF3 than WT, especially at 2 hours post-infection. Having said that, this reduction  
is nowhere near as marked as in cells lacking HOIP or HOIL-1 and was not visible in every 
experimental repeat. ELISA analysis during SeV infection showed higher levels of CXCL10 secretion in 
SHARPIN -/- cells, both at 6- and 24-hours post-infection (Figure 6.3.3C), aligning with qPCR data.  
These data show that SHARPIN is not essential for the RIG-I-driven immune response to RNA virus 
infection, in fact data from the two most sensitive techniques, qPCR and ELISA, suggest that 





Figure 6.3.3: SHARPIN is not required for the SeV-driven response in A549 cells 
SeV infection of A549 WT and SHARPIN -/- cells at 1:300 dilution. A) qPCR to measure transcription of 
indicated genes in A549 WT and SHARPIN -/- cells infected with SeV at 1:300 dilution (n=2, data representative 
of 2 independent assays), B) Western blotting analysis of signalling protein phosphorylation with (+) and 
without the presence of 10 μM MG-132 (data representative of 3 independent assays) and C) ELISA analysis of 
CXCL10 secretion (n=2, data representative of 2 independent assays). 
6.3.4. SHARPIN is not required for a RIG-I-driven immune response in MEF 
cells 
As the lack of requirement for SHARPIN in RIG-I-dependent antiviral signalling differed from what 
was seen for both HOIP and HOIL-1, we wanted to confirm this with an additional model cell line. 
Therefore, MEFs extracted from WT and cpdm mice were used to further study the requirement of 
SHARPIN for RIG-I-driven immune signalling508,571,572.  
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After Western blotting analysis confirmed loss of SHARPIN expression in cpdm MEFs (Figure 6.3.4A), 
transcription of immune genes was analysed by qPCR in WT and cpdm cells stimulated with 3p-
hpRNA, Poly(I:C) and SeV. 3p-hpRNA transfection resulted in transcription of Ifnb1, Cxcl10, Isg15 and 
Isg56, all of which appeared to be unaffected in cpdm cells (Figure 6.3.4B). On the other hand, 
during Poly(I:C) stimulation, transcription of Cxcl10, Isg15 and Isg56 all was reduced cpdm cells 
(Figure 6.3.4C), with only Ifnb1 not detrimentally affected. This was not as marked during SeV 
infection, where transcription of both Ifnb1 and Cxcl10 was consistently reduced in SHARPIN -/- cells 
through the time course, but not transcription of Isg15, Isg56, Nfkbia or Il6 (Figure 6.3.4D).  
As was described for A549 WT and SHARPIN -/- cells, the data generated in MEF WT and cpdm cells 
was not conclusive, with outcomes varying for different genes, assays and stimulation methods. 
Despite this, the data from both cell types allows us to conclude that SHARPIN is not required for 
RIG-I-driven IFN activation. Finally, as the phenotype in SHARPIN-deficient cells is different to that 
seen in HOIL-1-deficient cells, we can conclude that the phenotype in HOIL-1 -/- cells is not solely 
down to loss of HOIP activity caused by reversion to its auto-inhibited confirmation in the absence of 




Figure 6.3.4: SHARPIN is not required for RIG-I driven immune gene transcription in MEF cells 
A) Western blotting analysis of MEF WT and cpdm cells. qPCR to measure transcription of indicated genes in 
MEF WT and cpdm cells stimulated with B) 1 μg 3p-hpRNA (n=2, data representative of 2 independent assays), 
C) 1 μg Poly(I:C) (n=2, data representative of 2 independent assays) and D) SeV infection at 1:300 dilution (n=2, 
data representative of 2 independent assays). 
6.4 Discussion 
Through the work in this chapter, we analysed how the LUBAC accessory components HOIL-1 and 
SHARPIN regulate RIG-I signalling. Using A549 and MEF cells lines lacking expression of either HOIL-1 
or SHARPIN, we have shown differing contributions to RIG-I signalling outcomes. This exploration of 
the independent functions of HOIL-1 and SHARPIN resolves some of the conflicting literature 
regarding the role of LUBAC in RIG-I signalling and provides a more detailed analysis of the function 




6.4.1 HOIL-1, like HOIP, is required for RIG-I-driven immune responses  
Our data shows that HOIL-1 is required for activation of both IRF3 and NF-κB and the resultant 
downstream signalling by RIG-I, as was seen for HOIP. These observations support much of what we 
know about the role of HOIL-1 in other signalling pathways, where it has been shown to play an 
essential role in NF-κB activation during stimulation of cells with cytokines, PRR ligands, following 
genotoxic stress and in MAPK signalling in response to CD-40 and TNF338,501,508,511,528,574–576.  
However, our data disputes much of what has been previously published about the role of HOIL-1 in 
RIG-I signalling, possibly because very few previous studies have used a clean knockout system to 
study HOIL-1. Previously, studies utilising knockdown of HOIL-1 in multiple cell types including A549 
and MEFs have shown that loss of HOIL-1 results in increased IRF3 activation and IFN-I induction in 
response to infection with SeV and VSV135,213,505,542. Conversely, another study indicated that 
knockdown of HOIL-1 in A549 cells reduced IFN-I and IL-6 secretion during IAV infection534, which is 
more in line with our data.  
Many of the previous studies examining the role of HOIL-1 in RIG-I signalling also utilised cells from a 
mouse previously suggested to lack HOIL-1 expression507. Using cells from this mouse, ‘loss’ of HOIL-
1 expression has resulted in various outcomes during RNA virus infection, with both increased and 
unaffected IFN-I and IFN-III activation detected in response to SeV and VSV infection213,504. Having 
said this, during activation of MDA5 by MNoV and TMEV, these ‘HOIL-1 knockout’ cells had reduced 
IRF3, IFN-I and IFN-III activation504, despite both MDA5 and RIG-I converging at MAVS to signal via a 
common pathway46. Cells from this this mouse, however, are not completely HOIL-1 null as they still 
express a small amount (approximately 10%) of a 30 kDa truncated version of HOIL-1. This truncated 
HOIL-1 is missing its catalytic RBR E3 ligase domain, a region known not to be critical for m1-linked 
ubiquitination of substrates562. The truncated protein does, however, still contain the ubiquitin like 
(UBL) domain responsible for binding to HOIP in the LUBAC complex510, shown to be sufficient to 
support M1-Ub chain synthesis by HOIP510, and the NZF domain, which is required for binding to 
polyubiquitin chains and is essential for its role in NF-κB activation downstream of TNF and IL-
1B337,528,577. The biological importance of the expression of these domains of HOIL-1 is highlighted by 
the fact that Tokunaga HOIL-1 -/- mice and knock-in mice expressing the catalytically inactive HOIL-1 
RBR mutant are viable564, whereas complete HOIL-1 -/- mice die in utero335,528.  
The cells used in this study lack expression of any part of the HOIL-1 protein, meaning that both of 
the dual functions of HOIL-1, stabilisation of HOIP and as an E3 ligase, are prevented. Thus, this study 
shows the true effect of HOIL-1 on RIG-I signalling. 
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6.4.2 SHARPIN is not required for gene transcription following RIG-I 
activation 
Using two SHARPIN deficient cell lines we have shown that, in contrast to HOIP and HOIL-1, the third 
LUBAC component SHARPIN is not essential for RIG-I-driven immune responses. Generally, loss of 
SHARPIN had no effect on RIG-I signalling outcomes, with some SHARPIN-deficient cells even 
displaying increased immune signalling outputs following RIG-I activation. As with HOIL-1 -/- cells, 
this phenotype was not caused by loss of HOIP or HOIL-1 expression as has been previously 
observed338,547.  
Our data supports some of what has already been described about the role of SHARPIN in RIG-I 
signalling in MEF cells, where disruption of SHARPIN expression had no effect on IRF3 activation or 
IκBα phosphorylation and resulted in a modest increase in IFN-I production in response to SeV and 
VSV infection135,505. However, in these studies NF-κB activation and IFN-I production was reduced in 
cpdm MEFs during RNA virus infection. In TLR3 signalling, knockdown of SHARPIN or use of cells from 
cpdm mice also resulted in a mixed phenotype, with reduced NF-κB activation and chemokine 
secretion but unaffected IRF3 activation response to extracellular Poly(I:C)432. 
This opposes studies of the role of SHARPIN in other immune signalling pathways, which have been 
much more conclusive, showing that SHARPIN is required for activation of NF-κB and JNK/ERK 
signalling pathways in response to stimulation with TNFα, IL-1β, CD-40 and LPS338,508,511. Because 
SHARPIN does not have a RBR ligase domain, unlike HOIP and HOIL-1, its role in these pathways is 
solely attributed to its function within LUBAC. SHARPINs function in LUBAC instead depends on its 
protein-binding ability,  binding to and stabilising HOIP it in its active conformation338,528,578 and 
binding target proteins such as NEMO to facilitate conjugation of M1-linked ubiquitin chains330,331. 
The interaction between SHARPIN and NEMO has also been shown to be necessary for regulation of 
RIG-I signalling505. It is currently unclear why SHARPIN is definitively required for NF-κB activation by 
many immune receptors including RNA sensor TLR3 but has a non-essential function in RIG-I-driven 
IFN-I activation. This may be due to differing mechanisms of activating NF-κB between the pathways, 
requiring differing adaptor proteins, only some of which can be influenced by SHARPIN. 
Alternatively, this may be due to LUBAC-independent functions of SHARPIN in other pathways, as it 
is known to bind caspase-1 in a LUBAC-independent fashion579, as well as many proteins involved in 
regulation of NF-κB signalling580.  
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6.4.3 In addition to their function in LUBAC, HOIP, HOIL-1 and SHARPIN all 
have independent functions in signalling pathways 
Our data shows that HOIL-1 function similarly to HOIP in RIG-I signalling, with the phenotype 
observed in complete HOIL-knockout MEF cells phenocopying what we saw in HOIP-deficient A549 
cells: reduced activation of IFN-I and NF-κB-dependent responses. This data supports our model that 
LUBAC positively regulates RIG-I signalling in different cell types and in both humans and mice.  
Initially, we entirely attributed the phenotype seen in HOIL-1-deficient cells to its ability to stabilise 
HOIP in its active conformation, supported by the fact that the phenotype in HOIL-1 -/- cells was 
more moderate than in cells lacking HOIP, with higher levels of immune gene transcription detected. 
This was partially expected, as HOIP contains the catalytic domain of LUBAC responsible for the 
generation of M1-ubiquitin chains515. Furthermore, both HOIL and SHARPIN alone are able to 
stabilise HOIP sufficiently to induce NF-κB activation338,508,511,581, with knockout of HOIL-1 previously 
shown to severely impair HOIP expression both in MEFs and A549 cells213,528,534. We did not, 
however, detect altered HOIP expression in HOIL-1 -/- cells, so we can attribute the phenotype in 
HOIL-1-deficient cells to the function of HOIL-1, not indirect loss of HOIP. 
Although initially reported to have limited activity, recent studies demonstrating the ubiquitin ligase 
activity of the HOIL-1 RBR domain521,562,582,583, have lead us to consider that the phenotype seen in 
HOIL-1 -/- cells may also be caused by loss of HOIL-1 ligase activity. HOIL’s E3 ligase activity is 
required for the priming lysine modification then enables ubiquitin chain addition to NEMO562, as 
well as for the formation of unusual oxyester bonds between ubiquitin and serine and threonine 
residues on substrate proteins, important for controlling the outcome of immune receptor signalling 
564,566. This unusual E3 ligase activity of HOIL-1 occurs in a co-ordinated relay mechanism with HOIP 
to promote the generation of heterotypic K63/M1-ubiquitin chains in both TNF and TLR 
signalling566,584. Analysis of HOIL-1 E3 ligase mutant (C458S) mice, determined that this atypical chain 
formation can result in opposing  signalling outcomes. This has been demonstrated during IL-18 and 
TLR-driven myddosome activation in cytotoxic T cells and bone marrow-derived macrophages 
(BMDMs), where HOIL-1’s E3 ligase activity and the resulting ester-linked ubiquitin chains restrict IL-
18 signalling but are required for TLR-driven efficient IL-12 and IL-6 secretion584. IL-18 restriction 
occurs because the presence of both normal isopeptide-liked ubiquitin chains and ester-linked 
chains limits the size of the ubiquitin chain, reducing the recruitment of downstream signalling 
proteins like TRAF6. Conversely, ester-linked ubiquitin chains in TLR signalling enables ‘priming’ 
events, driving ubiquitination of IRAK2 that allows its interaction with TRAF6 and drives downstream 
cytokine secretion584,585. In addition to assisting in M1-ubiquitin chain formation, HOIL-1 can 
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negatively regulate LUBAC activity. HOIL-1’s RBR domain catalyses the conjugation of mono-
ubiquitin onto LUBAC subunits, on to which HOIP then adds M1-chains, attenuating the function of 
LUBAC in TNF signalling563. The importance of the ligase function of HOIL-1 is further highlighted by 
the fact that the E2 conjugating enzyme that binds HOIL, UBE2L3, is recruited to the TNF-RSC 
alongside LUBAC501,586 and findings showing that presence of full length HOIL-1 is required for the 
greatest ubiquitination activity of LUBAC, even though the UBA domain alone is sufficient to relieve 
HOIP auto-inhibition587.  
These previously described roles of the HOIL-1 RBR domain, whose expression is lost in Tokunaga 
HOIL -/- mice and cells, in negative regulation of LUBAC may explain the increased immune signalling 
seen in these cells. Expression of the UBL and NZF domains of HOIL-1, which are still expressed in 
Tokunaga HOIL -/- cells, are sufficient to stabilise HOIP enabling efficient function of LUBAC, but the 
lack of HOIL-1 RBR domain means that the negative regulation of LUBAC by HOIL-1 mono-
ubiquitination no longer occurs. This may also be the case for HOIL-1-knockdown, where cells 
express enough HOIL-1 to stabilise HOIP, but not sufficient to elicit its E3 ligase function to regulate 
LUBAC activity. 
Having said this, it must be acknowledged that studies using Tokunaga HOIL -/- mice or cells to 
examine the role of LUBAC in other signalling pathways have not seen the same phenotype that we 
did when studying RIG-I signalling, where HOIL-1 appears to negatively regulate signalling, although 
enhanced or delayed TNF-induced JNK activation has been reported in these cells508,528,576,588. 
Generally, in other signalling pathways, studies using these cells found that HOIL-1 was required for 
NF-κB activation. This difference could possibly be explained by differing primary outputs between 
TNF-RSC and RIG-I signalling, where TNFR only activates NF-κB activation, whereas the predominant 
output of RIG-I activation is IRF3-dependent IFN-induction. Thus, the mechanism of regulation of 
these signalling complexes by LUBAC may differ, possibly meaning a different requirement for the 
ligase activity of HOIL-1.   
Alternatively, the different outcomes of RIG-I and TNF signalling in ‘Tokunaga’ HOIL-1 -/- cells may 
also be explained by the described role for HOIL-1’s K48-linked E3 ligase activity as a negative 
regulator of many immune signalling pathways including TNF-R and IL-1R signalling589, PKC 
activation590–593 and anti-viral IRF3 activation213,542. In this instance, loss of RBR domain expression 
would not only result in loss of LUBAC activity but loss of negative regulation of these pathways, 
resulting in a positive phenotype. However, the function of HOIL-1 as a K48-ubiquitin ligase is 
disputed, as many of these studies relied on overexpression of HOIL- 1 or HOIL-1 mutants. 
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Overexpression of a catalytically active E3 ligase, as previously described for HOIP, may result in 
aberrant ubiquitination of proteins that would not generally a target of ubiquitination in 
physiological settings. The contribution of HOIL-1’s E3 ligase activity to its function in signalling 
pathways could be assessed more accurately through the use of an E3 ligase-inactive HOIL-
1[C458/460S] mutant, which was previously used to demonstrate the role of HOIL-1 in modulating 
HOIP’s activity521,564. 
Our data suggests that unlike HOIL-1, SHARPIN does not play a role in RIG-I signalling in our system, 
either in its requirement for stabilising HOIP for efficient LUBAC function, or for any independent 
functions. This is supported by data surrounding their biological significance because SHARPIN-
deficient mice, unlike mice lacking expression of either HOIP or HOIL-1, are viable, displaying an 
inflammatory phenotype, predominantly in the skin594. Additionally, whilst evidence of disease-
causing mutations in HOIP and HOIL-1 have been found in humans, no disease has been attributed 
to mutations in SHARPIN, suggesting that this may not be pathogenic in humans. 
Considering this, we suggest that the reason for differing requirements for HOIL-1 and SHARPIN in 
RIG-I signalling is not related to their shared function of stabilising the active LUBAC complex. Only 
one of HOIL-1 or SHARPIN is required to stabilise HOIP in its active conformation338,508, meaning in 
theory that in the absence of either protein, the other can compensate for this. Instead, we propose 
that their differing requirement is caused by the role of their alternative functions in RIG-I signalling, 
with the phenotype we see in HOIL-1-deficient cells caused by its other M1-ubiquitin chain related 
functions564,566 and the absence of a phenotype in SHARPIN-deficient cells suggesting that it does not 
have a specific role in RIG-I signalling besides stabilising HOIP. To test this, RIG-I signalling outcomes 
must be examined using a HOIL-1/SHARPIN double-knockout cell line rescued with stable expression 
of a ligase-inactive HOIL-1 mutant. One fact that may counter this hypothesis that LUBAC-
independent functions of HOIL-1 and SHARPIN are responsible for the differing phenotypes, is that 
the presence of all three LUBAC components results in the most efficient formation of M1-ubiuqitin 
chains by LUBAC338. However, we have shown that M1-ubiquitin chains are only partially required 
for the function of LUBAC in RIG-I signalling, and are not required for the initial activation of IRF3 and 
NF-κB, meaning potentially that SHARPIN would not be required for the initial activation of IRF3 and 
NF-κB by RIG-I. This may also explain why the requirement for SHARPIN differs between RIG-I 
signalling and other signalling pathways, as almost all immune signalling pathways except TCR 
signalling, B cell signalling, and now RIG-I activation have been shown to need the E3 ligase activity 
of LUBAC for efficient immune activation519,524.  
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Despite not being required for RIG-I signalling in A549 cells, the focus of most previous studies into 
SHARPIN may give us an insight into its primary function in immune signalling, namely regulating the 
activation of cell death pathways. SHARPIN-deficient cells are hypersensitive to TNF-driven cell 
death338,511, the activation of which in epidermal keratinocytes results in the chronic proliferative 
dermatitis phenotype seen in cpdm mice573. This is prevented by LUBAC-enabled activation of NF-κB, 
which protects the cells from apoptosis by activating transcription of anti-apoptotic genes such as 
Bcl2595–597, with SHARPIN seeming to play a predominant role in regulating this. SHARPIN also 
appears to protect cells from cell death activated by TLR-dependent RNA sensing pathways, with 
SHARPIN-deficient HaCaT cells and cpdm PMK cells sensitised to Poly(I:C)-induced cell death432. This 
is further supported by IAV-infected cpdm mice showing increased cell death in the lungs, 
independent of viral load432 and cpdm MEF cells being sensitised to RIG-I-driven cell death during 
VSV infection505.  
We did not specifically study the role of SHARPIN in RIG-I-driven cell death in our system. However, 
after 24 hours of SeV infection, only very limited CPE was visible in SHARPIN-deficient A549 and MEF 
cells, suggesting loss of SHARPIN did not sensitise the cells to SeV-driven death. The lack of cell death 
in our system may be caused by the fact we did not infect SHARPIN-deficient cells with an active 
replicating/productive virus. However, Poly(I:C), which has been used to induce TLR3-driven cell 
death432, did not induce visible cell death in our SHARPIN -/- cells, although this was only assessed at 
early time points. 
Despite not observing a cell death phenotype with SHARPIN in our system, previous data showing 
that SHARPIN is predominantly responsible for regulating cell death in other signalling pathways,  
coupled with our results showing that SHARPIN does not contribute to RIG-I-driven immune 
activation, allows us to propose this as an alternative function for SHARPIN in RIG-I signalling. We 
suggest a mechanism by which HOIP and HOIL act to drive immune activation by functioning as a 
scaffold and subsequently conjugate M1-ubiquitin chains to the RIG-I complex, and SHARPIN exists 
in the complex to block the activation of cell death pathways. SHARPIN may also play a role in 
determining the target of M1-ubiqutination in the signalling complex, as has previously been shown 
with NEMO in TLR signalling330,331, but this was not essential for effective function of LUBAC in the 
RIG-I signalling complex in our system. The lack of requirement for SHARPIN for directing M1-linked 
ubiquitin chains may be because there are multiple targets of M1-ubiquitination in the signalling 
complex, or multiple mechanisms of conjugating ubiquitin onto the same target, or because M1 
chains are conjugated onto other ubiquitin chains already present in the signalling complex.  
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6.5 Conclusion  
The data presented in this thesis shows that HOIP and HOIL-1 are required for optimal activation of 
both IRF3 and NF-κB by RIG-I, but that SHARPIN is not required for this process. We propose a two-
step model by which HOIP and HOIL-1 regulate RIG-I signalling in which LUBAC acts as scaffold to 
allow proper formation of the RIG-I signalling complex and then conjugates M1-Ub within the 
complex to enhance and stabilise recruitment of downstream signalling proteins, illustrated by 
schematics in Figure 6.5.1 and Figure 6.5.2 respectively. By comparing the phenotype we saw in 
HOIP- and HOIL-1-deficient cells and HOIP-C885S-expressing cells with the phenotype seen in cells 
lacking known RIG-I signalling components, we can adapt our earlier proposed RIG-I signalling model 
to include LUBAC. We suggest that LUBAC is recruited to the RIG-I signalling complex by binding K63-
ubiquitin chains, upon which it recruits/activates TBK1 and conjugates M1 chains to NEMO, 
enhancing its recruitment and boosting downstream signalling.  
We propose this as a mechanism because the phenotype seen in both HOIP- and HOIL-1-deficient 
cells is most similar to NEMO -/- cells, as they all show reduced activation of both IRF3 and NF-κB 
and the resultant immune gene transcription and chemokine secretion. This suggests that LUBAC is 
involved in either recruitment of NEMO to the RIG-I signalling complex, or in NEMO’s function within 
the complex. The only difference is that TBK1 phosphorylation is lost in HOIP and HOIL-1 -/- cells but 
is not affected by loss of NEMO. This suggests that in addition to modulating NEMO function, LUBAC 
is required for efficient activation and/or recruitment of TBK1. All of this is reinforced by our data 
showing that LUBAC interacts with both NEMO and TBK1 during RIG-I stimulation. M1-ubiquitin 
chains do not appear to be required for the role of LUBAC in regulating either TBK1 or IRF3 
activation, or the phosphorylation and degradation of IκBα to activate NF-κB, so this is only 
dependent on the presence of HOIP and HOIL at the RIG-I complex and not M1-ubiquitin chain 
formation. M1 chains are, however, required to enhance recruitment of signalling proteins and 
boost downstream responses. We suggest that this may be caused by the formation of M1/K63-
linked hybrid ubiquitin chains, that function to amplify IRF3 activation in the RIG-I signalling complex, 
likely modulating it around the level of NEMO recruitment and activation. 
The mechanism by which this regulation occurs also relies on our knowledge of LUBAC at the TNF-
RSC. In TNF signalling, both NEMO and LUBAC are initially recruited by binding to ubiquitin chains 
generated by cIAPs501,598,599. LUBAC then conjugates M1-linked ubiquitin chains to NEMO334,338,501, 
which enhances its recruitment and retention because NEMO has a much higher affinity for M1-
ubiquitin chains than K63/K11-linked chains599–603. The recruitment of TBK1 and IKKε to the TNF-RSC 
is also mediated largely by M1-ubiquitin chains, as well as TANK, NAP1 and SINTBAD333. Similarly, 
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TRAF proteins have been shown to produce K63-ubquitin chains that recruit NEMO to the RIG-I 
signalling complex. Therefore, we propose that K63-ubiquitin chains generated by TRAFs recruit 
LUBAC and NEMO to the RIG-I signalling complex, and that the presence of both LUBAC and NEMO 
here enables recruitment and activation of TBK1 and IRF3, as well as NF-κB. We cannot rule out the 
additional contribution of oxy-ester-linked ubiquitin chains catalysed by HOIL-1 in the RIG-I signalling 





Figure 6.5.1: Schematic of the proposed mechanism of LUBACs involvement in RIG-I signalling complex 
formation 
Complex initiation 
1. RIG-I binds to RNA with 5’ppp and regions of double-stranded secondary structure 
2. This alongside ubiquitination of RIG-I CARD domains by Riplet and TRIM25 activates RIG-I CARD, 
which is recruited to MAVS at the mitochondrial outer membrane 
3. Activation of MAVS by RIG-I (and a wealth of other modifications) causes oligomerization of MAVS via 
the CARD domain 
4. TRAF proteins are recruited to MAVS, where they add K63-linked ubiquitin chains to the CARD domain 
of MAVS 
5. NEMO and LUBAC are recruited by binding K63 ubiquitin chains 
IRF3 activation 
6. TBK1 and IKKε are recruited to the signalling complex where they phosphorylate MAVS 
7. IRF3 is recruited to the phosphorylated MAVS, and once in proximity with activated TBK1, is 
phosphorylated, inducing dimerization, translocation to the nucleus and activation of an IFN-I 
response 
NF-κB activation 
8. IKKα and β are recruited to the signalling complex,  
9. IKKβ phosphorylates IκBα to initiate its degradation 
10. NEMO facilitates the recruitment of the ubiquitin and proteasomal degradation machinery to IKKβ, 
where it ubiquitinates IκBα, inducing its degradation by the 26S proteosome 






Figure 6.5.2: Schematic of the proposed mechanism of LUBACs involvement in RIG-I signalling complex 
enhancement 
Complex initiation (as before steps 1-5) 
Complex enhancement 
6. LUBAC conjugates M1-linked ubiquitin chains to NEMO and K63-linked ubiquitin chains, generating 
K63/M1-linked chains and enhancing the recruitment of NEMO 
7. IRF3 and NF- κB activation continues via the same mechanism, but are enhanced due to stronger 




The data generated in this body of work has allowed us to suggest a mechanism by which 
LUBAC, M1-ubiquitin chains and the individual components HOIP, HOIL-1 and SHARPIN regulate 
RIG-I signalling. Additionally, our demonstration of the differing roles of the individual LUBAC 
components in RIG-I signalling goes some way to explain the highly conflicting literature 
surrounding regulation of RIG-I by LUBAC, as previously the individual function of all three 
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